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BACKGROUND
The goal of this thesis is to explore new methods for improving adenovirus 
and reovirus vectors for oncolytic virus therapy. Oncolytic virus therapy aims 
at treating malignancies with viruses that preferentially replicate in cancer 
cells. Oncolytic virotherapy can use both natural unmodified viruses as well 
as engineered viruses. The general concept to use viruses for eradication of 
malignancies dates back to the late 1800s and early 1900s [1]. In the first 
case reports, patients, most often suffering from hematological malignancies, 
went into remission after contracting an infectious disease, presumably of viral 
origin. Unfortunately remissions were often short-lived [1-3] and the cause of 
the remission remained vague. Physical evidence for the existence of viruses 
was not acquired until later in the 20th century. Around the 1950s developments 
in cell and tissue culture techniques led to the ability to propagate viruses in 
vitro. This allowed an increase in the general knowledge of virus biology and 
resulted in the evaluation of the oncolytic potential of a range of viruses on 
malignancies of different origins in cell and tissue cultures. Subsequently, 
studies in animal models and even humans were performed. Although there 
was anecdotal evidence of tumor remission in humans, the side effects, virus 
elimination by the immune system, and a number of ethical concerns together 
with the beginning of the era of chemotherapy resulted in a decrease of interest 
in oncolytic virotherapy [2-5]. 
 Renewed interest in oncolytic viruses arose in the early 1990s with the 
rise of recombinant DNA techniques and the increased knowledge in virus 
biology obtained in the previous decades [6]. The major breakthrough was the 
development of a thymidine kinase-negative herpes simplex-1 mutant with 
reduced neurovirulence which showed to be active in a murine glioblastoma 
model [7]. After the first encouraging paper more reports about genetically 
engineered viruses followed [8,9] and provided the field with new know-
how in virus biology, virus-cell interactions, replication cycles, and also virus 
modification strategies. In the same period general knowledge about cancer 
biology increased enormously. This increased knowledge of both virus and 
cancer biology resulted in a long list of potential oncolytic viruses, some of 
which even reached the clinic (reviewed in [4,5]). The first genetically modified 
oncolytic virus registered for clinical use is an adenovirus based vector. It was 
approved in China in 2005 for the treatment of head and neck cancers [10]. 
 However, in Europe and the USA no vector has yet been registered for 
oncolytic virotherapy and the road to develop effective oncolytic vectors has 
been more difficult than was expected in the beginning of this research era. 
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Nevertheless, the field has made enormous progress. For a number of viruses 
safety profiles were excellent, and the viruses could be produced in high titer 
at clinical grade. In addition the development and applicability of modifications 
strategies is facilitating new vector development. Currently, the major drawbacks 
in oncolytic virotherapy are insufficient tumor tropism and tumor cell-specificity, 
inefficient replication in tumor cells and limited spread in the tumor. In addition 
viruses can be rapidly cleared by the immune system and scavenged by non-
target cells. In this thesis research is focused on getting solutions for some of 
these issues. 
AIMS
The general aim of this thesis is to overcome some of the bottlenecks that 
limit efficacy of oncolytic virotherapy. We focused on four different approaches 
to generate more effective viruses and to obtain more reliable parameters of 
anticancer efficacy. 
1. Modification of capsid proteins to alter the tropism of the wild-type virus.
2. Forward-genetic strategies were used to obtain more potent viruses. 
3. The modified viruses, obtained with the help of forward genetics, have been 
analyzed and compared with wild-type viruses on primary cultures and stem-
like cultures. 
4. Mesenchymal stromal cells (MSC) were evaluated as carrier cells for reovirus 
delivery to cancer cells. 
Standard testing of oncolytic viruses is performed mainly on established cell lines. 
In the last decade, the appropriateness of established cell lines for predicting 
the effects on genuine tumor cells has been increasingly challenged. Primary 
cultures and tumor stem cells cultures have a closer resembles to tumors 
than conventional serum cultured cell lines [11,12]. It is therefore suggested 
that primary and tumor stem cells cultures are better models to predict of the 
clinical efficacy. So in this thesis two of the modified viruses were tested on 
primary cultures obtained from resected glioblastomas. Glioblastoma is the most 
aggressive form of brain cancer and even with the current treatment regimens 
the median survival is only between 12-15 months [6,13]. The poor prognosis is 
due to the rapid growth and invasive nature of the tumor and to its resistance to 
chemotherapeutic drugs and radiation therapy. Despite the extensive research 
of the last decades, only limited improvements in survival rate have been 
obtained [14]. In the quest to curative treatment modalities for this disease, 
oncolytic virus therapy has been heralded as a promising therapeutic agent. The 
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factors which make oncolytic virus therapy an ideal candidate for treatment of 
glioblastoma are 1) that the tumors are located in an enclosed environment and 
2) metastases outside the skull almost never occur. Additionally, the tumors are 
often surrounded by post mitotic cells, which have the advantages that viruses 
which require active cell division cannot replicate in these cells. At least fourteen 
oncolytic viruses have already been selected as candidate viruses for glioma 
therapy (listed in table 1.1) (reviewed in [15,16]).Seven of these viruses have 
been or are currently evaluated in clinical trials and case studies. Data of the 
completed studies provide evidence for the safety of the approach and, so far, the 
maximum tolerated dose has not been reached. Unfortunately the data reporting 
evidence significant therapeutic impact have been limited (reviewed in [15-17]). 
This demonstrates that new preclinical research is warranted to improve the 
therapeutic efficacy. Only then, the oncolytic viruses can be a useful addition 
to the armamentarium to combat this devastating disease (reviewed in [15]). 
Table 1.1 Candidate viruses for oncolytic virus therapy for glioma. Table adapted 
from Wollman et al. [15]
Virus Virus family Phase of development relating to glioma
Herpes simplex virus 1 Herpesviridae Clinical phase I/II
Newcastle Disease virus Paramyxoviridae Clinical phase I/II
Adenovirus Adenoviridae Clinical phase I
Reovirus Reoviridae Clinical phase I
H1 Parvovirus Parvoviridae Clinical phase I
Poliovirus Picornaviridae Clinical phase I
Measles virus Paramyxoviridae Clinical phase I
Vaccinia virus Poxviridae Preclinical in vivo
Myxoma virus Poxviridae Preclinical in vivo
Vesicular Stomatitis Virus Rhabdoviridae Preclinical in vivo
Pseudorabies virus Herpesviridae Preclinical in vitro
Minute Virus of Mice Parvoviridae Preclinical in vitro
Sindbis virus Togavridae Preclinical in vitro
Seneca Valley virus Picornaviridae Preclinical in vitro 
OUTLINE
Part I is divided in three chapters. After a general introduction to oncolytic 
virotherapy and the aim of this thesis, a brief introduction into the adenovirus 
biology and the development of recombinant vectors is provided. The third 
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chapter focuses on reovirus. Here, shortly, the structure, replication biology and 
genetic modification strategies of reovirus are discussed. This chapter ends with 
the motivation why reovirus is of interest as oncolytic agent. 
 Part II focuses on genetic modifications of the adenovirus in order to obtain 
an adenoviral vector with improved oncolytic efficacy. In chapter 4 the effect 
of deleting the minor capsid protein IX is investigated. As described in chapter 
2 the function of protein IX is still not fully clear. However, deleting this protein 
makes the particle more susceptible to heat and decreases the maximum 
genome size which can be packaged [18]. Here it is shown that deletion of 
protein IX expands the cell tropism but also the virus became more susceptible 
to the innate immune system in mice. These data provide more insight into the 
biological role of protein IX and can be of value for the development of oncolytic 
vectors. In chapter 5 the effect of truncating the adenovirus i-leader open 
reading frame (orf) on glioma cell lines and primary high-grade glioma cultures 
is described. Already in previous studies it was shown that truncating mutations 
in this i-leader region improved the cytopathic activity of human adenovirus-5 
(HAdV-5) in a panel of tumor cell lines [19,20]. Unfortunately, no glioma cultures 
were included in the published study. Here, the generation of the replication-
competent vector containing the single i-leader point mutation is described. 
After verification of the vector, the cytopathic effect is analyzed using cell based 
assays. It is shown that the cytopathic activity in glioma cultures increases by 
truncation of the i-leader orf. Although these are preliminary results and no in 
vivo data is presented it is important knowledge which may be implemented in 
future vectors. 
 Part III concentrates on reovirus as oncolytic vector. As described in chapter 
3, reovirus has a natural preference for transformed cell. Unfortunately its clinical 
efficacy as oncolytic agent is still limited. The first two chapters of section 3 focus 
on genetic modification of reovirus in order to modify the tropism. In chapter 
6 a strategy to replace the wild-type spike by a modified spike-protein with 
short peptide ligand is described. This strategy makes use of a helper cell line 
expressing the modified segment as conventional RNA polymerase II transcript 
which leads to the replacement of the wild-type segment by the modified 
segment. In chapter 7 modifications are based on classical forward-genetics 
strategies. Reovirus RNA-dependent RNA polymerase lacks the proofreading 
ability and therefore genomic mutations are easily introduced. Adaptation of 
wild-type reovirus to replicate on a cell line which does not express the reovirus 
high affinity receptor junction adhesion molecule-A (JAM-A) yields mutants 
with a modified tropism (JAM-A independent (jin) mutants). Additional genomic 
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analysis of the jin mutants indicates that mutations in the S1 segment, encoding 
the spike protein σ1, is responsible for the expanded tropism. These mutants 
could be of great interest as oncolytic agents for the treatment of tumors that 
lack JAM-A on the cell surface. 
 In the last decades, enormous progress has been made in elucidating cancer 
biology. Cancer stem-like cells have been assigned as a cell type which play 
an important role in the recurrence and metastases of tumors. In addition, 
these cells possess a high resistance to radiation and chemotherapy (reviewed 
in [21-23]). Therefore an efficient therapy requires the removal of these cells. 
In order to determine the susceptibility of human glioblastoma stem-like cell 
(GSC) cultures to reovirus a panel of GSC was exposed to reovirus (chapter 8). 
Because of a high variation of JAM-A expression between GSC cultures determined 
by flow cytometry, both wild-type as well as mutant jin-1 were applied. In this 
study it was shown that GSC were more susceptible to jin-1 than wild-type in 
monolayer experiments. However, in 3-dimensional (3D) tumor cell spheroids 
the viruses were equally effective. 
 A major bottleneck of oncolytic virus therapy is neutralization and scavenging 
of the virus by immune cells or non-target tissue reducing the effective dose. 
Hiding the virus from these factors and in the meantime delivering the virus to 
the target site could make the oncolytic virus therapy more effective. Of several 
cell types it is known that they home to tumors such as dendritic cells, T cells, 
NK cells, macrophages and several stem cell types [24]. In chapter 9 it is 
investigated whether mesenchymal stromal cells (MSC) can be potential carriers 
for reovirus. Since JAM-A is almost absent on MSC, wild-type reovirus and jin-1 
were applied to MSC cultures. Here it is shown that, although replication was 
not supported in MSC, these cells could still hand-off the virus to neighboring 
cells in monolayer and in 3D tumor cell spheroids. These results support the 
development of human MSC as cellular vehicles for the delivery of oncolytic 
reoviruses.

CHAPTER 2 
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BIOLOGY
One of the most popular viruses for the use in oncolytic virus therapy is the 
human adenovirus [3,25,26]. This virus was first isolated in the 1950s from cell 
cultures derived from adenoid-tissue [27,28]. In the same period the research 
on the use of viruses as oncolytic agent was expanding [3,4]. Therefore it is not 
surprising that not long after the initial isolation of adenovirus it was evaluated 
as a candidate in pre-clinical and clinical studies. Administration of adenovirus 
to cancer patients caused only modest side effects, but unfortunately survival 
of the patients was only minimally prolonged and infections were quickly 
abolished by the immune system (reviewed in [3]). In the consecutive years 
adenoviruses have been very important for in unraveling the principles of RNA 
splicing [29] and for developing techniques for naked-DNA transfer such as 
the calcium phosphate DNA-transfection method [30]. In addition, the study of 
adenoviruses has been instrumental for acquiring knowledge on fundamental 
viral processes and basic aspects of cell biology (reviewed in [31,32]). Together 
with the upcoming recombinant DNA techniques in the 1980s, the relative 
ease of the genetic modification of viruses, the high-titers of adenovirus vector 
batches, and the good safety profiles seen in clinical trials have made adenoviral 
vectors one of the most frequently used vectors in vaccine development, gene 
delivery, and oncolytic areas [25,33]. 
 The human adenoviruses belong to the family Adenoviridae and the genus 
Mastoadenovirus. Over 60 serotypes of human adenoviruses have been 
identified which are classified in seven species, A to G [34]. Depending on the 
serotype human adenovirus can cause respiratory, enteric, eye or urinary tract 
infections. However usually these infections are mild and self-limiting, and 
result in life-long immunity [25]. Serotype 2 and 5 of species C are among the 
first adenoviruses to be discovered. Most studies have used these serotypes 
and therefore most knowledge has been obtained on these serotypes. In this 
thesis we focus on modifying serotype 5 for generating vectors with potency in 
oncolytic virotherapy. 
 The human adenovirus 5 (HAdV-5) is a non-enveloped icosahedral virus of 
approximately 90 nm. The capsid is composed of three major proteins, hexon, 
penton and fiber, and four minor proteins IIIa, VI, VIII and IX (figure 2.1). Minor 
capsid protein IX it is the smallest capsid protein and a virion contains 240 
copies of this protein in the capsid. Protein IX consists of 3 conserved domains, 
the amino-terminal domain which is embedded in the capsid, the central-part 
and the carboxyl-terminal (C-terminal) domain. The exact function of protein IX 
is unknown, but vectors lacking this protein are more heat sensitive and unable 
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to package a full genome length. Therefore a cementing function have been 
assigned to protein IX. When only the C-terminal domain is removed less clear 
effects are demonstrated [35]. 
Figure 2.1 Schematic representation of the adenovirus. Adopted from Russell [36]. 
 Recently, by Cryo-electron microscopy (Cryo-EM), high resolution images of 
the adenovirus capsid have been made. These images reveal the interactions 
between the capsid proteins [37]. Hexon, the first animal virus protein which was 
crystallized [38], is the main building block of the capsid and serves mainly for 
stability. Furthermore, hexon plays an important role in establishing the immune 
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response and in 2008 the liver tropism of several human adenoviruses could be 
assigned to binding of coagulation factor X to the hexon [39,40]. The second 
major capsid protein, penton base proteins, form a pentameric structure, which, 
together with the fiber forms the pentons on the 12 vertices of viral capsid. The 
vertices are sensitive to heat fluctuations and pH changes and define the weakest 
part of the capsid. Penton-base contains a RGD-motif to which is important for 
the binding to cellular integrins during cell attachment. From the penton-base 
structure, the trimeric fiber extrude. Fiber is composed of three of three domains 
1) the N-terminal tail domain which is anchored in the penton base, 2) the 
shaft, existing of repeating motifs, and 3) the C-terminal domain which forms 
a globular head domain. The globular head-domain binds to the cellular high-
affinity receptor. For HAdV-5 and most other adenovirus serotypes the main 
high-affinity receptor is the coxsackie and adenovirus receptor (CAR) which is 
a transmembrane protein of the immunoglobulin superfamily associated with 
the formation of tight junctions. Docking to CAR is the first interaction between 
the virus and the cell in the multistep attachment process [32,36]. The next 
step is the association the RGD-motif located at the penton to cellular integrins 
which facilitate entry via the clathrin coated pits. This is the main entry route 
of adenovirus species C however there is also an alternative CAR-independent 
route via attachment of the shaft to heparin sulphate glycosoaminoglycans 
[32,36]. Acidification of the endosomes triggers the disassembly of the virion 
and release of the virus core into the cytoplasm. The virus core contains 
several viral proteins including IVa2, V, VII, terminal protein (TP), µ (mu), the 
adenovirus protease, and the adenovirus double stranded DNA genome. HAdV-5 
the genome length is 36 kb and is imported in the nucleus were transcription of 
viral genes is initiated. Adenovirus transcription is a tightly regulated process of 
early (E1-E4), intermediate (protein IX and IV2a) and late genes (L1-L5) and 
includes transcription of both strands and complex RNA splicing [41]. 
 Approximately 5-6 hrs after infection the transcription of the viral genes is 
initiated. The early genes prepare the cell for adenovirus replication. In addition, 
these gene products will inhibit the immune responses against the infected cell. 
The whole cascade starts with the transcription of the immediate early gene 
E1A, which force the cell to shift to S-phase of the cell cycle, which is the ideal 
environmental state for ensuing viral replication. In addition E1A activates the 
transcription of the other early genes. The E1B proteins play an important anti-
apoptotic role. The E2 proteins, the pre-terminal protein, the DNA-polymerase, 
and the single stranded DNA binding protein, have multiple functions all 
concerning viral transcription, mRNA transport, and replication. Transcripts of 
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the E3 unit act as important as down regulators of the host immune response 
against HAdV. The E4 proteins are involved in regulating the viral transcription 
and mRNA transport. After the initiation of the viral replication, the transcription 
shifts to the late genes which encode mostly the capsid proteins. Assembly of 
the particles starts already around 8 hrs after infection and after 30-40 hrs the 
cell will lyse initiated by de adenovirus death protein releasing all particles to the 
environment [25,42]. 
VECTOR BIOLOGY
Despite replication and cell lysis of HAdV-5 is not restricted to tumor cells it is 
still considered as potential virus for oncolytic virus therapy. Reasons to choose 
for HAdV-5 as vector are the wealth of fundamental knowledge. Furthermore, 
these viruses are able to infect dividing and quiescent cells and do not integrate 
their genome in the host genome, HAdV-5 can be produced at high-titer in 
clinical-grade quality and the safety profiles obtained from clinical trials have 
been good. In addition, in the last decades several methods are developed 
which make it possible to produce replication deficient vectors or vectors which 
specifically replicate in tumor cells, vectors with an expanded tropism or armed 
vectors with therapeutic genes. A number of these methods will be discussed in 
the next sections.
 
Replication deficient vectors
The first generation replication-deficient adenovirus vectors were E1 deleted. 
As described earlier E1 has an important function for the initiation of the viral 
transcription and deletion of this sequence yielded a transcription and replication-
impaired adenoviruses [41,43]. E1-deleted vectors are produced on a helper cell 
lines that complement for E1 functions in trans. The first established cell line 
expressing the HAd5-E1 sequence was the 293 cell line, a human embryonic 
kidney line transformed with sheared HAdV5 DNA [44]. Unfortunately, as results 
of homologues recombination between E1 region and the E1-deleted adenovirus 
vector contamination of replication-competent adenoviruses (RCAs) occurred in 
produced batches [45]. To reduce the risk of RCA formation, new cell helper lines, 
containing a smaller region of overlap between the E1 regions in the vector and 
in the helper cells, were developed [46,47]. This cell line, PER.C6, reduces the 
risk of RCA formation and together with the 293 and 911 helper cell lines are the 
most used cell lines for the production of first-generation vectors. Additionally, 
the E3 region which is involved in evasion of the cellular-immune response 
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and which is not essential for replication, was deleted from these vectors and 
generated more space for transgene inserts. Although the first generation of 
vectors was highly promising and proved to be safe, it induced a strong cellular 
immune response leading to a rapid eradication of the transduced cells. In 
reaction to this, a second-generation vector was developed by deleting the E2 
and/or E4 sequences. These vectors induced a reduced immune response [41,43] 
and therefore the transduced cells persisted longer than those transduced with 
first generation vectors. Subsequently, a third generation vector was developed 
[41,43]. In this vector all viral protein-coding sequences are removed except 
the sequences encompassing the inverted terminal repeats and the packaging 
signal. These vectors are also called gutless vectors or high capacity vectors. 
The benefits of these vectors are that the transgene insert can be up to ~35 kb 
in length, and the expression of the transgene is long-lasting also in immune 
competent animals as the absence of viral genes prevents triggering the immune 
system. Production of progeny virus requires the presence of a helper virus 
for providing all the gene products necessary for replication and packaging. A 
critical note which has to be made is that the produced vector batches can be 
contaminated with helper-virus. Contamination can be reduced by introducing 
site-directed recombination sites flanking the packaging signals of the helper 
virus. These method reduced the recombination events [41]. 
 All three replication-deficient vectors described above have their own pros and 
cons. The preferred vector depends on the goal to achieve, long-term or short-
term expression, insertion of a large or small transgenes and is activation of the 
immune system appreciated. In most studies activation of the immune system 
is seen as a negative side effect however there are studies which indicate that 
oncolytic virotherapy can lead to cancer immunotherapy (reviewed in [48]). How 
the immune system is stimulated by virotherapy to effectively target the tumor 
cells still needs to be solved, however it is worthwhile to investigate this further. 
Conditionally replicating adenoviruses (CrAds)
Previously the development of replication deficient vectors is discussed. A 
disadvantage of these vectors is that after the initial infection no new progeny 
virus is produced. To overcome this hurdle conditional replication adenovirus 
vectors (CrAds) have been generated. Several strategies can be employed to 
generate these vectors such as genomic deletions or insertion of tissue-specific 
promoters.
 In most tumors, cell division is impaired and cell-division checkpoints are 
defective. Wild-type adenovirus will drive cells into S-phase to initiate replication. 
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This knowledge was used to construct adenovirus which replicate selective in 
tumor cells. Typical adjustments are modifications of genetic elements which 
are involved in driving cells into S-phase which results in a vector which can 
only replicate in transformed cells. The archetype of such a vector is HAdV-5 
dl1520, its commercial name is Onyx-015. In this vector the E1B-55k gene is 
disrupted [49]. A function of E1-55k is to inactivate p53. The cellular p53 is a 
tumor suppressor protein and defective in almost all tumors. This resulted in a 
vector which preferentially replicated and killed tumor cells although additional 
research showed that the mechanism of replication is more complex and does 
not solely rely on the p53 status [50,51]. Subsequently vectors containing 
deletions in the E1A-encoding sequence were generated. E1A is known to 
bind the retinoblastoma protein (Rb) family members, which are also tumor 
suppressor proteins. A 24-bp deletion in the E1A sequence impairs the binding to 
Rb. Therefore the vectors are not able to drive cells into S-phase and replication 
is inhibited in poorly dividing and quiescent cells [52] (reviewed in [25]). Both 
of these vectors are subjected to extensive clinical trial research. Results of 
these trials demonstrated a good safety profile and tumor-selective replication 
unfortunately the antitumor response was limited [25].
 Using the characteristics of tumor biology to generated tumor-specific 
vectors is one way. Another approach is to generate vectors in which essential 
viral genes are under control of a tissue or tumor-specific promoter. For 
example placing E1A region under transcriptional control of the tissue-specific 
glial fibrillary acidic protein (GFAP) promoter resulted in efficient and specific 
replication in malignant glioma cells in vitro and in vivo [53]. Disadvantages of 
this approaches are that the size of the tissue specific promoter is restricted and 
the occurrence of leakage of E1A regulatory functions resulting in non-specific 
replication. The last disadvantages can be solved by placing E1A in the reverse 
orientation, or by placing other essential viral genes under control of a specific 
promoter (reviewed in [25])
Modification of the exterior 
Effective treatment relies not only on effective oncolysis but also on effective 
infection of the target tumor. There are a number of factors inhibiting the infection 
of tumor cells, including infection of non-target CAR-expressing tissue, and the 
absence of CAR on the target tumor. But also rapid removal of the vector after 
intravenously administration is a major problem. Vectors in the blood stream 
will effectively transduce liver cells by binding to coagulation factor X (FX) and 
Kupffer cells. Furthermore the particles will be scavenged by other blood factors 
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or neutralized by the immune system. To increase the targeting of the tumor 
cell and reduce virus sequestering and to evade neutralization of the immune 
system different strategies have been developed to reduce these effects such as 
modification of the capsid proteins and shielding the particle. 
Retargeting of the vector
To overcome the issue of the absence of CAR on target cells the therapeutic 
adenovirus has been subjected to retargeting strategies. Most of these strategies 
resulted in an expanded tropism of the vector. Retargeting can be achieved 
by modifying capsid proteins. The main focus have been on fiber protein 
modifications since this is the major attachment protein. In this perspective 
three different strategies are described. First fibers have been swapped by fibers 
of other adenovirus serotypes but also synthetic fibers and fiber-like proteins of 
other viruses have been used to replace the wild-type fiber. Secondly, adenovirus 
have been subjected to studies replacing only the fiber knob and knob-shaft 
domains by knobs or knob-shafts of other serotypes. Finally, also the CAR-
binding sequences in the knob has been replaced by short peptide sequences 
such as the integrin-binding Arg-Gly-Asp (RGD)-motif. Other capsid proteins 
used for retargeting are hexon, penton base, and the minor capsid proteins 
IIIa and IX (reviewed in [25,54-56]). And although protein IX is the smallest 
capsid protein, the exposure at the exterior of the capsid and the abundant 
number in the capsid makes protein IX an interesting anchor for fusing targeting 
polypeptides [35]. It was shown that incorporation of peptide ligands on protein 
IX had no effect on the viral titers and stability of the virus [18]. Improvement 
of the presentation of the ligand was accomplished by inserting an alpha-helical 
spacer before the ligand [57]. In addition, a protein IX-producing helper cell line 
system have been developed for protein IX-pseudotyping as an alternative for 
genetic modification of the vector [58].
 A non-capsid modifying retargeting strategy for adenovirus delivery is the 
adaptor strategy. Bi-functional antibodies bridge between the vector and the 
target cell. The strategies is copied from the chemical anti-cancer delivery 
strategies and proved to be useful for adenovirus targeting [55]. Advantages of 
this strategy are that modification of the adenovirus genome is not necessary 
and high titer production, and purification protocols do not need to be adapted. 
But to guarantee clinical efficacy extensive test studies need to be performed 
since the therapy is dependent on two separate factors. The modification is lost 
after replication, just as by the capsid-protein pseudotyping. 
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Reduction of scavenging 
Most of the capsid modifications resulted in an altered tropism, but unfortunately 
scavenging by non-target tissue was not solved. It was only in 2008 that 
scavenging of adenovirus via coagulation FX was described [39,40]. Binding 
to FX mediates the uptake by hepatocytes in the liver. The adenovirus capsid 
protein responsible for binding to FX is hexon. Genetically modifications of the 
amino acids responsible for the binding resulted in a decreased liver transduction 
in vivo [59]. The prevention of sequestration by other blood factors, such as 
erythrocytes, neutralizing antibodies, and kupffer cells still needs to be solved. 
 Vectors can also be coated by polymers of taken up by carriers to shield them 
from scavenging factors. Shielding adenovirus particles increases the circulation 
in time in the blood stream and reduced liver toxicity in animal models. Polymer 
shielding of vectors have been taken from the drug carrier industry. Different 
polymers have been subjected of which polyethylene (PEG) and poly-[2-(2-
hydroxypropyl) methacrylamide] (pHPMA) are the most studied. The advantages 
of coating are that it occurs after the virus production and purification and 
retargeting to tumor-targets is relatively straight forward [60]. The counterpart 
of chemical shielding is biological shielding. Adenovirus particles can be “loaded” 
onto carrier cells. Loading can be achieved by infecting but also by attaching to 
the carrier cell, the main goal is that vectors are hidden from the blood stream. 
Important is that the cellular carriers deliver the load to the tumor-target. Tumor 
homing has been shown for immune cells such as dendritic-cells and T-cells, but 
also stem cells home to tumors. Studies with mesenchymal stromal cells have 
shown great promise but more research needs to be done [61,62] (reviewed 
in [25,55]). Both methods, the chemical shielding and the biological shielding, 
have as disadvantages that it shields only the vector for the first replication 
round. 
Increasing efficacy
Adenovirus vectors have been armed with therapeutic genes to increase the 
spread after the initial infection. These therapeutic genes can roughly divided in 
four groups, apoptosis inducers, gene repair mechanisms, immune modulators 
and angiogenesis inhibitor and prodrug-converting enzymes [25,63]. Probably 
the best known therapeutic gene is the suicide gene also called prodrug-converting 
enzyme thymidin3e-kinase of the herpes simplex virus (HSV-tk). The enzyme 
thymidine-kinase is of itself not toxic, but it can convert ganciclovir (GCV) into 
a toxic product. Expression of HSV-tk followed by GCV administration kills cells 
selectively [63,64]. A promising replication deficient adenovirus vector encoding 
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the HSV-tk gene is sitimagene ceradenovec or Cerepro® (Ark Therapeutics 
Group plc, UK and Finland). This vector was conducted in phase III clinical trials 
for the treatment of primary high grade gliomas [65]. Yet not approved, the 
committee for Medicinal Products for Human use (CHMP) reviewed the effect 
of Cerepro® of the phase III trials as not significantly effective. Furthermore, 
treatment was associated with increased risk of side effects such as paralysis and 
seizures. Therefore it was recommended that Ark Therapeutic need to conduct 
further clinical evaluation before the vector can be approved into the clinic [63].
Random modification
Most of the above described modifications strategies are based on in silico 
design of the vectors. Since there is so much knowledge about adenovirus and 
the current techniques available this was also the most obvious way to perform 
the research. Recently random modification approaches gained more interest 
in the oncolytic adenovirus field. Reports describing improved oncolytic vectors 
obtained by chemical virus treatment followed by bioselection on a target 
cell line obtained unexpected mutations [19,20,66]. Alternatively, directed 
evolution or making use of a sloppy-polymerase can be instrumental in genetic 
diversification.
 In chapter 5 the oncolytic efficiency of adenovirus mutant containing a point 
mutation in the i-leader sequence is investigated on glioblastoma cells. This 
point mutation was identified by Yan et al. [20]. They subjected adenovirus to 
a chemical treatment followed by selection for mutants on a human colorectal 
cancer cell line. The selected mutants, which replicated more rapidly, were 
subjected to detailed analyzes. Although two of the mutants contained several 
mutations the mutation in the i-leader region was shared. Further analysis 
confirmed that truncation of the i-leader region resulted in the enhanced 
oncolytic efficacy. Similarly, an i-leader mutant was isolated after UV-treatment 
and bioselection on epithelial cancer cell lines by Subramanian et al. [19]. 
This confirmed that truncation of the i-leader protein could be relevant for the 
development of oncolytic vectors. According a similar approach a vector with 
enhanced antitumor activity was isolated by Gros et al. This mutant contained a 
mutation in the E3/19K protein which enhanced the viral release and improved 
the anti-tumor efficacy [66]. 
 Very differently to the previous approach are the following modification 
strategies described. Kuhn et al. made us of the ‘directed evolution’ approach. 
First they pooled different adenovirus serotypes and passaged them under 
conditions that stimulated the rearrangements of the genes. After harvesting, 
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the progeny were subjected to stringent culture conditions which yielded potent 
anticancer vectors [67]. Alternatively, the strategy pursued by Uil et al. was to 
cripple the adenovirus polymerase, making it more error-prone, followed by 
adaptation of the vector to the target cell line [68]. This approach has a lot of 
similarities with the adaptation strategies performed with RNA viruses which 
naturally lack the polymerase proofreading resulting in a high mutation rate 
[69]. Also this strategy yielded a mutants with improved cytolytic activity. Also 
here the regions affected by the mutations were never considered or described 
during in silico vector design experiments.
 Altogether, this proves that the random mutagenesis approach, also called 
directed evolution, is a powerful strategy for isolating novel and improved 
oncolytic vectors.
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BIOLOGY
Mammalian reoviruses are members of the orthoreovirus genus of the family 
of Reoviridae. They were first isolated from the gastrointestinal and respiratory 
tracts of healthy and sick humans in the early 1950s (reviewed by [70]). The 
name reovirus is an acronym of Respiratory and Enteric Orphan virus. The 
term ‘orphan’ is used to indicate that no serious disease is linked to this virus 
in humans, given that a large proportion of the human population has been 
exposed to the virus and built neutralizing immunity to reoviruses [71,72]. The 
orthoreoviruses have a wide geographic distribution and are isolated from a 
broad range of mammals, birds and reptiles. Although in humans the mammalian 
orthoreoviruses are non-pathogenic, in newborn mice they can cause severe 
disease [73].
 The capsid of the orthoreovirus is a non-enveloped icosahedral structure 
composed of outer and inner protein shell. In 1963 it was discovered that the 
genome consists of double-stranded RNA (dsRNA) [74], and soon after it was 
found that the genome of mammalian orthoreoviruses consist of 10 distinct 
genome segments [75]. 
Taxonomy
To date three orthoreovirus species groups are recognized. In this manuscript 
we will focus on the mammalian orthoreoviruses. In this species group three 
serotype strains of mammalian orthoreoviruses have been identified, with the 
type 1 Lang (T1L), type 2 Jones (T2J), type 3 Abney (T3A) and type 3 Dearing 
(T3D) as the prototypical representatives. The serotypes are classified according 
to their neutralization by specific antibodies and by the classical hemagglutination 
inhibition assay [76,77]. Genomic variation between the serotypes is found 
for all segments. The S1 segments, coding for the σ1 attachment protein, has 
the largest sequence divergence. The sequence variations can have biological 
consequences [73]. It was observed by reassortment studies between T1L and 
T3D that the S1 segments define the pathology. While the serotypes T1L and 
T3D both infect the central nervous system (CNS) in new born mice, their routes 
of infection differ. T1L causes hydrocephalus by spreading hematogenously in 
the CNS by infecting ependymal cells. In contrast, T3D causes viral encephalitis 
by spreading via the neural routes in the CNS [78]. In this thesis we focus on 
T3D as oncolytic vector therefore the ‘term’ reovirus is limited to serotype T3D. 
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Genome segments and their proteins 
Structural proteins
The genome of the reovirus consists of 10 dsRNA segments with a total size of 
23.5 kb. The segments are named according to their sizes [75]. There are three 
large segments (L1, L2 and L3) ranging in size from 3854 to 3916 nt, three 
medium segments (M1, M2 and M3) with sizes between 2206 to 2304 nt, and 
four small segments (S1, S2, S3 and S4) varying from 1196 to 1416 nt [73,79] . 
Each segment encodes a single protein, with as a sole exception the S1 segment 
which encodes two proteins [80,81]. The proteins are named and numbered 
according to their apparent molecular weight on SDS-PAGE. The names are 
derived from the Greek character of the segment it was translated from, the 
L segments code for the λ proteins, the M segments code for the μ proteins, 
and the S segments encode the σ proteins. The numbering of the proteins does 
not always correspond to the genome size of the segment from which they are 
transcribed [73]. An overview of the segments, and the proteins that they code 
for is provided in table 3.1.
 The non-enveloped icosahedral outer capsid is about 70 nm in diameter. 
The inner capsid or core structure is about 52 nm in diameter. Together, these 
capsids are composed of eight structural proteins (figure 3.1). The five structural 
proteins forming the inner core structure are λ1, λ2, λ3, μ2 and σ2. The λ1 
protein is encoded by L3 segment and is a major structural protein of the inner 
capsid. This protein is involved in transcription. The λ2 protein is translated 
from L2 RNA and forms the pentameric turrets of the core structure. During 
primary transcription this protein adds a methylated cap structure to nascent 
plus-strand RNA (discussed below). The λ3 protein is encoded by L1 segment 
and functions as the RNA-dependent RNA polymerase (RdRp) and it transcribes 
the plus and the minus strands [82]. The exact function and location in the 
core of the μ2 protein, encoded by the M1 segment, is still unknown. However 
it has been suggested as a cofactor or second subunit of RdRp. The σ2 protein, 
encoded by the S2 segment, is involved in the assembly of the core particles. 
This protein decorates the λ1 shell (reviewed by [73,79]).
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Figure 3.1 Schematic representation of the mammalian orthoreovirus. The virus 
contains a non-enveloped icosahedral capsid, containing 10 dsRNA segments. These 
encode the structural proteins: five proteins comprise the inner capsid, and the three 
others form the outer capsid. The positions of the various capsid components are indicated. 
 The outer capsid is composed of three structural proteins. The two major 
outer-capsid constituents are σ3 and μ1 proteins. The third minor outer-capsid 
protein σ1 forms the spikes at the vertices of the icosahedron and functions 
as the attachment protein. The σ3 protein is encoded by the S4 segment and 
provides stability to the capsid and functions as a shield for μ1. Removal of σ3 
protein occurs through proteolytic cleavage upon entrance. The μ1 protein is 
encoded by the M2 segment and provides stability to the outer capsid. This 
protein is by proteolysis cleaved during viral entry to yield the μ1N and μ1C 
proteins. This is an important process during replication. Removal of σ3 and 
cleavage of μ1 yield a partially uncoated particle, the so-called intermediate 
subviral particles (ISVP). These ISVPs have the capacity to disrupt cellular 
membranes and may function in endosomal escape. Moreover, ISVPs generated 
in vitro by treatment of purified reovirus particles with chymotrypsin or in vivo 
in the lumen or small intestines by proteases, yields particles that retain their 
infectivity, and can enter the cell independent of the presence of the canonical 
reovirus receptor JAM-A (also known as junction adhesion molecule 1, or JAM-1) 
(reviewed by Coombs (2006) and Tyler and Fields (2001)).
 Trimers of σ1 proteins encoded by S1 segment form the spikes on the vertices 
of the icosahedral capsid (see representative figure at Viralzone, 2011 [83]). The 
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spikes contain a tail and a head domain and interacts with cellular receptors. 
Furthermore, the spike is anchored in the λ2 protein turret. Through removal of 
σ1 protein during virus entry, the λ2 turrets undergo a conformational change 
and becomes active. 
Non-structural proteins
At least three nonstructural proteins are generated during infection. The σ1NS 
is translated from the second open reading frame of the S1 mRNA. This is a 
nonessential protein which causes cell cycle arrest during infection [80,81]. The 
second nonstructural protein, σNS, is encoded by the S3 segment. This protein 
has a strong affinity with single stranded RNA (ssRNA) [84]. It is suggested that 
it plays a role in replication and assembly of core particles [85]. Furthermore it 
associates with μNS and μ2 to form inclusion domains or viral factories.
 The μNS protein is encoded by the M3 segment. It is the third nonstructural 
protein and associates with the viral mRNA shortly after transcription, and to viral 
cores, probably to anchor viral components needed for assembly or replication 
[86-89]. In addition, by proteolytic cleavage of μNS μNSC is generated. The 
precise function of this protein is unknown [73].
Replication 
Receptors
Wild-type reovirus T3D binding to target cells is a multistep attachment process 
[90]. Initially a low-affinity interaction is established with sialic acid residues 
on the cell surface via interactions with the tail of the spike. Sialic acids were 
the first molecules identified to bind reovirus T3D [91,92]. Subsequently, high-
affinity interactions can establish between the head domain of the spike and 
JAM-A. Campbell and colleagues defined that only JAM-A and not JAM-B or 
JAM-C can serve as a receptor for reovirus type 1, 2 and 3 [93,94]. Transient 
expression of JAM-A renders reovirus-resistant cells sensitive to infection [93]. 
Subsequently, Arg-Gly-Asp (RGD) domains in the λ2 protein bind β1-integrins 
on the cell surface and mediate particle entry by endocytosis [95,96]. 
Entry and uncoating
As for most RNA viruses, genome replication of reoviruses takes place in the 
cytoplasm, schematic represented in figure 3.2. First reoviruses are internalized 
into the endosomes. Upon acidification, the particles are partially uncoated, 
yielding so called ISVPs. The uncoating process includes removal and proteolytic 
cleavage of σ3 and μ1 and subsequent detachment of σ1 molecules. The 
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hydrophobic peptides of µ1 penetrate and locally disrupt the membrane initiating 
the escape of the activated particles from the endosomes [97]. Through removal 
of μ1 and σ1 the λ3 RdRp is activated and initiates transcription, yielding full-
length plus-strand RNA molecules. The conformational change of λ2 pentamers, 
through removal of σ1, turns them into channels for the release of plus-strand 
mRNA into the cytosol. In addition, the λ2 turrets add a methylated cap structure 
to the 5’ end of the plus-strand RNAs [98-100]. On these transcripts the 3’ end 
remains non-poly-adenylated. The methylated cap structure (7-methyl guanosine 
triphosphate (m7G(5’)ppp)) is identical to the cap structures of cellular mRNAs 
and is therefore recognized by the host ribosomes and translated. Initially 
the four segments L1, M3, S3 and S4 are transcribed and translated which 
stimulates subsequent transcription and translation of all segments [78,101-
103]. At this stage in the replication cycle translation of viral and host proteins 
occurs simultaneously. 
Figure 3.2 Schematic representation of the reovirus’ genome replication. After cell 
entry the viral particle is partially uncoated, and penetrates the endosomal-membrane. In 
the cytoplasm the primary transcription process yields capped plus-strand RNA molecules, 
which are translated and can associate with the newly assembled cores. In the cores these 
transcripts serve as templates for minus-strand synthesis yielding double-stranded RNA. 
Subsequently the secondary transcription process yields uncapped transcripts which are 
translated and associate with the new core particles. Minus-strand synthesis proceeds to 
yield double-stranded RNA genome segments. The particles mature and egress from the 
cells. In the figure only one of the genome segments is drawn.
Reovirus
39
3
 The assembly of new particles occurs in newly formed non-membranous 
structures in the cytoplasm, the so-called viral factories. These may aid in 
shielding the viral processes from the host cell’s components of the innate 
immune system. The plus-strand transcripts are incorporated into these new 
cores. Within the core-particles the minus-strand synthesis takes place to yield 
dsRNA [85,104]. In the newly formed core particles, a secondary round of plus-
strand synthesis initiates, yielding uncapped viral transcripts. The uncapped 
viral transcripts are translated very efficiently since the reoviruses employ a 
mechanism to modify the ribosomes in such a way that non-capped transcripts 
are preferentially translated. At this point the host cell protein synthesis is 
shutdown. This mechanism ensures that the host cell’s protein synthesising 
machinery is used for synthesis of viral proteins rather than for cellular proteins 
(reviewed in [79]).
Lytic infection 
Reoviruses normally cause a lytic infection in permissive host cells. The reovirus-
induced cell death is independent of productive infection. Exposure of cells to UV-
inactivated virus particles can still induce apoptosis. The primary determinants 
of reovirus induced-apoptosis are associated with the outer capsid protein µ1, 
although attachment of σ1 to the cell surface strongly enhances the apoptotic 
signal. The cleavage of the µ1 protein during internalisation is essential for 
the induction of apoptosis. If the disassembly of the viral particles is blocked 
by monoclonal antibodies against σ3 or µ1, apoptosis is not initiated. Also 
monoclonal antibodies against σ1 inhibit apoptosis; however the mechanism here 
is prevention of binding to the cells surface. Pro-apoptotic signals are generated 
by binding of the attachment protein to sialic acid and JAM-A. Reovirus mutants 
lacking the sialic acid binding capacity are still able to induce apoptosis albeit to 
a lesser extent [78,105-107]. 
Cis-acting sequences
Knowledge in the replicative cycle of reoviruses has been essential for the 
development of a reverse genetics system. The essential cis-acting sequences 
that reside in the genome segments need to be identified. Such sequences include 
the elements required for the initiation of plus and minus-strand synthesis, the 
sequences in the plus-strand RNA that function as segment-identity labels, and 
the sequences that are required for incorporating the plus strand RNA’s into the 
newly formed cores. Also it is crucial to identify other constraints that may limit 
the incorporation of heterologous sequences in reovirus genome segments. In 
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the following paragraphs we will describe the functional elements identified in 
reovirus genome segments.
Non-translated regions
The particle to infectious unit ratio of reoviruses is low [108], indicating that 
the assembly of new particles is effective and precise and the infection process 
is highly efficient. The encapsidation involves assembly of 8 structural proteins 
with one copy of each of the 10 segments. The precise sorting mechanism which 
directs one copy of each segment into the particle is not yet well understood. 
Sequences contained within the 130 nt at the 5’ terminus serve as identity 
label for each of the segments [109,110]. The termini of all segments contain 
relatively short (15-33 nt) non-translated region (NTR) with short (4-5 nt) 
identical sequences at the extreme ends. The 5’ end of the plus-strand RNA 
starts with the tetranucleotide sequence GCUA- and the sequence at the 3’ end 
is a pentanucleotide –UCAUC. No other sequence homology exists in the NTR 
regions of the segment termini [104,111,112].
Assortment of the segments 
The first indications that the 5’ and 3’ ends of the segments are important for 
replication and assembly stem from work by Schlesinger et al. (1977), and later 
by Zou and Brown (1992). In these studies deletion mutants were used. These 
deletions mutants were formed spontaneously when T3D was passaged at a high 
multiplicity of infection and contained deletions in the middle of the segments. 
The deleted segments were replicated and encapsidated in new particles 
although the presence of helper virus was required. It led to the hypothesis that 
sequences near the 3’ end are necessary to function as promoter for the RdRp 
and that the termini are needed for the assembly of new particles [113,114].
By employing a reverse genetics system for inserting a chloramphenicol acetyl 
transferase (CAT) reporter gene in different genome segments (discussed below) 
more information on the required cis-acting sequences at the 5’ and 3’ ends was 
obtained [115]. From three segments, e.g. S2, M1 and L1, the regions which 
are important for assembly have been determined. The lengths of these regions 
were identified through varying the length of the 5’ and 3’ ends and measuring 
the CAT activity of the progeny virus. The lengths of the elements required for 
encapsidation correlated with the lengths of the genome segments. L1 required 
the longest 5’ and 3’ regions (i.e. respectively 129 nt and 139 nt) while S2 
needed the shortest regions, at the 5’ end 96 nt and at the 3’ end 98 nt. The 
M1 segment required at the 5’ end 124 nt and 172 nt at the 3’ end [109,110]. 
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These results indicate that the cis-acting sequences do not only encompass the 
non-translated regions, but extend into the coding regions of the segments. 
Furthermore, Roner et al., in 2004 and 2006, demonstrated that the signals 
at the 5’ end act independently from the signal at the 3’ end. In the process 
the signals at the 5’ end function as the segment-identity labels. This became 
apparent from the observation that chimeric segments, containing the 5’ end of 
S2 or M1 and the 3’ end of L1 are incorporated as S2 or M1 segments, not as a 
L1 segment [104,116].
Genome-size constraints
The genome of the mammalian reoviruses is packaged within the 52 nm inner 
core. In comparison to other RNA viruses, reoviruses have one of the most 
densely packaged genomes [110]. Experiments of the group of Roner and 
colleagues indicate that the maximum amount of RNA that can be included into 
the core is almost reached. They showed with their reverse genetics system that 
upon increasing the length of L1 with 726 nt this segment was still incorporated. 
However, when creating chimeric segments with the 5’ end of M1 or S2 and 
the 3’ end of L1, and increasing the size of the resulting segments by 2307 
nt or 2500 nt respectively, full incorporation of these segments was inhibited. 
The modified 5’-L1.CAT.3’-S2, 5’-M1.CAT.3’-S2 and 5’-S2.CAT.3’-L1 segments, 
in which the sizes were decreased by approximately 980 bp, were still packaged 
[110]. These data suggest that there are limitations to the packaging capacity 
of reoviruses. Such limitations are important if one considers developing 
heterologous transgene-containing reoviruses.
GENETIC MODIFICATION 
In virology, reverse genetics has been extremely useful for delineating 
the functions of individual viral genes. More recently, reverse genetics have 
allowed rational design of improved viruses for use in clinical applications such 
as vaccination and experimental oncolytic-virus therapy. In Reoviridae, the 
development of reverse-genetic strategies has been thwarted by their segmented 
double-stranded RNA genomes. Therefore, much of the knowledge on reovirus 
biology has been derived from the studies involving the more classical forward-
genetics techniques. The latter studies employed reassortants, chemical-induced 
mutagenesis and spontaneous mutants, as well as bioselection strategies. In 
these studies, the mammalian orthoreoviruses have often served as a model for 
the family. While these approaches have been extremely rewarding and yielded 
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a wealth of information, efficient reverse genetics techniques are still needed 
for further identification of segment functions and for improving the reovirus 
based oncolytic virus therapies. Several groups have reported the generation 
of genetically modified human reoviruses by reverse genetics. In this section 
we will review the systems used, and discuss the strengths and weaknesses of 
each of these. 
Forward-genetics in orthoreoviruses 
In forward-genetics studies aberrant phenotypes are isolated followed by the 
identification of the mutation responsible for this phenotype. One of the strategies 
used most commonly was the selection of temperature-sensitive mutants after 
chemical mutagenesis. This method was often used in combination with the use of 
reassortants. A third strategy discussed here is the selection of natural mutants. 
Temperature-sensitive mutants
The initial isolation of many reovirus temperature sensitive (ts) mutants was 
after chemical mutagenesis of reovirus stocks. The mutated reoviruses were 
plated and propagated at a low permissive temperature (usually 32°C), yielding 
virus which could efficiently replicate at this temperature. Subsequently, clones 
were isolated that exhibited an impaired growth at a higher temperature (often 
39°C was used).
 With this strategy large series of mutants with aberrant phenotypes have 
been generated, and designated as ts mutants. These ts mutants were classified 
in complementation groups on basis of the absence of complementation between 
pairs of ts mutants. Subsequently these complementation groups could be 
assigned to the different genome segments of the reovirus (reviewed by [79]). 
A summary of the different groups and the segments to which they have been 
mapped is provided in table 3.1. 
 The phenotypes of these mutants have been instrumental in defining the 
roles of the individual viral proteins in the infectious pathways of the human 
reoviruses [79]. 
Reassortants 
In addition to ts mutants, reassortment strategies were applied. The reassortants 
can arise during co-infections of cells with two different ts mutants or between 
different orthoreovirus serotypes. Co-infection can lead to exchange of entire 
genome segments between the viruses. During co-infection, a reassorted 
genome can be detected in up to 15 % of the progeny viruses [117].
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Natural selection/bioselection 
A third forward-genetics strategy is the isolation of spontaneous mutants and 
naturally occurring reoviruses [118,119]. The absence of proofreading in the 
reoviral RdRp leads to a high mutation rate [120]. This leads to rapid adaptation 
of the reoviruses and the selective outgrowth of mutants that have favorably 
adapted to the host [69,121]. 
What did we learn?  
A key role of σ1 in cell binding
Since the early sixties it was well established that Reovirus T3D, but not T1L, 
could hemagglutinate bovine erythrocytes [122]. Reassortment studies identified 
σ1 protein as haemagglutinin. In these studies T1L x T3D reassortants were 
generated and by using serotype-specific σ1 antisera it was demonstrated that 
the capacity to haemagglutinate the bovine erythrocytes was strictly correlated 
with the presence of the σ1 protein of T3D [76,77,123,124]. Further studies 
using these reassortants and serotype specific sera pinpointed σ1 also as the 
protein responsible for infection of permissive nucleated cells [125]. 
Sialic acids play an important role
Attachment studies of the T3D virus to different cell types (erythrocytes, L 
cells, lymphocytes and murine erythroleukaemia (MEL) cells) made clear that 
haemagglutination (HA) in erythrocytes is caused by binding to terminal sialic 
acids of glycoproteins on the cell surface [122,126-129]. Sialic acid is a generic 
term for the N- or O-substituted derivatives of neuraminic acid and also the 
name of the most common neuraminic acid, the terminal N-acetylneuraminic 
acid (NeuAc). With S1 reassorted viruses of T3D and T1L (reassortants T1L+S1-
T3D (1HA3) and T3D+S1-T1L (3HA1)) it was demonstrated that reovirus 
attachment to sialylated oligosaccharides on glycoproteins was solely mediated 
by the σ1 attachment protein [130].
 The σ1 protein is present as a homo-trimer [131,132] at the vertices of the 
viral particle. It has a distinct ‘head’ and ‘tail’ region [133,134]. The domains 
that interact with cellular receptors have been identified. The knowledge of the 
interaction of the σ1 protein with cellular sialic acids was derived from studies 
employing reovirus T3D field isolates that differ in their capacity to agglutinate 
human and bovine erythrocytes and to bind sialic acids. Sequence analyses of 
the S1 genes of the different virus isolates revealed single point mutations that 
only cause weak haemagglutination and which are unable to bind sialic acids. 
These mutations all cluster in one region in the σ1 tail, residue 198-204, which 
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demonstrated that not only the head but also the tail region of the spike is 
exposed on the capsid in such a way that it can interact with cellular receptors 
[135]. 
 The phenomenon that only T3D and 1HA3 and not T1L viruses could infect 
MEL cells was exploited in studies that mapped the sialic-acid binding-domain 
of σ1. The capacity of the viruses to infect MEL cells is strictly correlated with 
the viruses’ capacity to haemagglutinate erythrocytes. This suggested sialylated 
proteins to be involved in MEL cell binding [136]. To further identify the receptor 
binding region of the σ1 tail, reovirus type 3 field isolates which were unable to 
bind sialic acids were adapted by serial passaging to grow in MEL cells. Sequence 
analyses of these MEL adapted (MA) viruses revealed point mutations that were 
clustered near the residues 198-204 that had previously been identified as the 
sialic acid binding region of the σ1 tail. These data demonstrated that this part 
of the tail of the spike is involved in sialic-acids binding [118].
 Similarly, T3D reoviruses were selected for growth in the presence of a 
monoclonal antibody that inhibited haemagglutination. This selection yielded 
mutants that exhibit a strongly reduced neurovirulence upon inoculation of 
newborn mice [119]. These data demonstrate the relative ease with which 
reovirus mutants can be obtained by conventional forward genetics strategies. 
Junction adhesion molecule-A is essential
JAM-A, the canonical reovirus receptor, is a 25kDa type I transmembrane protein 
with two extracellular Ig domains (D1 and D2) and a short cytoplasmic tail. 
The protein is concentrated at the apical region of intercellular tight junctions 
of epithelial and endothelial cells (for reviews [137-139]). And the membrane 
distal extracellular domain (D1) forms a homodimer [137]. 
 Structure-guided mutational analysis revealed three amino acids located in 
the D1 domain of JAM-A which are individually required to bind σ1. The amino 
acids Glu61 and Lys63 participate in salt bridges with opposing amino acids and 
thereby have a role in stabilization of the D1 dimer. The amino acid Leu72 is part 
of a hydrophobic interaction with a residue of the opposing dimer [95]. Since 
all amino acids required for binding σ1 were located in the dimeric interface 
of the D1 domain, it was reasoned that σ1 first disrupts the JAM-A dimer and 
then binds to the monomeric form of the D1 domain. Binding studies indeed 
showed that the binding affinity between σ1 and the monomeric form of the 
D1 domain is higher than between the JAM-A homodimers. In addition using 
cryocrystallography it was clearly demonstrated that only monomers of JAM-A 
were bound by σ1 [140]. Insight in the amino acid residues important for 
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binding JAM-A was obtained by using the helper-free reverse-genetics system 
(see below) [141]. The engineered reoviruses with mutant forms of σ1 revealed 
that the JAM-A binding domain is located at the lower part of the head domain. 
Moreover, one reovirus σ1 molecule can bind three JAM-A monomers [140] 
(Picture of JAM in [95] and JAM-σ1 interaction in [140]). 
 The knowledge of reovirus T3D binding to its cellular receptors culminated 
in a multi-step binding model in which attachment protein σ1 first engages 
sialic acids on the cell surface in a low-affinity interaction and subsequently 
binds JAM-A with high affinity [141,142]. The virion is internalized via clathrin-
mediated endocytosis upon interaction between β1-integrins on the cell surface 
with the capsid protein λ2 [96]. This has been suggested since λ2 contains the 
integrin binding sequences Arg-Gly-Asp (RGD) [96]. Furthermore, β1 integrins 
contain a cytoplasmic domain containing two Asn-Pro-any amino acid-Tyr (NPXY) 
motifs which are required for functional reovirus entry [143].
Persistent infection
Rather than causing a lytic infection, the T3D reovirus can establish a persistent 
infection. The initial observations stem from experimental infections of cultured 
human embryonic cells [144]. Infectious virus could be recovered from the 
cultures after 9-12 passages without appearance of overt cytopathic effects. 
 Taber and colleagues (1976) isolated a culture of persistently infected 
CHO cells. In these cultures a large number of cells were infected, and the 
cultures produced reoviruses that were cytopathic for the parental CHO cell 
line [145]. This suggests that the persistently infected cell lines adapted to 
resist the reovirus-induced cytopathic effects. Ahmed and coworkers (1981) 
demonstrated in an L-cell system that the persistently infected cells as well as 
the reoviruses propagated in the persistently infected cultures acquire changes 
and thus eventually differs from the parental virus and host cells. The L cells 
cured from the persistent infection had an increased resistance to wild-type T3D 
viruses, suggesting that the cells adapted by genetic or epigenetic mechanisms, 
leading to increased virus resistance [146]. More recently it was demonstrated 
that persistently infected cells express reduced amounts of the cathepsins B and 
L, which are known to be involved in reovirus uncoating [147-149] . These data 
suggest a co-evolution of host and virus to eventually reach a state of a stable 
but dynamic equilibrium. 
 Persistently infected L-cell cultures obtained after co-infections with T2J, which 
does not result in persistent infections, together with T3D, which is able to give 
persistent infections, yielded various hybrid recombinant mutants containing all 
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the S4 segment of T3D. This suggested that sequences in this segment underlie 
the capacity of the virus to establish a latent infection [150]. Via a similar approach 
the capacity of human reoviruses to inhibit host cell RNA and protein synthesis 
was also been mapped to the S4 segment [151]. Taken together, these data 
imply that persistent infection can only exist if the host cells retain the capacity 
to synthesize proteins. Strong inhibition, as is the case upon infection with T2J, 
would be incompatible with such persistence. Furthermore, sequence analyses 
of the persistent infections demonstrated acquisition of additional mutations 
in the S4 segment and an increased resistance to ammonium chloride, a weak 
base that inhibits the pH decrease in endosomes and lysosomes. This again 
suggests that the viruses adapted to selective pressure operating at the level of 
cell entry. 
 In addition to alterations in S4, sequence analyses of the viruses causing 
persistent infection also revealed mutations in the S1 segment, encoding 
the spike protein [150,152-154]. The σ1 protein is known to be involved in 
the induction of apoptosis in reovirus infected cells [78]. Isolation of an S1 
attenuated reovirus mutant form from persistently infected cells, revealed that 
although virus replication was maintained the apoptotic potential was reduced. 
Sequence analysis revealed that the most significant mutation was a nonsense 
mutation which truncated the σ1 protein, however it could not be ruled out that 
other mutations in S1 and S4 too are involved in this phenomenon [152]. It 
would therefore be interesting to test whether the mutations found in the S1 
segments of the persistently infected viruses affect the capacity of σ1 to bind 
sialylated proteins and to induce apoptosis [155,156].
 In the preceding section the conventional forward-genetics strategies have 
been discussed as well as some of their applications. Although they have been 
instrumental for determining the functions of the different segments, these 
techniques have their limitations. No directed mutations can be introduced. 
Therefore, reverse genetics systems have been developed, facilitating not only 
new studies into the functions of individual reovirus proteins, as well as the 
development of new reoviruses for use as oncolytic agents. 
Reverse-genetics in orthoreoviruses
So far development of reverse genetic systems for reoviruses has been 
notoriously difficult. Although in 1982 the cDNAs of all the genome segments 
had been cloned for the purpose of sequencing [157], the first reverse genetics 
system was only described in 1990 [158]. Genetically modified particles were 
generated with the aid of helper reoviruses. In 2007 the first helper-free system 
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was described [141]. To date, three different systems have been developed 
which have all their merits and weaknesses. 
The Infectious-RNA system 
The first method for reverse genetics in reovirus T3D employs RNA transfections 
of all the 10 genome segments, a cell-free translation system, and helper 
reoviruses [158].
 Active core structures, generated by in vitro disassembly of reoviral particles, 
were used for transcription of plus-strand RNA’s in vitro. The RNA transcripts 
were translated using a rabbit reticulocyte lysates (RRL) system. While this step 
was not essential, it increased the efficiency by 2-3 orders of magnitude. The 
newly translated viral proteins, together with dsRNA, and ssRNA, were introduced 
into mouse L fibroblasts by lipofection. Usage of only ssRNA or dsRNA in this 
mixture is possible but less efficient. A few hrs later the helper virus, which can 
be either serotype 1 or serotype 2, is added to the cultures. Between 24 to 48 
hrs post infection, virus can be harvested. Either plaque purification, or the use 
of serotype-specific neutralizing antisera, was required to eliminate the helper-
viruses [158,159].
 This technique was used to generate a compound ts mutant. Two ts mutants 
were chosen both of which contain a ts mutation albeit on different genome 
segments (genome segment M2 coding for μ1 and segment S2 encoding σ2). 
These segments were jointly incorporated in progeny virions generating the 
compound double ts mutant. Creating these double ts mutant required removal 
of the corresponding wild-type segments from transfected RNA pool. This can 
be accomplished by sequence-specific degradation of the wild-type segments 
through addition of complementary oligonucleotides and RNase H treatment. 
This enzyme degrades the RNA-strand in complementary DNA/RNA duplexes. 
Analysis of the double mutant showed that the ts phenotype was enhanced 
compared to the parental single ts mutants. Furthermore, exposure of mice 
revealed that the double ts mutant was less pathogenic than the parental 
viruses, while protective neutralizing immunity was still induced [160].
Transgene-containing reoviruses
The first example of the introduction of a heterologous transgene gene in 
the reovirus genome was described by Roner and Joklik in 2001. To this end 
the infectious RNA-system was used. In this experiment the S2 segment was 
replaced by an S2 segment modified to include the chloramphenicol acetyl 
transferase (CAT) gene, as a reporter. The coding sequence of the CAT gene is 
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smaller than the coding sequence of σ2 (753 nt versus 1331 nt, respectively), 
and its activity can be easily monitored in cell lysates [115].
 The CAT gene was placed in-frame in the S2 open reading frame. The total 
lengths of the S2 sequences flanking the CAT gene were 198 nt at the 5’ end and 
284 nt at the 3’ end. The modification inactivated the σ2 open reading frame. 
Therefore all experiments were performed in helper cells that expressed an intact 
copy of S2 to trans-complement the missing σ2 protein. To generate infectious 
virus with the modified S2 gene, the wild-type S2 was removed from viral RNA 
preparation by addition of an oligodeoxyribonucleotide complementary to the 
S2-transcript and RNase-H treatment. To provide the modified S2 transcripts, 
the capped S2-CAT RNA was generated by transcribing a cloned version of this 
S2-CAT segment by T7 RNA polymerase. After removal of the wild-type S2 RNA 
and addition of capped S2-CAT RNA the mixture was lipofected into helper cells, 
yielding reoviruses carrying the CAT gene in their S2 segment.
 This system was used to identify the regions that are essential for replication 
and packaging of the segments. These regions were mapped at the segment 
termini. In an experiment in which the CAT gene was inserted between the 
5´ terminal end of the L1 segment and 3´ terminal of the S2 segment, the 
CAT containing segment was found to replace the L1 segment, but not the 
S2 segment. Similarly, a chimeric 5´-S2.CAT.L1-3´ segment and a 5´-M1.CAT.
L1-3´ replace the S2 and M1 segments, respectively. These data indicate that 
the 5´ terminus determines the segment identity in the segment assortment. 
Moreover the 5’ and 3’ termini act independently [110]. 
 In similar studies, the size constraints were established for packaging and 
replication as discussed in genome-size constraints. These data show that 
although the size of the segments can be increased by inserting heterologous 
sequences, the capacity is limited [110]. 
 The infectious-RNA method has been effectively used to engineer alterations 
in the reovirus genome. However, the method is technically demanding. The 
RNase H procedure is not fully efficient, resulting in the presence of residual RNA 
of the targeted segment, and appearance of viruses with wild-type segments. In 
addition, the requirement of helper viruses during the generation of the modified 
viruses is undesirable. The helper virus may yield the formation of reassortants 
between the ‘helper’ viruses and the generated virus, although the use of T2J as 
helper reduces the magnitude of the problem [159]. Despite these weaknesses, 
the results obtained with this system have been extremely informative. 
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The segment-replacement technique
Van den Wollenberg et al. recently described an alternative approach for 
generating genetically modified reoviruses (chapter 6). In an effort to modify the 
σ1 spike, an S1 segment was generated encoding a σ1 that harbors a C-terminal 
histidine-tag. The presence of this tag would allow particles to infect JAM-A-
negative cells that express on their surface a single-chain antibody recognizing 
the His-tag, as an artificial receptor [161]. 
 This strategy was based on experiments by Rouault and Lemay [162]. These 
authors expressed modified versions σ1, μ1, and σ3 and used these proteins 
to recoat reovirus ISVPs and cores in vitro [163-165] to study reovirus capsid 
protein structures and functions. In a proof of principle study a foreign eipitope, 
viz. a hexa-histidine tag, was added to the amino terminus of σ3 [162]. For 
recoating, purified wild-type virions were treated with chymotrypsin to generate 
ISVPs. The ISVPs were incubated with cellular extracts that contain mutant 
σ3 proteins. Free σ3 proteins were removed from the recoated ISVPs and by 
immunoblotting procedure the modified σ3 on the recoated ISVPs could be 
detected. While this strategy can be used to introduce modified proteins in the 
capsid, the modification will not persist upon replication since the viral genome 
is not modified.
 Van den Wollenberg et al. produced particles with modified proteins 
incorporated in their capsid by propagating reoviruses on helper cell lines 
that synthesize modified reoviral proteins. These modified proteins would be 
incorporated in the capsid during replication of the reovirus. In a first series of 
experiments reoviruses were propagated on modified cells that express a S1 
segment that included a His-tag at the carboxyl terminus of the σ1-encoding 
open reading frame. It was anticipated that the viruses harvested from these 
cells would carry the σ1-His in their capsid, but would not carry the modified 
S1-His segment. However, the authors noted that propagation of wild-type 
reoviruses on cells expressing the σ1His-encoding segment as a conventional 
RNA polymerase II transcript led to frequent replacement of the wild-type 
genome segment with the modified version. The resulting viruses could be 
serially passaged on JAM-A-deficient U118MG cells that were modified to express 
the single-chain Fv capable of binding a His-tag. Hence, this technique allowed 
generating reoviruses that are genetically retargeted. It also demonstrates 
that the C-terminus of the σ1 protein is a suitable location for the insertion of 
oligopeptide ligands and shows that it is possible to use genetic modification to 
retarget the infection of reoviruses [161].
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 The precise mechanism by which the modified segment is incorporated is still 
unclear. Two mechanisms could be envisaged. In a first mechanism, the RNA-
polymerase II transcript that contains the modified S1 segment, associates with 
newly formed core particle despite the presence of the long 3’ extension and a 
poly-A tail. In the core particle the minus-strand synthesis would start even with 
the 3’ extension and poly-A tail. This would yield a partially double-stranded 
RNA copy of the polymerase II transcript. If this dsRNA copy serves as template 
for secondary plus-strand synthesis, new plus strands would be generated that 
harbor the modified σ1 open reading frame, but are otherwise identical to the 
wild-type S1 segment. Alternatively, one could anticipate a mechanism that 
would involve RNA recombination or a template switch during replication of the 
reovirus genomes. Future studies will aim at resolving the mechanism for the 
replacement of genetic information.
 The segment-replacement system is relatively straightforward, as it is based 
on the selective advantage for the modified σ1 over the wild-type σ1. The 
selection is essential for selectively expanding the viruses that have the wild-
type genome segment replaced by the modified version. Unfortunately, this 
method is thwarted by the fact that, with a low frequency, mutants arise in 
these cultures that have the capacity to infect the U118MG cells independent of 
JAM-A and the His-tag-specific scFV. This leads to the occurrence of replicating 
reoviruses that do not carry the desired mutation. Therefore plaque purification 
and screening is important to characterize and purify the desired mutants. 
A helper-free reverse-genetics systems
A fully helper-free system for reverse genetics was described by Kobayashi and 
colleagues. It employs 10 different plasmids, each containing a single cloned 
genome segment. The method starts with infection of susceptible cells with an 
attenuated vaccinia virus expressing the T7 RNA polymerase, and is followed 
by naked-DNA transfection of the 10 plasmids encoding each of the genome 
segments. The genome segments are inserted in the plasmid as full-length cDNA 
clones derived from the wild-type T3D. These cloned segments are inserted 
downstream of a bacteriophage T7 promoter. The 3’ terminus of each cloned 
segment was fused to the hepatitis delta virus (HDV) ribozyme, which generates 
native 3’ ends without poly-A tail by self-cleavage of the RNA transcript, and by a 
T7-termintor sequence. The attenuated vaccinia virus is replication-deficient and 
serves to express the T7 RNA polymerase at high level. The supernatants of the 
transfected cultures were plaque assayed on L-cells and replication-competent 
viruses could be isolated. The method is robust and productive, viral infection 
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could be established in approximately 1 in 105–106 cells transfected. This 
system was validated to confirm that a single amino acid change in σ1 conferred 
resistance of σ1 to trypsin cleavage, and that a single amino acid change in 
σ3 accelerates proteolytic disassembly of the reovirus. Furthermore, with this 
system the functional domains in μ1 responsible for the induction of reovirus 
apoptosis in host cells could be mapped [106,166]. Introduction of the enhanced 
green fluorescent protein (eGFP) gene into the S4 segment demonstrated that 
the technology allowed the incorporation of heterologous transgenes into the 
reovirus genome. Since this virus lacks a normal S4 segment, the σ3 encoded 
by S4 needs to be provided in trans. Therefore the T3D/S4-GFP virus could only 
be propagated in cells genetically modified to produce the σ3 protein [141].
Taken together, these data show that this helper-free reverse genetics method 
can be used for generating viruses with single amino-acid changes as well as for 
generating viruses carrying heterologous transgenes. 
 The advantage in comparison of the two other systems is that there is 
no requirement for helper viruses. The system is easily amendable for the 
introduction of various kinds of mutations. However, the efficiency may need 
further improvement since it is estimated that about 1 in 105-106 transfected cells 
can establish viral progeny. As a first step of improvement, instead of inserting 
the genome segments in 10 separated plasmids, the system has been amended 
to four plasmids including all the 10 segments. Each plasmid contains the cDNAs 
of two or four of the reovirus genome segments. In these plasmids each of the 
cloned genome segments is preceded by the T7 promoter, and succeeded by 
the HDV ribozyme and T7 terminator sequences. Furthermore, instead of using 
the attenuated vaccinia virus, BHK cells stably expressing the T7 polymerase 
under control of cytomegalovirus promoter can be used, further simplifying the 
technology [167]. With these improvements, the reverse genetics system is 
more effective in generating progeny virus. 
Rotavirus
Rotaviruses are classified in a separate genus of the Reoviridae. Unlike the 
mammalian orthoreoviruses, the human rotaviruses are very pathogenic, 
causing severe diarrhoea, especially in young children [168]. It is a major health 
problem, particularly in developing countries [169]. At this moment attenuated 
live virus is used as vaccine [170]. The development of a reverse genetics 
system would allow gaining more knowledge about the biology of rotaviruses.
 Rotaviruses are very similar to the mammalian orthoreoviruses. They 
contain 11 dsRNA genome segments encoding 13 proteins, and they have a 
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non-enveloped three-layer icosahedral capsid structure [171]. Although they 
resemble reovirus, the development of a reverse genetics system is even more 
difficult.
 So far attempts to generate a plasmid-based reverse genetics system have 
remained unsuccessful. A first reverse-genetics system was described in 2006 
by Komoto et al. [172]. These authors managed to replace the spike-encoding 
segment of a human rotavirus by that of a simian homologue. The system 
employed resembles the segment-replacement technique described above, 
except the cDNA of the simian spike-encoding segment was flanked by a T7 
promoter and the HDV ribozyme. Infection of a vaccinia virus vector expressing 
T7 polymerase was required to provide the T7 polymerase. Selection of the 
modified virus employed neutralizing antibodies against the human spike-
protein, selectively enriching the virus population for the viruses containing 
the simian spike-protein [172]. So far this method relied on a high selective 
pressure for the modified rotavirus which limits the application of the technique.
 More recently, Troupin et al. describe a modified version of the Komoto 
method to generate a recombinant rotavirus carrying an artificially rearranged 
rotavirus segment 7, coding for non-structural protein 3 (NSP3) [173]. Their 
method is based on the observation that rearranged segments 7 and 11 are 
preferentially packaged [174]. The usefulness of this system is under debate 
[175], since it requires extended passaging at a high multiplicity of infection to 
recover the recombinant virus. 
 The latest development on rotavirus reverse genetics is based on the 
method of Komoto et al. together with a dual selection mechanism [175]. Trask 
et al. combined a ts mutation of non-structural protein 2 (NSP2), with RNAi-
mediated degradation of NSP2 transcripts to select for a recombinant rotavirus 
evading both mechanisms, ts and RNAi degradation. Therefore, the recombinant 
segment 8 cDNA, coding for NSP2, was modified to contain silent mutations 
in the region targeted by the RNAi to avoid degradation. The combination of 
the ts helper virus with the RNAi-mediated selection significantly improved the 
recovery of the recombinant rotavirus. An analysis demonstrated that eight of 
eight rotavirus isolates contained the recombinant segment 8.
 This “two-hit” method may enhance the efficiency of recombinant virus 
recovery. One limitation for this system is the requirement for gene-specific 
RNAi, which may not equally effective for all the 11 segments of the rotavirus. 
 So far, reverse genetic systems for introduction a foreign gene in rotaviruses 
have not been reported.
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Concluding remarks
To date, several reverse-genetics systems have been described for manipulation 
of mammalian orthoreovirus genomes. These systems have already proven their 
effectiveness and were used to reveal new viral functions and facilitated the 
introduction of modified genome segments. Nevertheless, the robustness of these 
techniques should be further improved to make them more widely applicable. 
Some of these systems require selection methods to enrich the mutant viruses. 
The developments of genetically modified variants should be accompanied by 
the parallel development of procedures to make the mutant reoviruses a safe 
pharmaceutical product. This requires manufacturing processes that prevent 
reversion of the mutants to wild-type viruses. To ensure that the mutations 
are retained during the prolonged passaging that is required for production 
of large clinical-grade batches, the production systems should be developed 
in parallel. Such systems must provide a continued positive-selection pressure 
for the presence of mutations or modifications. Only if the development of 
reverse genetics systems goes hand in hand with the development of dedicated 
production systems, the new technology can be employed to generate improved 
mammalian orthoreoviruses for clinical application. 
REOVIRUS AS ONCOLYTIC AGENT
The human reovirus Type 3 Dearing is an interesting candidate for oncolytic 
virotherapy because of its well documented inherent preference for replication 
in transformed cells. Reovirus type 3 was isolated from the intestinal tract from 
an apparently health individual. Serology demonstrates that most humans 
are exposed to human reoviruses before that age of 5, presumably with an 
asymptomatic infection [73,176]. The impetus for the use of human reovirus 
T3D as an oncolytic agent has been the observation that although reovirus 
T3D is non-pathogenic, it preferentially lyses tumor cells, especially those 
with an activated Ras signaling pathway. The human reovirus’ preference for 
replication in transformed cells has been much studied [176]. A hallmark study 
was published by Patrick Lee’s group which showed that activation of the Ras 
signaling pathway can sensitize cells to reovirus replication [177]. This study 
revealed the essential role of the double-stranded-RNA-dependent protein 
kinase (PKR). In normal cells, the double-stranded reovirus RNA activates a PKR 
response and leads to PKR phosphorylation. This triggers phosphorylation of 
eukaryotic initiation factor 2a, which in turn, inhibits translation of mRNA. Strong 
and coworkers demonstrated that Ras signaling inhibits PKR phosphorylation, 
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allowing translation of the reovirus plus-strand RNAs [177]. Further studies 
implicated the Ras/RalGEF/p38 signaling in the regulation of reovirus replication 
and cytolysis [178]. These data offered an explanation for the reovirus’ 
preferential cytolytic effects on transformed cells. This renewed the interest 
in the use of reovirus as oncolytic agents. Already in 1978, Theiss, Stoner and 
Kniazeff reported that infusion of reovirus type 3 into the lungs of mice reduced 
the progression of chemically induced pulmonary adenomas, and that multiple 
infusions enhanced the antitumor effect [179]. More elaborate studies confirmed 
the feasibility of reovirus based cancer therapeutics [180,181], and boosted the 
interest in developing reoviruses as an oncolytic agent [182], as is evident from 
an increase in the number of publications on this topic figure 3.3. In Canada, the 
company Oncolytics Biotech, Inc. was founded, which is committed to exploring 
the oncolytic capability of reovirus as oncolytic agent [183]. 
Figure 3.3 Cumulative number of entries found in PubMed using (reovirus AND 
oncoly*) as search term. The Y axis represents the number of entries with a publication 
date before January 1st of the indicated year. The diamonds and the solid line represent 
the total number of publications and the circles and dashed line indicated the number of 
reviews on this topic. Note that approximately 30% of the publications represent review 
papers. Data gathered on August 25, 2009.
 The relationship between Ras signaling and reovirus replication has been 
much debated [184-186]. The PKR relation should not be taken too dogmatically 
as also other steps in the replication cycle may determine the cell’s susceptibility 
to reovirus-mediated cytolysis. Kranenburg and collaborators demonstrated that 
activation of the Ras pathway sensitized the cells to reovirus-induced apoptosis, 
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both in mouse [187] and in human tumor models [188]. However, virus yield 
was not affected by ras status. Reovirus T3D was strongly cytopathogenic in 
cells with activated Kras, but not in cells in which the Kras gene was inactivated. 
Similarly, viral uncoating is critical in determining the cells sensitivity to 
reovirus infection. Efficient uncoating is dependent on cellular proteases, such 
as cathepsin B and L. The expression of these proteases is often upregulated 
in tumor cells [189,190]. Conversely, down regulation of cathepsin L leads to 
reovirus resistance as this thwarts reovirus disassembly [149]. Also late events 
in the reovirus life cycle, such as the assembly of infectious viral particles, are 
correlated with Ras status [191]. It should be noted here, that it is probable 
that not the Ras-status itself, but rather the functional consequences of Ras 
signaling, are sensed by the reoviruses. Rubin and collaborators set up a gene-
trap method to identify cellular genes involved in virus infection and cell killing. 
Intriguingly, the screen suggests that expression of the IGF-II gene could confer 
resistance to reovirus infection [192,193]. Along similar lines the reovirus S4 
gene may affect the efficiency of virus replication in Ras transformed cells [194].
Clinical studies: limited efficacy 
The preference for transformed cells plus the absence of significant pathology 
in humans made reoviruses excellent candidates for oncolytic virus therapies. 
The Canadian company Oncolytics Biotec, Inc. initiated several clinical trials with 
their lead product, Reolysin, which based on the wild-type T3D strain. At this 
moment at least 24 clinical trials are active or completed in the UK, US, Canada, 
and Belgium. The indications comprise a range of cancer types, including 
prostate cancer, malignant gliomas, pancreatic cancer, lung cancer, head and 
neck cancer [195]. Initially, the virus was administered as mono-therapy but 
in more recent clinical trials reoviruses are combined with more conventional 
treatment modalities. In these studies no dose-limiting toxicity was reached, 
underscoring the safety of reovirus-based oncolytic virus therapy [196]. Despite 
anecdotal evidence of antitumor activity, the efficacy has been limited. Currently, 
several factors such as insufficient tumor penetration of the therapeutic virus, 
limited spread of the virus within the tumor cell mass, insufficient expression of 
the reovirus receptor JAM-A on tumor cells, and preexisting humoral immunity, 
have been proffered to explain the limited tumor-cell transduction [24]. It is 
anticipated that technology to modify reovirus genomes by reverse genetics 
may aid the generation of new mutants that overcome these current limitations.
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Optimizing reovirus therapy 
While the reovirus receptor is widely expressed in several tissues, some tumor 
cells may have downregulated the receptors on their cell surface. For instance, 
Kranenburg and collaborators described that none of the 13 freshly isolated 
tumor fragments from patients with colorectal metastases were susceptible to 
reovirus T3D infection [197]. This is probably due to absence or inaccessibility 
of the reovirus receptor JAM-A on the tumor cells. Immunohistochemistry on 
tissue microarrays showed that JAM-A was expressed at very low levels in liver 
metastases and improperly localized in the cytoplasm of colorectal tumor cells. 
Remarkably, tissue fragments and single-cell populations isolated from human 
colorectal tumor biopsies were susceptible to ISVPs, which have the capacity 
to directly penetrate the cell membrane independent of reovirus receptors 
[197]. Similarly, infectivity of the non-permissive human glioblastoma cell line 
U118MG could be restored by transfer and expression of a JAM-A cDNA clone 
[161]. This confirms that the receptor scarcity contributes to the resistance 
of tumor cells to reovirus T3D. This may be specific to particular tumor types. 
A recent study shows that reovirus T3D induces regression of human breast 
cancer primary tumor samples xenografted in immunodeficient mice. In addition, 
reoviruses not only eradicated the differentiated breast tumor cells, but also the 
cancer stem cells [198]. Interestingly, expression of the JAM-A molecule has 
suggested as a prognostic factor in breast cancer. JAM-A has been suggested to 
function as a key negative regulator of cell migration and invasion. While JAM-A 
is robustly expressed in normal human mammary epithelium, its expression is 
downregulated in metastatic breast cancer tumors. MDA-MB-231 cells, which 
are highly migratory, expresses low amounts of JAM-A. Forced overexpression 
of JAM-A in MDA-MB-231 cells inhibited both migration and invasion through 
collagen gels, whereas knockdown of JAM-A using siRNAs enhanced the 
invasiveness. These data suggest that JAM-A serves as a negative regulator 
of breast cancer cell invasion and possibly metastasis [199]. Similarly, recent 
data suggest a role for JAM-A in progression of renal cell carcinoma [200] and 
endometrial carcinoma [201]. In contrast, based on patient survival studies and 
in vitro studies, McSherry and collaborators came to the opposite conclusion 
[202]. They suggest a correlation between increased JAM-A expression and 
reduced survival of breast cancer patients.
 Taken together the data summarized above demonstrate that particular 
aspects of tumor biology, such as receptor availability, Ras signaling, cathepsin 
expression, antiviral immunity, etcetera, may affect the anti-tumor efficacy of 
reovirus-mediated oncolytic strategies. So how do we go from here, and how can 
we generate modified reoviruses with enhanced anti-tumor efficacy? 
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Generating improved oncolytic reoviruses
Bioselection
In virology two approaches are available to isolate viruses with distinct 
phenotypes. The classic approach involves bioselection for the desired phenotype, 
and subsequent characterization of the mutants, including the characterization of 
the genetic changes that underlie the new phenotype. In human reoviruses this 
method has been employed successfully, and has been used to select receptor 
mutants, interferon-resistant mutants, and temperature-sensitive mutants 
[118,203]. Studies on such mutants provided insight in the biology of reoviruses. 
As described in the chapter section ‘Sialic acids play an important role’ starting 
with an isolate of T3D that could not be passaged in murine erythroleukemia 
(MEL) cells, Dermody and colleagues isolated mutants that were adapted to 
grow in MEL cells [118]. These studies demonstrated that receptor mutants of 
reoviruses can be selected for with relative ease. However, it should be noted 
that in these studies for a phenotype was selected that is present in many of the 
T3D isolates. Therefore it remains to be seen whether reoviruses with completely 
novel receptor specificities can be isolated with similar ease. Along similar lines 
Lemay and colleagues isolated T3D mutants with varying interferon sensitivity. 
One of the mutants had an interferon-hypersensitive phenotype. Interestingly 
this mutant was more dependent on Ras signaling than other viral isolates 
[204]. These data demonstrate that bioselection may be used to isolate reovirus 
mutants that are more efficient as oncolytic agent. 
 Alternatively, reverse genetics strategies can be used to genetically 
modified reoviruses. As described in the chapter section ‘Reverse-genetics 
in orthoreoviruses’ viruses can be modified to encode new receptor-binding 
ligands in one of their capsid proteins. In this approach the lessons learned from 
generating adenovirus-C mutants that bypass the dependency of the adenovirus 
receptor, can be very helpful. Adenovirus-C is widely studied as oncolytic virus. 
The attachment protein of adenovirus-C, fiber, recognizes the coxsackie and 
adenovirus receptor (CAR) receptor. Although the adenovirus fiber and the 
reovirus spike have no sequence similarity, their 3-dimensional (3D) structures 
are remarkably similar [94,205]. In the adenovirus fiber protein a wide variety 
of ligands have been inserted. Such ligands include single-chain Fv domains, 
single-chain T-cell receptors, so called affibody™ molecules, and integrin-binding 
RGD motifs. This successfully changed the cellular tropism of the adenoviruses 
[206-208]. It remains to be determined whether the same approach is equally 
effective in modifying the cellular tropism of reoviruses.
 In the chapter section ‘The segment-replacement technique’ it was already 
mentioned that the N-terminus of σ3 and the C-terminus of σ1 are promising 
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locations for insertion of heterologous peptides. Such peptides sequences could 
act as alternative receptors but are also attractive for small targeting peptides. 
Such peptides could be the integrinbinding ‘RGD’-containing oligopeptides that 
have been inserted successfully in the fiber of the adenovirus and facilitate 
adenovirus-receptor-independent infection of cells [209]. It remains to be 
determined, however, whether these sites tolerate insertion of larger targeting 
peptides. If this proves feasible, then targeting ligands that have been successfully 
incorporated in the capsids of other non-enveloped oncolytic viruses may be 
incorporated in reoviruses. Such ligands could include single-chain Fv domains, 
single-chain T-cell receptors, or so-called affibodies [208].
 Not only the infection efficiency, but also the tumor-cell specificity of 
infection can be enhanced. To avoid the infection of non-target cells expressing 
JAM-A, the σ1 protein can be modified to ablate its association with JAM-A. As 
discussed in section ‘What did we learn?’ reovirus S1 mutants were generated 
which strongly reduced JAM-A binding in surface plasma resonance analyses, 
as well as to neuraminidase treated HeLa cells [140,141]. Interestingly, these 
mutants were viable and could be propagated on L929 cells, infecting the cells 
presumably via direct association with sialic acid residues. Furthermore, viruses 
with reduced JAM-A binding have been isolated [140,152], these mutants were 
still viable and infected cells presumably via binding to sialic acid residues 
[140]. The mutant with the truncated σ1, isolated by Kim and colleagues, still 
preferentially targeted tumor cells, however, it showed a reduced toxicity in 
vivo. Also exposure of naïve mice to this virus still resulted in the induction of 
neutralizing immune response. Such viruses may facilitate the development of 
more efficacious tumor-cell selective reoviruses for application as oncolytic agent.
Where do we go from here?
With these tools and techniques available and with evidence of excellent safety 
of the wild-type reoviruses in clinical studies we may further define key factors 
that may limit clinical efficacy. In what fields are new developments necessary 
to fulfill the promise of efficacious cancer-targeted reovirus vectors? 
Cells for delivery
Many preclinical and clinical studies have demonstrated that delivery of viral 
vectors to the tumor is often disappointingly inefficient. As outlined above, the 
expression of the reovirus receptor JAM-A may be low, or the receptor proteins 
are inaccessible to the virus particles. In addition, the high interstitial fluid 
pressure within most tumors causes a convective flow away from the tumor. 
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This inhibits the passive diffusion of viral particles into the tumor. Moreover, the 
extracellular matrix may form physical barriers that prevent efficient spread of 
viral vectors [210,211]. 
 Given the inefficiency of virus delivery to tumor cells, new delivery methods 
are essential. An attractive option is to use cells with the capacity to migrate 
to tumors as delivery vehicles of oncolytic viruses. In this strategy the tumor 
targeting cells are loaded with viruses and administered to the patient. After 
migration, the cells should hand off the cell-associated viruses to the tumor cells. 
Several cell types can migrate to tumors in vivo, including cytokine induced-
killer cells, tumor-antigen-specific T cells, macrophages, endothelial progenitor 
cells, and mesenchymal stem cells [212]. 
 Cellular delivery may also circumvent the effects of neutralizing immunity 
[213,214]. This is evidenced in a recent study that employed human reovirus 
T3D as oncolytic agent. In reovirus-naive mice with B16tk lymph node melanoma 
metastases, free reovirus or reovirus delivered through mature dendritic cells 
(DC) or T cells was detected in the tumor-draining lymph nodes three days 
after treatment. Here, these viruses could eradicate local tumor cells. Only T 
cells carrying reovirus generated anti-tumor immune responses and long-term 
tumor clearance. In reovirus-immune mice, however, the results were different. 
Delivery of free reovirus was ineffective as a therapy, but if mature DC as well as 
T cells were used as carriers, reovirus was effectively delivered to melanoma in 
vivo [213]. These data show that whereas systemically administered reoviruses 
may not be suitable for therapy, DC may be an appropriate vehicle for delivery 
of significant amounts of reovirus to tumors. This and several other studies 
suggest that cellular delivery is feasible and may be applicable for delivery of 
viral oncolytic agents at the tumor sites. However, cellular delivery also adds a 
new level of complexity to the clinical studies, and is logistically challenging.
Which cells to target?
With the aid of genetic modification and bioselection strategies new reovirus-
derived cancer gene therapeutics can be developed that ensure efficient 
infection of cells within the tumor. It is known that tumors are usually markedly 
heterogeneous, consisting of complex mixtures of cancer cells with various 
grades of differentiation. A cell type that has attracted much attention in recent 
years is the tumor-initiating cell, or cancer stem cell. The tumor-initiating cell is 
a cell with the capacity to self-renew and differentiate into any of the lineages 
of cancer cells that comprise a tumor [215]. Presumably the tumor-initiating 
cells are derived from organ stem cells [216]. The latter are long-lived and 
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change over the course of time by accumulating (epi)genetic alterations. In this 
model, the characteristics of cancer-initiating cells and therefore of the resulting 
tumor, depend (in part) on these alterations. The cancer stem cell population in 
a tumor may not only govern tumor progression, but may also be responsible 
for the establishment of distant clones (metastases) [215,217]. Therapeutic 
efficacy may therefore be directly related to the efficiency with which a particular 
treatment eradicates the cancer stem cell population. It may therefore be 
important to ensure that new reoviral oncolytic agents have the capacity to 
transduce and kill cancer stem cells [198]. It may even be desirable to generate 
reovirus variants that specifically target the cancer stem cell population, rather 
than the more differentiated tumor cells.
Conclusion
Recent years have witnessed a reemergence of the oncolytic virus approach to 
cancer treatment. Initial clinical safety studies have demonstrated the validity 
of the concept, and feasibility of current approaches. The reovirus T3D used in 
the clinical studies reported on so far are well tolerated and safe. In recent years 
the knowledge of mammalian reoviruses, their biology and their interaction with 
the host have expanded rapidly. Whereas genetic modification of reoviruses’ 
segmented double-stranded RNA genomes was notoriously difficult, new 
techniques facilitate the development of genetically modified variants. These 
techniques can be used to generate new tumor-targeted oncolytic reoviruses 
that will hopefully be as safe as current ones, but more efficacious.
Expert opinion
Reovirus-based oncolytic virus therapies have been safe, but so far the efficacy 
is limited. As with other oncolytic viruses the efficacy may be enhanced by 
combining the oncolytic virus approach with more conventional therapeutic 
approaches such as radiation and chemotherapy [218,219]. This concept is now 
being explored clinically [220]. 
 In parallel, the new techniques for reverse genetics together with more 
classical genetic approaches can be used to overcome some of the hurdles 
that thwart efficacious oncolytic virus therapy. Several factors limit the efficacy 
of treatment with oncolytic viruses. These include the inefficient delivery 
of oncolytic viruses to the tumors, the limited infectivity of the cancer cells 
within the tumors, preexisting immunity in the patient population, and the 
marked heterogeneity of many tumor types. With the new (reverse-) genetics 
techniques, new tumor-targeted oncolytic reoviruses can be generated with 
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improved efficacy and applicability. Hereby, the gene therapist can be guided 
by our knowledge in parallel fields. In this respect, the large body of knowledge 
on oncolytic adenoviruses may be extremely valuable. Despite the differences 
in their genomic constitution, adenoviruses and reoviruses have several aspects 
in common. Although reovirus T3D and human adenovirus-C recognize different 
receptors, there are overt structural similarities between the T3D spike and the 
adenovirus fiber [205,221]. Hence for developing tumor-targeted reoviruses it 
may be useful to parallel the approaches that have been explored so successfully 
in the oncolytic adenovirus field [206-208]. 
 Transient immune suppression may overcome immunological barriers that 
impede effective reovirus delivery [222,223], although it should be realized 
that this approach should be employed with caution. Reovirus infection can 
be associated with severe morbidity in immune compromised NOD/SCID mice 
[224]. Interestingly, it may be possible to select mutants with significantly 
reduced viral pathogenesis in immune compromised animals [225]. On the other 
hand, the immune system is an important mediator of anti-tumor activity, and 
the oncolytic virus infection may activate antitumor immune activity [48,226]. 
 Reverse genetic techniques can be used to generate reoviruses carrying 
heterologous genes [115,141]. Transgenes may be included to arm the oncolytic 
viruses, for instance by including transgenes encoding cytokines for activating 
the immune system. This may increase the anti-tumor efficacy [227]. Also 
the replication of reoviruses may be reduced by insertion of microRNA target 
sequences, similar to the method used to prevent replication of adenoviruses 
in hepatocytes [228,229]. Already, Dermody and colleagues demonstrated that 
RNA interference can be used to inhibit reovirus replication [230]. It remains to 
be established whether reoviruses carrying foreign sequences (i.e., transgenes, 
microRNA targets) are genetically stable enough to allow production of clinical-
grade batches.
 In cases where the use of mutants may be ineffective, other changes to the 
virus particles could be used. One such hurdle is the occurrence of reovirus 
immunity in the human population. While it is unlikely that mutants can be 
isolated that are insensitive to preexisting immunity, polymer shielding may be 
used to mask the epitopes in the capsid. This approach has been found to be 
extremely effective to protect adenovirus vectors, and it seems reasonable to 
anticipate that this strategy will also be effective in reoviruses [60].
 Despite the new opportunities there is one factor that may limit use of 
genetically targeted reoviruses. Reoviruses display a high mutation rate 
compared with many DNA viruses. As a result, during prolonged passage 
reovirus mutants have a tendency to change or revert, forming so-called 
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quasispecies. This genetic drift may be reduced by propagating the viruses 
under appropriate selective pressure. For large-scale production of reoviruses 
for clinical use, product consistency is important. Therefore, it is essential to 
design culture conditions that limit the expansion of mutants or revertants in 
the vector preparation. It remains to be seen whether that is feasible for novel 
tumor-targeted oncolytic reoviruses with new phenotypes. It is anticipated that 
the development of new production systems may be necessary, and should be 
developed in parallel with appropriate pre-clinical testing methods. This can 
warrant safe clinical application of new oncolytic reoviruses. With these we can 
keep the gene therapists’ promise of providing new and effective treatment for 
malignant neoplastic disease.
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ABSTRACT
In human adenoviruses (HAdV), 240 copies of the 14.3-kDa minor capsid 
protein IX stabilize the capsid. Three N-terminal domains of protein IX form 
triskelions between hexon capsomers. The C-terminal domains of four protein 
IX monomers associate near the facet periphery. The precise biological role 
of protein IX remains enigmatic. Here we show that deletion of the protein 
IX gene from a HAdV-5 vector enhanced the reporter gene delivery 5 to 25-
fold, specifically to coxsackie and adenovirus receptor (CAR)-negative cell lines. 
Deletion of the protein IX gene also resulted in enhanced activation of peripheral 
blood mononuclear cells. The mechanism for the enhanced transduction is 
obscure. No differences in fiber loading, integrin-dependency of transduction, or 
factor-X binding could be established between protein IX-containing and protein 
IX-deficient particles. Our data suggest that protein IX can affect the cell tropism 
of HAdV-5, and may function to dampen the innate immune responses against 
HAdV particles. 
Enhanced transduction of CAR-negative cells by protein IX-gene deleted adenovirus 5 vectors
85
4
INTRODUCTION 
Protein IX is a non-essential protein in the capsid of human adenoviruses 
(HAdV). The protein has a size of 14.3 kDa, is present at 240 copies per virion, 
and has three highly conserved regions present in the amino (N) terminus, the 
central part (alanine-rich), and the carboxy (C) terminus (leucine-rich). The 
location and function of protein IX in the virus capsid has been the subject of 
investigation and debate for many years [1]. Recent work by different groups 
has brought consensus on its location and topology in the capsid [2,3]. The 
N-terminus of the protein is located in between hexon cavities of the groups 
of nine (GON) hexons, presumably stabilizing the GONs. The C-terminus of 
the protein forms an alpha-helix and is exposed on the capsid surface in close 
contact with hexon hypervariable region 4 (HVR4) [3]. C-terminal domains of 
three protein IX molecules associate in a parallel orientation, whereas a fourth 
domain binds in an antiparallel orientation [2]. The role of protein IX in the 
capsid remains enigmatic. In vitro analysis revealed the N-terminus of protein 
IX to confer a thermostable phenotype on HAdV-5 capsids [4]. Propagation of 
protein IX gene deleted HAdV-5 in cell culture yields wild-type like virus titers, 
demonstrating that protein IX is dispensable for virus replication in vitro. 
 Protein IX has potential as an anchor for the attachment of different types 
of polypeptides to the viral capsid. Targeting of HAdV-5 to tumor cells has 
been achieved by genetically fusing protein IX to a single-chain T cell receptor 
directed against MHC class I in complex with MAGE-A1 peptides [5]. Similarly, 
integrin-binding Arg-Gly-Asp (RGD) peptides, as well as single-chain antibody 
fragments have been incorporated in this way [6,7]. Alternatively, targeting 
ligands can be coupled to protein IX via the genetic inclusion of cysteine residues 
and subsequent chemical coupling of ligands to the reactive thiol groups [8]. 
Multiple polypeptides can be incorporated simultaneously [9]. A triple-mosaic 
HAdV-5 vector was developed with a poly-lysine motif, the herpes simplex virus 
type 1 (HSV-1) thymidine kinase, and the monomeric red fluorescent protein 
fused with protein IX, thereby combining targeting, therapeutic, and imaging 
modalities. Recently, it was demonstrated that HAdV-5 vaccine vectors with 
pathogen-specific antigens fused to protein IX can stimulate robust protective 
immune responses in animals, suggesting a new route for the development of 
improved HAdV-5 based recombinant vaccines [10,11].
 Here we report on the enhanced delivery of transgenes into CAR-negative 
cell lines as a result of protein IX-gene deletion from a HAdV-5-based vector. 
Furthermore, the protein IX-deficient particles demonstrated enhanced 
activation of peripheral blood mononuclear cells (PBMCs), and had a different 
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in vivo distribution after intravenous delivery in a mouse model. The exact 
molecular mechanism behind this ‘ΔpIX effect’ remains to be delineated. Our 
data suggest that protein IX can affect the cell tropism of HAdV-5, and may 
function to dampen the innate immune responses against HAdV particles. 
MATERIALS AND METHODS 
Cell lines 
All cell lines were maintained as monolayers at 37°C in a humidified atmosphere 
of 5% CO2. The human cell lines HeLa (cervical cancer), A549 (carcinomic 
alveolar epithelium), MEL2A (melanoma), MZ2-MEL3.0 (melanoma) [5], VH10 
(primary foreskin fibroblasts) [12], HepG2 (hepatocellular carcinoma), and 
911 cells (HAdV-5 E1-transformed human embryonic retinoblasts) [13] were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco-BRL, Breda, 
The Netherlands) supplemented with 8% fetal bovine serum (FBS) (Gibco-BRL, 
Breda, The Netherlands) and penicillin–streptomycin mixture. 
 Lentivirus transduction was used to create a MZ2-MEL3.0 cell line stably 
expressing human CAR. To this end, the CAR gene was PCR-amplified by using 
primers 1 and 2 (table 4.1) from plasmid pCMV_hCAR (kindly provided by Dr. J.M. 
Bergelson [14]). The PstI+NheI digested PCR product was ligated in between 
the corresponding restriction sites of pLV.CMV.IRES.PURO [15], resulting in pLV.
CMV.CAR.IRES.PURO. The virus LV.CMV.CAR.IRES.PURO was produced by a 
previously described procedure involving cotransfection of pLV.CMV.CAR.IRES.
PURO together with ‘helper’ plasmids encoding HIV-1 gag-pol, HIV-1 rev, and 
the VSV-G envelope [16]. The methods for determining the titer of the LV.CMV.
CAR.IRES.PURO vector stock and the procedures for transduction of the MZ2-
MEL3.0 cells have been described before [15]. Selection for antibiotic resistance 
was achieved by seeding the cells in medium with 0.6 μg/ml puromycin (MP 
Biomedicals, Amsterdam, The Netherlands). 
Viruses 
The vectors HAdV-5.CMV.GFP/LUC (Vellinga et al., 2006) (Ad5ΔE1+pIX) and 
HAdV-5ΔpIX.CMV.GFP/LUC [17] (Ad5ΔE1ΔpIX) contain a green fluorescent 
protein (GFP) gene as well as a firefly luciferase (LUC) gene, which are both driven 
by a human cytomegalovirus (CMV) promoter. The vector HAdV-5pIXΔ100-114.
CMV.LUC (Ad5ΔE1pIXΔLEU), encoding LUC only, was described previously as well 
[4]. Titration of the vector stocks was performed by a PicoGreen-DNA binding 
assay to determine the concentration in physical vector particles per ml (pp/ml) 
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[18]. A standard agar overlay plaque assay on 911 cells was used to determine the 
infectious virus concentration in plaque forming units per ml (pfu/ml) [13]. The 
pp/pfu ratios of the three vectors were very similar, within the range of 10 to 12. 
 The replication-competent viruses HAdV-5.ΔE3.ADP.eGFP (Ad5+pIX) and 
HAdV-5.ΔE3.ADP.eGFP.ΔpIX (Ad5ΔpIX) were constructed by recombination of the 
shuttle plasmids pShuttle+E1+pIX (pSh+pIX) and pShuttle+E1ΔpIX (pShΔpIX) 
with a HAdV-5 backbone plasmid containing the eGFP gene in the E3 region (pBB). 
The plasmids pSh+pIX, pShΔpIX and pBB were constructed as follows. The wild-
type HAdV-5 BsrGI–MfeI fragment containing the E1 genes (nucleotides 193–
3925) was isolated from pTG3602 (kindly provided by Dr. M. Luski, Transgene, 
Strasbourg,France),and cloned into the BsrGI–MfeI digested pTrackCMV-GFP/
LUC [17], thereby replacing the GFP/LUC genes with the HAdV-5 E1 region. By 
using site-directed mutagenesis (QuikChange site-directed mutagenesis kit; 
Stratagene) (primers 3, 4, 5, 6 (table 4.1)) two restriction sites were introduced 
in the protein IX gene; a ScaI site at the start codon of protein IX and a SpeI site 
upstream of the protein IX stop codon, thereby creating pShuttle+E1+pIXScaI/SpeI. 
Next, the pShΔpIX plasmid was constructed by ScaI/SpeI digestion and re-ligation 
of the protein IX-gene-deleted fragment. The pSh+pIX plasmid was created by 
introducing the protein IX sequence (amplified from pAd5pIX [6] by using primers 
7 and 8 (table 4.1)) into the ScaI/SpeI linearized pShuttle+E1+pIXScaI/SpeI. The 
ScaI-site was restored to the wild-type HAdV-5 sequence by exchanging the 
ScaI-overlapping MfeI/HindIII fragment with the corresponding fragment from 
pTG3602. The SpeI site and the downstream ‘pIX-remainder sequence’ were left 
intact, since part of this sequence forms a hairpin-loop structure situated over the 
polyA site of the E1B transcript, which might be essential for efficient polymerase 
slippage needed for polyadenylation [19]. 
Table 4.1 Oligonucleotide used in the cloning procedure
Name Sequence 5’-3’
1 FWD CAR_PstI 5′-GATGTACTGCAGATGGCGCTCCTGCTGTG-3′
2 REV CAR_NheI 5′-CGACGCTAGCTATACTATAGACCCATCCTTGCTCTG-3′
3 FWD ScaI_correct 5′-TTGCAGCAGCCGCCGCCGCCAGTACTAGCACCAACTCGTTTGATGG-3′
4 REV ScaI_correct 5′-CCATCAAACGAGTTGGTGCTAGTACTGGCGGCGGCGGCTGCTGCAA-3′
5 FWD SpeI_correct 5′-GGTTTCTGCCCTGAAGGCTTACTAGTCTCCCAATGCGGTTTAAAAC-3′
6 REV SpeI_correct 5′-GTTTTAAACCGCATTGGGAGACTAGTAAGCCTTCAGGGCAGAAACC-3′
7 FWD pIX_ScaI 5′-CGCGGAAGTACTATGAGCACCAACTCGTTTGATGG-3′
8 REV pIX_SpeI 5′-CGCACTAGTTTAAACCGCATTGGGAGGGGAGG-3′
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 The pBB backbone plasmid was constructed by replacing the E3-lacking 
SpeI–PacI fragment (nucleotides 27238–33443) of pAdEasy-1 [20] with the 
corresponding SpeI–PacI fragment of pShuttle-ΔE3-ADP-EGFP-F2 [21], thereby 
introducing eGFP in the E3 region under control of the viral major late promoter. 
The coding sequence for the E3 Adenovirus Death Protein (ADP) was retained. 
The kanamycin resistance gene (inserted with the pShuttle-ΔE3-ADP-EGFP-F2 
fragment) was removed by ClaI digestion and re-ligation of the two largest fragments. 
 Recombination of pBB with pSh+pIX and pShΔpIX in E. coli and subsequent 
virus rescue in A549 cells were performed as described elsewhere [20]. Virus 
was purified by a standard double cesium chloride gradient protocol, dialyzed 
against sucrose buffer (5% sucrose, 140 mM NaCl, 5 mM Na2HPO4.2H2O, 1.5 mM 
KH2PO4) and stored at -80°C. The virus titer was determined by the PicoGreen-
DNA binding assay [18] (for pp/ml measurement), and a plaque assay on 
A549 cells [13] (for pfu/ml measurement). For analysis of virus spread, GFP-
positive plaques were photographed (Olympus Camedia Digital Camera C-3030, 
installed on an Olympus CK40 microscope) and the plaque size was determined 
in arbitrary units (Olympus DP-soft v.5.0 Soft imaging System software). The 
median plaque size of Ad5ΔpIX was normalized to the plaque size for Ad5+pIX. 
Analysis of CAR presentation on the cell surface 
Flow cytometry was performed to determine the levels of CAR presentation on 
the cell surface. Cells in suspension (in PBS with 0.5% bovine serum albumin 
and 0.02% sodium azide) were incubated with mouse monoclonal anti-CAR 
antibody (clone RmcB, Upstate Biotechnology, Lake Placid, NY, diluted 1:1000) 
for 30 min on ice, followed by incubation with phycoerythrin (PE)-conjugated 
rabbit-anti-mouse secondary antibody (Caltac Laboratories, Burlingame, CA, 
USA) for 30 min on ice. Flow cytometry data were analyzed with CellQuest 
software (Becton Dickinson). 
 Immunohistochemistry was performed on the cell line MZ2-MEL3.0/CAR. After 
washing with phosphate-buffered saline (PBS), the cells were fixed in acetone/
methanol (1:1) for 10 min at room temperature. Staining was performed with 
the anti-CAR antibody (clone RmcB, Upstate Biotechnology, Lake Placid, NY, 
diluted 1:500). Fluorescein isothiocyanate (FITC)-conjugated rabbit-anti-mouse 
antibody (Jackson ImmunoResearch, France) was used as secondary antibody. 
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Virus transduction assays 
Luciferase expression 
The transduction efficiency of CAR-positive (HeLa, A549, MEL2A, MZ2-MEL3.0/
CAR) and CAR-negative (MZ2-MEL3.0, VH10) cell lines by Ad5ΔE1+pIX and 
Ad5ΔE1ΔpIX was compared by measuring luciferase expression. Transduction 
was performed in triplicate in 24-well plate wells in 500 μl DMEM/8% FBS. After a 
two-hr incubation the virus-containing medium was replaced with fresh medium 
without virus. At 24 hrs post transduction the cells were washed once with PBS 
and lysed in 100 μl LUC–lysis mix (25 mM Tris–phosphate (pH 7.8), 2 mM CDTA, 
2 mM DTT, 10% glycerol and 1% Triton-X in PBS). Luciferase production was 
determined with the Promega Luciferase Assay by adding 25 μl luciferase assay 
reagent to 10 μl lysate. Light intensity measurement was performed in a Victor 
Wallac 2 microplate reader (PerkinElmer, Inc., Waltham, MA, USA). 
Integrin blocking 
Indirect blocking of integrin-mediated virus uptake was performed by incubating 
cells with EDTA. MZ2-MEL3.0 cells were harvested from semi-confluent tissue 
culture plates, washed three times in PBS with 5 mM EDTA, and resuspended 
in standard PBS or PBS supplemented with 0.9 mM CaCl2 and 0.5 mM MgCl2 
(PBS++). The Ad5ΔE1+pIX and Ad5ΔE1ΔpIX stocks were adjusted to equal 
pp concentrations by adding sucrose buffer and were diluted 1:1 in a 5 mM 
EDTA solution in PBS. Virus (100 pp/cell) was added to 5x105 cells in 1 ml PBS 
or PBS++ and incubation was performed for 60 min at 37°C under constant 
agitation. Subsequently, the cells were pelleted by centrifugation, dissolved in 5 
ml medium and transferred to 24-well plate wells (500 μl per well). Cells were 
incubated for 24 hrs and analyzed for GFP expression by flow cytometry. Data 
were analyzed with CellQuest software (Becton Dickinson). 
 The anti-human CD51/61 monoclonal antibody (MAb LM609), an αVβ3 integrin 
antagonist, and MAb P1F6, an αVβ5 integrin antagonist (both obtained from 
Millipore) were used to test the inhibitory effect of anti-integrin antibodies on 
virus transduction. Cells grown as monolayers were pre-incubated with medium 
only or with medium containing integrin function-blocking MAbs (10 mg/ml). 
After 30 min of incubation, the excess antibody was removed by gentle washing 
followed by virus transduction (100 pp/cell). Reporter gene expression was 
measured 24 hrs post transduction by performing a standard luciferase assay.
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Virus incubation with coagulation factor X 
HepG2 and A549 cells were plated in 24-well plate wells. After a PBS wash step, 
Ad5ΔE1+pIX or Ad5ΔE1ΔpIX (100 pp/cell) was added in serum-free medium 
containing 8 μg/ml factor X (FX) (HCX-0050, Haemotologic Technologies Inc.), 
8 μg/ml Gla-domainless factor X (FXMUT) (HCX-GD, Haemotologic Technologies 
Inc.) or no FX/FXMUT. After 2 hrs the medium was replaced by normal medium. 
Luciferase expression was measured 24 hrs post transduction. 
Immunoblot analysis and electron microscopy 
Immunoblot analyses were performed to assess the incorporation of proteins into 
the capsid of Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. The western blotting and detection 
procedures were described previously [5]. Virus lysates were prepared by 
adding 5×109 virus particles directly to western sample buffer. Capsid proteins 
were visualized with rabbit polyclonal anti-protein IX serum (1:2000) [22] goat 
polyclonal anti-hexon (1:1000, ab19998, Abcam, Cambridge, UK), and mouse 
monoclonal anti-fiber (1:5000, 4D2, Abcam) [23]. Secondary antibodies were 
horseradish peroxidase (HRP)-conjugated goat-anti-rabbit and rabbit-anti-
mouse (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). 
 Electron microscopy was performed on Ad5ΔE1+pIX and Ad5ΔE1ΔpIX 
samples adsorbed into glow-discharged carbon coated copper grids and 
negatively stained for 30 sec with 2% phosphotungstic acid (pH 7). The viruses 
were examined with a FEI Tecnai Spirit BioTwin transmission electron microscope 
operating at 120 kV. Images were recorded on a 4k × 4k Eagle CCD camera. 
PBMC analysis 
Buffy coats were obtained from healthy donors after consent (Sanquin 
Bloodbank, Leiden, The Netherlands) and centrifuged on a Ficoll gradient to 
obtain PBMC. PBMC (1×106) were added to a well of a 24-well plate in 0.5 ml 
medium (RPMI/10% FCS) and virus was added at the indicated MOI in 0.5 ml 
medium. After incubation at 37°C and 5% CO2 for two days, the supernatants 
were isolated for interferon gamma (IFN-γ) measurement, and the cells were 
prepared for flow cytometry analysis. Cells were washed twice with PBS/0.02% 
sodium azide, fixed for 10 min in 4% paraformaldehyde, washed twice with 
PBS/0.5% BSA/0.02 sodium azide, and stained with antibodies. Antibodies used 
were anti-CD3-PerCP-Cy5.5, anti-CD4-PE, anti-CD14-APC, anti-CD14-PerCP-
Cy5.5, anti-CD19-PE, anti-CD19-PerCP-Cy5.5, anti-CD69-PE and anti-CD86-
PE (Becton Dickinson, Franklin Lakes, NJ, USA), anti-CD8-APC and anti-CD56-
APC (Beckman Coulter, Brea, CA, USA). Activation of NK cells was evaluated 
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as increased CD69 expression on CD3-,CD14-,CD19-,CD56+ cells. Monocyte 
activation was analyzed as increased CD86 expression on CD3-, CD19-, CD14+ 
cells. Fluorescence was measured by flow cytometry on a FACS Calibur (Becton 
Dickinson) and data were analyzed with CellQuest software (Becton Dickinson). 
IFN-γ in supernatants was measured by ELISA using the PeliPair reagent set for 
human IFN-γ (Sanquin, Amsterdam, NL). 
Viral distribution after intravenous delivery 
Ad5ΔE1+pIX or Ad5ΔE1ΔpIX (109 pp) was injected in the tail vein of 6-week-
old athymic nude mice (NMRI nu/nu; Taconic M&B A/S, Ry, Denmark), followed 
by sacrificing the animals and harvesting of multiple organs at 3 days post 
injection. Four hrs before Ad5ΔE1+pIX and Ad5ΔE1ΔpIX injection, pre-dosing 
was performed with the empty vector HAdV-5.CMV (replication-deficient and 
not encoding a transgene) (5×1010 pp) to saturate Kupffer cell macrophages. 
Tissue samples from each organ were lysed in LUC–lysis mix and the luciferase 
expression was measured according to the Promega Luciferase Assay. The 
protein concentration in the lysates was determined by using the bicinchoninic 
acid protein assay (Pierce, Perbio Science BV, Etten-Leur, The Netherlands), 
enabling the calculation of luciferase expression per total protein. The experiment 
was performed under the Dutch Experiments on Animals Act that serves the 
implementation of “Guidelines on the protection of experimental animals” by 
the Council of Europe (1986), Directive 86/609/EC, and only after a positive 
recommendation by the Animal Experiments Committee. 
RESULTS 
Enhanced transgene expression in CAR-negative cells with 
Ad5ΔE1ΔpIX 
To study the role of protein IX in the HAdV-5 transduction of cells, we compared 
the vectors Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for luciferase transgene expression in 
a panel of cell lines (figure 4.1 A). Cell lines with varying expression levels of CAR 
were included (figure 4.1 B). Whereas similar expression levels were obtained 
with both vectors in the CAR-positive cell lines HeLa, A549, and MEL2A, the 
vector Ad5ΔE1ΔpIX yielded higher levels than Ad5ΔE1+pIX in the CAR-negative 
cell lines MZ2-MEL3.0 and VH10. Since these results suggested a specific role 
of the protein IX lacking vector in mediating relatively higher transduction in 
the absence of CAR, Ad5ΔE1+pIX and Ad5ΔE1ΔpIX were analyzed for reporter 
gene expression in MZ2-MEL3.0 cells versus MZ2-MEL3.0/CAR cells (figure 
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4.2 B). MZ2-MEL3.0/ CAR cells stably expressed CAR via transduction with a 
recombinant lentivirus, which was confirmed by flow cytometry and immune 
fluorescence staining (figure 4.2 A). In MZ2-MEL3.0 cells the reporter gene 
expression upon infection with Ad5ΔE1ΔpIX was found to be ten-fold increased 
compared to infection with Ad5ΔE1+pIX, while in MZ2-MEL3.0/CAR cells 
the difference was a mere two-fold (figure 4.2 B). The enhanced transgene 
expression for Ad5ΔE1ΔpIX on the CAR-negative cell line MZ2-MEL3.0 appeared 
to be not affected by the establishment of protein IX expression in the cells 
(by using the recombinant lentivirus LV-CMV-pIX-IRES-NPTII [17] prior to the 
transduction) (result not shown). 
Figure 4.1 (A) Transduction of CAR-positive and CAR-negative cells with the replication-
deficient vectors Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. At 24 h post transduction (at 10 pp/cell) 
the luciferase expression was measured as indicated by the relative luciferase units (RLU) 
(NS signifies Not Significant, *pb 0.02 versus Ad5ΔE1+pIX). Error bars represent SEM 
(n= 3). (B) Flow cytometry with anti-CAR antibody and PE-labeled secondary antibody 
to analyze cell surface expression level of CAR (white histograms). The gray histograms 
represent incubation with secondary antibody only.
 As a next step, the involvement of the C-terminal region of protein IX in the 
observed phenomenon was investigated. This domain, which is rich in leucine 
amino acids and is exposed on the HAdV-5 capsid as an alpha-helical structure 
[2,3], is highly conserved in human adenoviruses. The biological function 
of this conserved domain of protein IX is unknown. We analyzed the vector 
Ad5ΔE1pIXΔLEU, which lacks a major part of the C-terminal region of protein IX 
(amino acids 100 to 114) for reporter gene expression in MZ2-MEL3.0 and MZ2-
MEL3.0/CAR. Ad5ΔE1pIXΔLEU demonstrated enhanced transduction of the CAR-
negative cell line, very similar to the Ad5ΔE1ΔpIX vector (figure 4.2 C). 
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Figure 4.2 Transduction assays on MZ2-MEL3.0 and MZ2-MEL3.0/CAR. 
(A) Detection of CAR expression in MZ2-MEL3.0 cells by immune-fluorescence staining 
with anti-CAR antibody and FITC-labeled secondary antibody. The insets represent flow 
cytometry histograms after staining with anti-CAR antibody and PE-labeled secondary 
antibody. (B) Luciferase expression in MZ2-MEL3.0 and MZ2-MEL3.0/CAR after 
Ad5ΔE1+pIX and Ad5ΔE1ΔpIX transduction. Error bars represent SEM (n=3). (C) Fold 
enhancement of MZ2-MEL3.0 transduction with Ad5ΔE1ΔpIX and Ad5ΔE1pIXΔLEU as 
compared to the transduction with Ad5ΔE1+pIX. The fold enhancements are normalized 
to the vector transduction ratios on MZ2-MEL3.0/CAR (*p<0.05, **p<0.005 versus 
Ad5ΔE1+pIX). Errors bars represent SEM (n=3).
 To assess the appearance of the vector particles and to check for the absence 
of microaggregation, electron microscopy was performed on Ad5ΔE1+pIX and 
Ad5ΔE1ΔpIX vector batches. This showed identically shaped virus particles 
(figure 4.3 A). No signs of microaggregation were observed. The Ad5ΔE1ΔpIX 
stock appeared to contain more small particulate matter, possibly virus debris. 
As previously described, pIX-deficient HAdV-5 particles have an enhanced 
tendency to partly dissociate into fiber-and penton base- lacking particles [24]. 
However, our vectors had similar capsid incorporation levels of fiber and hexon 
proteins, as evident from immunoblot analyses (figure 4.3 B), thus ruling out 
differences in particle dissociation for the vector preparations.
Chapter 4
94
Figure 4.3 (A) Electron microscopy on Ad5ΔE1+pIX and Ad5ΔE1ΔpIX samples with 
negative staining of the vector particles in phosphotungstic acid. (B) Immunoblot detection 
on Ad5ΔE1+pIX and Ad5ΔE1ΔpIX lysates to analyze capsid incorporation levels of protein 
IX, hexon, and fiber proteins.
Transduction with Ad5ΔE1ΔpIX is integrin-dependent 
Wild-type HAdV-5 enters cells via high affinity binding of the fiber knob domain 
to CAR [14]. Subsequently low affinity interaction of the penton base with 
cellular integrins αVβ3 and αVβ5 promotes virus internalization in clathrin coated 
pits [25,26]. To answer the question if Ad5ΔE1ΔpIX still uses integrins for cellular 
uptake, we analyzed Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for transgene expression 
(GFP) in the presence or absence of bivalent cations, which are necessary for 
integrin-mediated uptake of wild-type HAdV-5 into cells [26] (figure 4.4 A). This 
experiment again displayed a stronger reporter gene expression of Ad5ΔE1ΔpIX 
in MZ2-MEL3.0 cells compared to Ad5ΔE1+pIX. For both vectors the transduction 
appeared to be totally dependent on the presence of bivalent cations, with a 
complete reduction to background GFP levels for the cation-negative incubation. 
This is consistent with integrin-mediated uptake for both vectors. More specifically, 
the integrin-dependency of Ad5ΔE1ΔpIX was confirmed by a small but significant 
(approximately two-fold) decrease in transduction after incubation of MZ2-
MEL3.0 cells with antibodies directed against αVβ3 and αVβ5 integrins (figure 
4.4 B). Similar antibody-blocking (1.5-fold reduced transduction for anti-αVβ3 
and anti-αVβ5) was observed for Ad5ΔE1+pIX. Incubating the cells with higher 
concentrations of antibodies did not result in further reductions in transduction 
levels (data not shown). Anti-integrin mediated blocking of transduction was 
also observed on A549 cells (figure 4.4 B). From these data we conclude that the 
vector Ad5ΔE1ΔpIX still uses integrins for cell internalization in CAR-deficient cells. 
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Figure 4.4 The effect of integrin blocking on transduction of cells with 
Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. (A) MZ2-MEL3.0 cells were treated with EDTA to 
remove bivalent cations necessary for HAdV-5 interaction with integrins. Subsequent 
transduction was performed in the presence (PBS++) or absence (PBS) of bivalent cations 
and GFP expression was measured, as indicated by the mean fluorescence intensity (MFI). 
Error bars represent SEM (n =3). (B) Vector mediated luciferase expression in MZ2-
MEL3.0 and A549 cells in the presence or absence of antibodies directed against αVβ3or 
αVβ5 integrins in the infection medium (*p<0.05 versus control treatment). Error bars 
represent SEM (n =3). 
Reduced virus spread of the replication-competent virus 
Ad5ΔpIX 
Our data from the comparative transduction analysis suggest an alternative 
interaction of HAdV-5 particles lacking protein IX with the cell surface. In parallel 
to cell tropism extending capsid modifications described for other viruses [27], it 
is likely that protein IX deletion from a replication-competent HAdV-5 virus would 
result in a modified ability to spread in monolayer cell cultures. To investigate 
this, we constructed the replication-competent HAdV-5 viruses Ad5+pIX and 
Ad5ΔpIX. Both viruses expressed GFP, allowing accurate measurement of plaque 
size. On A549 cells the plaque size for the Ad5ΔpIX virus (median 30 arbitrary 
surface units (ASU), range 20–170) appeared to be significantly smaller than 
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the plaque size for Ad5+E1+pIX (median 100 ASU, range 30–290). A similar 
difference in plaque size was observed on the CAR-negative cell line VH10, 
with Ad5ΔpIX (median 50 ASU, range 30–150) yielding much smaller plaques 
compared to Ad5+pIX (median 100 ASU, range 75–280). From these analyses 
we conclude that protein IX-gene deletion from the genome of the replication-
competent virus results in a decrease in virus spread in CAR-positive (A549) as 
well as CAR-negative (VH10) monolayer cell cultures. 
Enhanced activation of peripheral blood mononuclear cells by 
Ad5ΔE1ΔpIX 
Our findings on the modified transduction characteristics of protein IX-deficient 
HAdV-5 vectors are of relevance for: (i) fundamental adeno-virology (as the 
findings point towards a novel biological function of protein IX), and (ii) the 
development of protein IX-modified HAdV-5 vectors for gene therapies. For 
both these aspects, it will be highly interesting to determine the effect of 
protein IX-deletion on the interaction of HAdV-5 vectors with white blood cells. 
Therefore, we incubated freshly isolated human peripheral blood mononuclear 
cells with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX, and analyzed GFP expression and the 
expression of cellular activation markers. This revealed relatively high levels 
of GFP expression in the monocyte population. The percentage of GFP-positive 
monocytes was similar for both vectors, varying between 10% and 30% at 100 
pp/cell, depending on the donor (data not shown). For both vectors the GFP 
expression in the T cell, B cell, and NK cell populations was very low (<1% GFP-
positive cells). Although Ad5ΔE1+pIX and Ad5ΔE1ΔpIX showed identical GFP 
expression levels in the monocytes, the incubation with Ad5ΔE1ΔpIX resulted 
in a remarkably higher level of monocyte activation, as indicated by enhanced 
CD86 expression (figure 4.5 A). The percentage of CD86 positive monocytes as 
well as the mean fluorescence intensity for CD86 was significantly higher for 
the pIX-lacking vector. This enhancement in monocyte activation was observed 
for monocytes derived from PBMCs of three different donors and with different 
virus batches. The up-regulated CD86 level involved the entire Ad5ΔE1ΔpIX-
incubated monocyte population, not only the GFP-positive cells (figure 4.5 A). 
Incubation with Ad5ΔE1ΔpIX also resulted in enhanced activation of NK cells, 
as demonstrated by an increase in CD69 expression (figure 4.5 B). Interferon-
gamma (IFN-γ) ELISA of PBMC supernatants revealed higher levels of IFN-γ 
production after incubation with Ad5ΔE1ΔpIX at the higher input virus levels 
(figure 4.5 C). 
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Figure 4.5 Activation of peripheral blood mononuclear cells (PBMCs) after 
incubation with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for two days. (A) Activation of 
the monocyte population. The graphs on the left show the percentage of CD86 positive 
cells and the mean CD86 expression levels (MFI) for three different donors. The flow 
cytometry figures on the right illustrate the CD86 up-regulation for transduced (GFP-
positive) monocytes and non-transduced (GFP-negative) monocytes (from donor 1). (B) 
Activation of the NK cell population. The percentage of CD69 positive cells and the mean 
CD69 expression levels (MFI) are shown for three different donors. (C) Measurement of 
IFN-γ levels in PBMC supernatant (from a single donor) after incubation with Ad5ΔE1+pIX 
and Ad5ΔE1ΔpIX. The data represent mean values of two independent measurements.
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Enhanced liver transduction upon intravenous administration 
of Ad5ΔpIX 
To study the functional consequences of protein IX-gene deletion on biodistribution 
in mice, Ad5ΔE1+pIX and Ad5ΔE1ΔpIX viruses were administered via tail vein 
injection. Luciferase expression in multiple organs was determined at 3 days post 
injection. The vector lacking protein IX yielded a more than ten-fold higher luciferase 
activity in the liver (figure 4.6 A). These data show that the absence of protein 
IX in the viral capsid strongly affected the biodistribution of HAdV-5 particles. 
Figure 4.6 (A) Distribution of Ad5ΔE1+pIX and Ad5ΔE1ΔpIX in mice after tail vein 
injection of 109 vector particles. Prior to vector injection, pre-dosing was performed with 
the vector HAdV-5.CMV to saturate Kupffer cell macrophages. Organs were harvested 
three days post injection and the luciferase expression per total protein was measured 
(*p=0.057, **p=0.006 versus Ad5ΔE1+pIX). Error bars represent SEM (n=2). (B) 
Luciferase expression in HepG2 and A549 cells after transduction with Ad5ΔE1+pIX and 
Ad5ΔE1ΔpIX in the presence of coagulation factor X (FX), Gla-domainless mutant factor X 
(FXMUT), or no coagulation factors (mock). Error bars represent SEM (n =3). 
 Recent reports have described the involvement of plasma proteins, such as 
the blood coagulation factor X (FX), in HAdV-5 transduction of the liver [28,29]. 
To study whether removal of protein IX influences the effects of clotting-factor 
binding we compared the FX-mediated transduction for Ad5ΔE1+pIX and 
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Ad5ΔE1ΔpIX (figure 4.6 B). In vitro incubation of A549 cells and HepG2 cells 
with FX resulted in a similar enhancement in transduction for Ad5+pIX and 
Ad5ΔpIX. As expected, no effect on transduction was observed after incubation 
with the mutant FX (FXMUT), which lacks the domain necessary for binding to the 
HAdV-5 capsid [29]. From these data we conclude that the absence of protein 
IX does not affect the binding of coagulation factor X.
DISCUSSION 
From our data we conclude that the omission of protein IX from HAdV-5 
vectors enhances viral transduction of cell lines that are low in expression of 
the adenovirus receptor CAR. This finding is of relevance for the development 
and implementation of protein IX-gene modified HAdV-5 vectors. Also, the 
findings enhance our knowledge on HAdV-5 biology and evolution, which 
especially becomes clear if stating our conclusion in a ‘backwards’ manner: the 
introduction of protein IX in HAdV-5 (making it wild-type HAdV-5) decreases viral 
transduction of cell lines that are low in CAR expression. Although speculative, 
it is very well possible that the presence of protein IX in the HAdV-5 capsid 
negatively interferes with non-specific cell transduction, and thereby plays a 
role in determining the virus tropism. Noteworthy, the extended cell tropism 
of the Ad5ΔE1ΔpIX vector, as presented by its enhanced transduction of CAR-
negative cells, did not come with a loss in ability of CAR-mediated transduction 
of cells. This is clear from the comparison on MZ2-MEL3.0 and MZ2-MEL3.0/
CAR. Introduction of CAR in the CAR-negative cells significantly increased 
transduction levels with Ad5ΔE1ΔpIX. It is conceivable that in CAR-expressing 
cells the protein IX-deficient particles can use either the CAR/fiber-dependent 
mechanism, or the CAR-independent pIX-dependent mechanism. Quantifying 
the relative contribution of each of these mechanisms to the total transduction 
requires tools for specifically blocking the new pathway. Such inhibitors remain 
to be identified. 
 Interestingly, the vector Ad5ΔE1pIXΔLEU had Ad5ΔE1ΔpIX-like properties, 
implicating the importance of the C-terminal domain of protein IX in inhibiting 
transgene expression in CAR-negative cell lines. The specificity for the C-terminal 
domain of protein IX excludes differences in viral capsid stability as a cause for 
the observed phenomenon, since deletion of this domain does not result in 
reduced capsid stability [4]. 
 Wild-type HAdV-5 enters cells via high affinity binding of the fiber knob 
domain to CAR [14], followed by interaction of the RGD motif of the penton 
base with cellular integrins αVβ3 and αVβ5 promoting rapid adenovirus cell entry 
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into clathrin-coated vesicles [25,26]. Similar to the Ad5ΔE1+pIX control virus, 
Ad5ΔE1ΔpIX requires the presence of bivalent cations for its transgene delivery, 
indicating the usage of cellular integrins for cell internalization [26]. More 
specifically, blocking cells with anti-integrin antibodies resulted in a decrease 
in transduction for Ad5ΔE1ΔpIX, thereby confirming the integrin-dependency. 
Unfortunately, our efforts to compare the vectors for a general difference in cell-
binding affinity, using Alexa488-TFP (tetrafluorophenyl) labeled vector particles, 
were not conclusive as a result of strong and reproducible negative effects of 
the labeling procedure on the pIX-deficient vector particles. The effects were not 
identical for protein IX-positive and protein IX-negative particles, making the 
results obtained with these particles in comparative binding assays unreliable. 
Alternative protocols for fluorescent- or radio- labeling of vector particles might 
be more suitable for comparing the cell-binding affinity. Labeled vector particles 
might also be used for analyzing differences in cell surface motility between 
protein IX-containing and protein IX-lacking vectors. Through largely unknown 
mechanisms HAdV-5 particles migrate on the cell surface and alterations in viral 
movement can result in modified transduction [30]. 
 The removal of the protein IX gene from a replication-competent HAdV-
5 virus results in a small-plaque phenotype on CAR-positive as well as CAR-
negative cell lines. This suggests the tropism modifying mutation affects the 
virus’s capacity to spread from cell to cell. Such small-plaque phenotypes of 
extended tropism mutants is not unprecedented: similar phenotypes have been 
described for murine corona virus mutants that acquired the capacity to bind 
heparin [27]. 
 To investigate the effect of protein IX-gene deletion on the interaction 
of HAdV-5 with human mononuclear leukocytes, we compared the vectors 
Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for GFP expression in PBMCs. Flow cytometry 
analyses demonstrated GFP expression almost exclusively in monocytes, with 
similar expression levels for both vectors. However, increased activation of the 
entire monocyte population (so not exclusively restricted to the GFP-positive 
population) was observed for Ad5ΔE1ΔpIX, as demonstrated by an enhancement 
in CD86 expression. CD86 is an activation marker on antigen-presenting cells 
such as monocytes, macrophages, dendritic cells, and B cells, and is important 
for co-stimulation of T cells [31]. The increased activation of monocytes despite 
similar levels of transduction (GFP expression) could be due to a direct effect on 
the monocytes themselves or indirectly via a more efficient stimulation of T cells 
or NK cells. Uptake of the protein IX-deleted vector may be increased and/or may 
follow different intracellular trafficking routes [32,33]. As a consequence, more 
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efficient viral antigen loading onto human leukocyte antigen (HLA) molecules, 
or an increase in CD86 expression, could lead to more T cell activation, and 
e.g. IFN-γ secretion. Of note, most healthy adult donors have HAdV specific T 
cells [34]. Indeed, Ad5ΔE1ΔpIX incubation resulted in enhanced production of 
IFN-γ. Protein IX-gene deletion appeared to affect NK cell activation as well, 
resulting in increased expression levels of CD69, which is an activation marker 
for lymphocytes including NK cells [35]. Increased T cell activation could have 
been accompanied by increased levels of other T cell cytokines like interleukin-2 
(IL-2). IL-2 is a known activating cytokine of NK cells [36,37]. Alternatively, 
the increased production of IFN-γ in the supernatant would also be consistent 
with increased activation of NK cells by the vector lacking pIX, without the 
involvement of T cells. 
 Irrespective of the mechanism, the increased activation of monocytes and NK 
cells as a result of protein IX deletion is likely to have important consequences 
for the in vivo implementation of protein IX modified HAdV-5 vectors, since 
monocytes (after differentiation to Kupffer macrophages in the liver) as well as 
NK cells are important players in the sequestration of HAdV-5 vectors from the 
blood after systemic delivery (reviewed in [38]). Furthermore, the observed 
differences in PBMC activation between Ad5ΔE1+pIX and Ad5ΔE1ΔpIX suggest 
a biological function of protein IX in diminishing the immune response against 
HAdV-5. Further studies will be necessary to fully determine the effects of 
protein IX deletion from HAdV-5 on the activation of immune cells. 
 Omission of protein IX from the capsid resulted in a remarkable difference 
between Ad5ΔE1+pIX and Ad5ΔE1ΔpIX upon intravenous administration 
in mice. Administration of Ad5ΔE1ΔpIX yielded more than ten-fold higher 
luciferase activity in the liver, for reasons that remain to be clarified. Extensive 
research has been devoted to defining the molecular mechanisms behind the 
sequestration of intravenously administered HAdV-5 in the human liver, with the 
aim to eventually improve the therapeutic efficacy of intravenously delivered 
HAdV-5 vectors (reviewed in [39]). The uptake of HAdV-5 in the liver has been 
found to occur in a CAR-independent manner and involves binding of the virus 
particles in the blood to complement factors and immunoglobulins (mediating 
uptake in Kupffer cell macrophages) [28,40], and coagulation factors (resulting 
in hepatocyte transduction) [28,29]. The enhanced transduction of the liver with 
Ad5ΔE1ΔpIX observed in our mouse model seems not to be a result of more 
efficient binding of the vector to coagulation factor X (FX), as can be concluded 
from our in vitro FX-binding assay. An alternative explanation might be that the 
absence of protein IX extends the HAdV-5 tropism, enabling the transduction 
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of cells in the liver that do not present CAR. Of interest, primary human 
hepatocytes were recently found to have CAR localized at cellular junctions that 
are inaccessible to the hepatic blood flow [41]. This localization is in contrast to 
the CAR molecules on hepatocellular carcinoma cells (like HepG2), being highly 
available for HAdV-5 binding [41,42]. 
 Protein IX is strongly conserved in all primate adenoviruses indicating the 
importance of the protein. A biological role for protein IX in HAdV-5 capsid 
stabilization has been proposed, based on in vitro heat-stability assays [4]. Our 
findings point toward other biological functions of protein IX in (i) determining 
the cell tropism of HAdV-5, and (ii) negatively interfering with the innate 
immune response against HAdV-5. More insight into the mechanisms by which 
the presence of protein IX affects gene transfer and activation of immune cells 
may be of use for enhancing the efficiency of current (e.g. Atencio et al.; [43]) 
and future gene therapies involving protein IX modified HAdV-5 vectors. 
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ABSTRACT 
The survival of glioma patients with the current treatments is poor. Early clinical 
trials with replicating adenoviruses demonstrated the feasibility and safety 
of the use of adenoviruses as oncolytic agents. Antitumor efficacy has been 
moderate due to inefficient virus replication and spread. Previous studies have 
shown that truncation of the adenovirus i-leader open reading frame enhanced 
cytopathic activity of HAdV-5 in several tumor cell lines. Here we report the 
effect of an i-leader mutation on the cytopathic activity in glioma cell lines and in 
primary high-grade glioma cell cultures. A mutation truncating the i-leader open 
reading frame was created in a molecular clone of replication-competent wild-
type HAdV-5 by site-directed mutagenesis. We analyzed the cytopathic activity 
of this RL-07 mutant virus. A cell-viability assay showed increased cytopathic 
activity of the RL-07 mutant virus on U251 and SNB19 glioma cell lines. The 
plaque sizes of RL-07 on U251 monolayers were seven times larger than those 
of isogenic control viruses. Similarly, the cytopathic activity of the RL-07 viruses 
was strongly increased in six primary high-grade glioma cell cultures. In glioma 
cell lines the RL-07 virus was found to be released earlier into the culture 
medium. This was not due to enhanced viral protein synthesis, as was evident 
from equivalent E1A, Fiber and Adenovirus Death Protein amounts, nor to higher 
virus yields. The cytopathic activity of replicating adenovirus in glioblastoma 
cells is increased by truncating the i-leader open reading frame. Such mutations 
may help enhancing the antitumor cytopathic efficacy of oncolytic adenoviruses 
in the treatment of glioblastoma. 
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INTRODUCTION
The poor prognosis of high grade gliomas with the current treatments prompted 
an ongoing search for alternative treatments. A new strategy for glioma 
treatment involves the use of viruses as oncolytic agents, such as Human 
Adenoviruses (HAdV), Herpes Simplex viruses and, more recently Reoviruses 
[44-48]. Of these, the use of HAdV has been explored most rigorously, including 
replication-defective HAdV vectors carrying heterologous transgenes, as well 
as replication-competent HAdV in which replication is restricted to tumor cells. 
 HAdV transduce both dividing and quiescent cells with high efficiency, they 
can be genetically modified with relative ease, and the technology for clinical-
grade production is available. Their biology, which is understood in detail, also 
facilitates modification of the viral genome for creating Conditionally-Replicating 
Adenoviruses (CRAds). In addition, viral-tissue tropism can be modified by 
incorporating ligands that target specific receptors on tumor cells, for example 
by fusing ligands with the fiber [49] or with the minor capsid protein IX [5]. Also 
modifications have been described that promote interactions with the tumor-
specific receptors. Such mutations can be used to increase transduction of 
target tissues [50-53]. 
 The first phase I clinical trial with a replication-competent HAdV on malignant 
glioma was performed with ONYX-015 [44], which is based on HAdV-5 and 
harbors a deletion in the open reading frame encoding the 55 kDa E1B protein 
[54]. Although ONYX-015 has antitumor activity, the precise mechanism behind 
its tumorcell preference is still controversial [55]. While the ONYX-015 study 
provided evidence of the safety of CRAds in glioma-patients [44], the anti-tumor 
efficacy of this virus was limited, presumably due to inefficient replication and 
poor intratumoral spread. 
 To isolate HAdV-5 mutants with improved cytopathic activity, two groups used 
random mutagenesis and bioselection strategies. Both studies yielded mutants 
containing point mutations in the i-leader region of the late transcription unit 
[56,57]. The i-leader is a 440-nucleotide long sequence that is found between 
the 2nd and 3rd element of the tripartite-leader sequence in a significant fraction 
of the major-late transcripts. This sequence contains an open reading frame 
which encodes a small protein of approximately 16 kDa in size [58]. It has been 
suggested that it reduces the half-life of L1 mRNAs, however the precise function 
of the i-leader protein is unknown [58,59]. A common point mutation, C8350T, 
which created a stop codon in the i-leader open reading frame, was isolated 
by Yan et al. [57] after bioselection on the HT29 colon carcinoma cell line. Also 
the C8299T mutation, isolated by Subramanian and coworkers in a screen for 
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large plaques on A549 adenocarcinomic human alveolar basal epithelial cells, 
truncated the i-leader open reading frame [56]. Yan and colleagues demonstrated 
that their mutants ONYX-201 and ONYX-203, which contain next to the i-leader 
mutation some additional mutations, strongly enhanced the cytopathic activity of 
HAdV-5 not only in the cells used for bioselection, but in a larger panel of tumor 
cell lines [57]. Unfortunately, no glioma cell lines were included in their study. 
 In this study we compared the cytopathic activity of a HAdV-5 virus containing 
the single i-leader point mutation with that of wtHAdV-5 in glioma cultures. To 
do so, we created a HAdV-5 that contains the C8350T mutation, which truncates 
this open reading frame. To facilitate identification of the mutant-virus genomes, 
an XhoI restriction site was created 6 nucleotides downstream of this mutation. 
We found the cytopathic activity in glioma cells of the mutant vector (RL-07) to 
be strongly increased compared to the wild-type vector (wtHAdV-5). While the 
mutation does not affect timing of viral protein synthesis and virus yields, the 
mutant virus was found to be released earlier from infected cells. These results 
demonstrate that improved adenoviruses with enhanced spreading activity in 
glioma cells can be generated by introduction of a mutation that truncates the 
i-leader. Such mutations may help enhancing the antitumor efficacy of oncolytic 
adenoviruses in the treatment of gliomas. 
MATERIALS AND METHODS 
Cell lines 
In this study we used the malignant glioma cell lines U251 and SNB19, the 
HAdV-5 E1 transformed human embryonic retinoblast cell lines 911 and PER.
C6, and the A549 lung carcinoma cell line as described before [60]. Cultures of 
freshly resected glioma cells were started from resection material of the Dept of 
Neurosurgery at Erasmus MC and used before the fifth passage. All cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco-BRL, Breda, the 
Netherlands) supplemented with 8% fetal bovine serum (FBS, Gibco-BRL) and 
penicillin-streptomycin at 37°C in a humidified atmosphere containing 5% CO2. 
Adenovirus vector 
We used replication-competent HAdV-5 vectors. The mutant, containing the 
i-leader mutation C8350T and the extra XhoI restriction site (HAdV-5/RL-
07), was generated by homologues recombination in E. coli BJ5183, using 
the pTG3602 plasmid [61] as backbone. The mutated i-leader fragment 
was generated by mutagenesis PCR using synthetic oligo nucleotides 
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5’GACAACATCGCGTAGATGACTCGAGTCCATGGTCTGG and 3’-CCAGACCATGGA-
CTCGAGTCATCTACGCGATGTTGTC. The nucleotide corresponding to nt 8350 is 
represented in bold, and the XhoI restriction site is italicized and underlined. 
The HAdV-5/RL07 virus was rescued on 911 cells, propagated on PER.C6 cells, 
purified by double CsCl density gradient centrifugation, dialyzed, and stored at 
-80°C in sucrose buffer. Infectious particle titers were determined by plaque 
assay on 911 cells. The presence of the C8350T mutation and the XhoI restriction 
site was verified by restriction and sequence analyses (supplementary figure 
5.1 and 5.2). The wtHAdV-5 virus used in this study was recovered in identical 
manner, using a wt HAdV-5 i-leader fragment, to ensure isogenicity of the RL-07 
virus and the wtHAdV-5. The nucleotide sequence of the entire RL-07 virus is 
available upon request. 
Viral titer 
Plaque assays were performed to determine the biological titers (as plaque 
forming units per ml) as described [13]. Briefly, 911 cells were seeded in 6-well 
plates 1 day prior to viral infection. The cultures were exposed to serial dilutions 
of the virus. After 4 hrs viral medium was removed and cells were overlaid with 
0.5% agar/F15 media supplemented with 2% horse serum. Plaque titers were 
read at day 10 post infection (p.i.). 
 The concentrations of viral genome copies were determined by picogreen 
assay [18]. Purified virus was inactivated in a final concentration of 0.05% SDS 
in storage buffer and loaded in microtiter plates. After adding picogreen, the 
fluorescence was measured and viral genomes were calculated using purified 
bacteriophage λ DNA as a standard. 
Propagation on 911 cells 
911 cells were seeded in 6-well plates 1 day before infection. Cultures were 
infected with wtHAdV-5 or RL-07 in parallel MOI=3. 48 hrs p.i. virus was 
harvested and viral titers were defined by plaque assays as described above. 
Cell viability assay 
WST-1 reagent (Roche, Woerden, The Netherlands) was used to determine 
the viability of the cultures after adenoviral infection. Cells were seeded in 96-
well plates and infected with various amounts of virus. The cell viability of the 
cultures was determined 4 days p.i. for the established cell lines, and 7 days p.i. 
for the primary glioma cultures by adding the WST-1 reagent according to the 
manufacturer’s instructions. 
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Viral plaque formation 
The plaque surfaces were determined on U251 cells according the plaque titration 
protocol as for 911 cells. The agar was removed 10 days p.i., and the cells were 
subsequently fixed with methanol and stained with 0.5% crystal violet solution. 
The relative plaque surfaces were determined with Olympus DP-software.
 
Viral release 
To determine the viral release, media and cells were collected separately at 30 
and 48 hrs p.i. of U251 and SNB19 cultures infected with wtHAdV-5 and RL-07 
at MOI=3. The titers were determined by plaque titration on 911 cells. 
Immunoblot procedure 
To study the viral protein synthesis after infection an immunoblot procedure was 
used. U251 and SNB19 were seeded in 6-well plate o/n and infected with RL-07 
or HAdV-5 at MOI=1. Cells were harvested 24, 40, 48, 64, and 70 hrs p.i. in 
radioimmunoprecipitation assay lysis buffer (Ripa) (50 mM Tris-Cl, pH 7.5, 150 
mM NaCl, 0.1% SDS, 0.5% DOC, and 1% NP40) supplemented with protease 
inhibitors (Complete mini tablets, Roche Diagnostics, Almere, The Netherlands). 
Per sample 50 μg of protein lysate, defined by the Pierce BCA protein assay kit 
(Thermo Scientific Rockford, USA), and after addition of western sample buffer 
(final concentrations: 10% glycerol, 2% SDS, 50 mM Tris-Cl (pH 6.8), 2.5% 
b-mercaptoethanol and 0.025% bromophenol blue) was loaded onto a SDS-
polyacrylamide gel. The proteins were transferred to Immobilon-P (Millipore, 
Etten-Leur, The Netherlands). Detection of fiber, E1A and ADP was performed 
with the antibodies 4D2 (anti-fiber tail [23]) and M73 (anti-E1A [62]), a rabbit 
antiserum raised against an ADP peptide (P63-77 [63]; a kind gift from Dr. 
W. S. M. Wold), respectively, and visualized by enhanced chemiluminescence. 
ImmunO anti-actin clone C4 (MP Biomedicals, Amsterdam, The Netherlands) 
was used as loading control. 
Colony-based survival assay 
Suspensions of U251 and SNB19 were infected with wtHAdV-5 or RL-07 with a 
MOI=100 in 2%FBS/ DMEM, non-infected cells were used as control. Cells were 
incubated for 1 hr at 37°C, washed 3 times with PBS supplemented with 1:500 
diluted Immunoglobluline I.V. (stock 60 mg/ml) and plated in a concentration 
of 500 cells/dish, medium was supplemented with 1:500 dilution of IVIg. After 
10 days cells were fixed with methanol and stained with 0.5% crystal violet 
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solution. Single colonies were counted and number of colonies of wtHAdV-5 was 
compared to the number RL-07 colonies. 
Trypan blue exclusion-based survival assay 
This procedure was performed as described by Tollefson et al. [64]. In short, 
U251 and SNB19 were seeded at 4.105 cells per well in a 6-well plate. The next 
morning cells were infected with MOI=100 in 1 ml DMEM/2% FBS. After 2 hr 
1 ml DMEM/14%FBS was added to each well. From day 1 up to day 5 media 
and cells were harvested and trypan blue was added to the cells in a final 
concentration of 0.02%. A total of 500-600 cells were counted and percentage 
of viable cells was calculated. 
RESULTS 
The aim of this study was to evaluate whether truncation of the i-leader open 
reading frame enhances the cytopathic effect of HAdV-5 in human glioma cell 
lines. Since the ONYX-234 virus [57], which consists of HAdV-5 with the C8350T 
mutation, was unavailable to us, we recreated this mutant by site-directed 
mutagenesis and homologous recombination. To facilitate straightforward 
identification of this mutant, we inserted an XhoI-restriction site 6 nucleotides 
downstream of the C8350T mutation (supplementary figure 5.1 and 5.2). 
From the cloned virus DNA, viruses were generated by transfection of the 
viral genomes on 911 helper cells. Viral plaques were picked and the viruses 
expanded and propagated on PER.C6 cells. No consistent differences in viral 
particle to plaque forming unit (pfu) ratios were observed (table 5.1) in RL-07 
and wtHAdV-5 virus bathes produced in parallel. Also on 911 cells, the RL-07 
viruses could be propagated efficiently, with the kinetics and yields very similar 
to the wtHAdV-5 (table 5.2). 
Table 5.1 Overview viral yield in pfu/ml and vp/ml after CsCl-purification
Plaque assay
(pfu/ml)
Picogreen assay
(vp/ml)
vp/pfu ratio
Batch 1
wtHAdV-5 3x1011 5.5x1012 18
RL-07 1.1x1011 1.6x1012 15
Batch 2
wtHAdV-5 2.8x1011 3.2x1012 11
RL-07 1.3x1011 1.6x1012 12
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Table 5.2 Viral yield (pfu) of wtHAdV-5 and RL-07 on 911 cultures
 wtHAdV-5 RL-07
Culture 1 1.35x109 1.24x109
Culture 2 1.42x109 1.13x109
Culture 3 1.25x109 1.34x109
Average 1.34x109 1.23x109
SD 8.8x107 1.08x108
Figure 5.1 Relative survival as determined by WST-1 assay. Cytopathic activity of 
RL-07 (grey bar) compared to wtHAdV-5 (black bar) is higher on glioma cell lines U251 
and SNB19. Error bars represent the SD (n=3). * - statistical significance; unpaired, two-
sided t-test, p<0.01. Cells were seeded in 96-well plates 1 day before infection with RL-07 
and wtHAd5 (MOI range 0-100 pfu/cell). Viability of the cultures was determined 4 days 
p.i by WST-1 assay. Very similar results were obtained in a repeat experiment. 
 To analyze the cytopathic activity of RL-07, two glioma cell lines (U251 and 
SNB19, both CAR-positive) and two control cell lines (911 and A549) were 
infected with RL-07 and wtHAdV-5 at multiplicity of infections (MOI) ranging 
from 0 to 100 pfu/cell. Four days p.i., the cell viability was determined by WST-
1 assay (figure 5.1), RL-07 had a significant higher cytopathic effect on glioma 
cell lines and A549 compared to the control virus wtHAdV-5. On 911 cells, no 
differences in the induction of cytopathic effects were detected. 
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 To determine whether the decreased viability of RL-07 infected cells in the 
WST-1 assay correlates with enhanced spread in monolayers of glioma cells, a 
plaque assay was performed on U251 cells. Monolayers of U251 were infected with 
RL-07 and wtHAdV-5 with a 109 times diluted virus stock (batch 1) and overlaid 
with agar. Plaque sizes were scored 10 days p.i. (figure 5.2). The plaques formed 
upon infection with RL-07 are on average 7-fold larger in size than the plaques 
obtained with wtHAdV-5, demonstrating that the mutation enhances viral spread. 
Figure 5.2 Viral plaque formation on U251 cells. Monolayers of U251 were infected 
with RL-07 or wtHAdV-5 with a MOI of 2.2x10-5 and 6x105 respectively, and overlaid 
with 0.5% agar in F15 media supplemented with 2% Horse serum. Ten days p.i. the agar 
was removed and cells were stained with 0.5% crystal violet solution. (A) Photograph of 
plaques of wtHAdV-5 and RL-07 on U251 monolayer (B) Relative plaque surface of 10 
plaques. *-statistical significance; unpaired, two-sided, t-test, p<0.01. wtHAdV-5 - black 
closed triangles; RL-07 - grey closed triangles.
 To compare the kinetics of virus release, U251 and SNB19 cells were infected 
with either RL-07 or wtHAdV-5. At 30 and 48 hrs p.i. the medium was carefully 
separated from the adherent cells and both were collected. In both fractions the 
viral particles were quantified by plaque assays on 911 cells (figure 5.3). In both 
cell lines approximately 7-fold more virus was found in the medium of the RL-07 
infected cells than in the medium of the wtHAdV-5 infected cells at 30 hrs p. i.. 
At 48 hrs p.i. media of RL-07 infected U251 cells contained approximately 22 
times more virus than those infected with wtHAdV-5. Similarly, the amount of 
RL07 in the media of SNB19 cultures was at least 13 times higher at 48 hrs p.i.. 
From these data we conclude that the RL-07 virus is released in to the medium 
earlier than wtHAdV-5. 
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Figure 5.3 Virus releases in culture media. At 30 and 48 hrs p.i. with wtHAdV-5 and 
RL-07 the cells and the media of the U251 and SNB19 cultures were collected separately 
and assayed in a plaque assay. The fraction of the total yield recovered in the medium is 
plotted. Black bars represent wtHAdV-5 and the grey bars RL-07. Error bars represent the 
SD (n=3) * - statistical significance; unpaired, two sided t-test.
 Having established that the RL-07 virus was released earlier than wtHAdV-5, 
we examined the expression pattern of the viral proteins E1A, fiber, and the 
adenovirus death protein (ADP). U251 and SNB19 cells were infected at MOI=1 
and harvested at several time points after infection and viral proteins were 
visualized by immunoblotting (figure 5.4). In our time series no differences 
between fiber, E1A and ADP levels were observed between RL-07 and wtHAdV-5. 
This shows that the rapid release of RL-07 particles does not result from more 
rapid viral protein synthesis. 
 In addition to the WST-1 assay, which determines the metabolic activity 
of the remaining viable cell population, two more direct survival assays were 
performed. These are the colony-based survival assay and the trypan blue 
exclusion-based survival assay. The colony-based survival assay measures the 
number of residual colony-forming cells after exposure of the cells to the virus. 
In this assay no differences in the number of colonies were noted between 
wtHAdV-5 and RL-07-infected U251 or SNB19 cells (data not shown). With the 
trypan-blue based assay the fraction of dead cell was assessed by trypan-blue, 
starting 1 day after infection with MOI=100. Up to day 5 the cell viability of the 
U251 and SNB19 cultures were determined and plotted (figure 5.5). At one day 
p.i. there was no increase in cell death discernible. At two days after infection 
the viability started to decrease. On the U251 cells no differences were observed 
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between the two viruses. On the SNB19 cell line, from day 2 up to day 5 p.i. a 
significant higher proportion of dead cells were detected in the cultures infected 
with RL-07 compared to wtHAdV-5. This indicated that RL-07 accelerates cell 
death on this cell line. 
Figure 5.4 Protein immunoblot assay for detection of viral proteins. Fiber, E1A, 
ADP levels were detected upon infection with RL-07 or wtHAdV-5 at various time points 
p.i.. Actin was used as loading control. Cells were seeded o/n in a 6-well plate and infected 
with MOI=1. Cells were harvested 24, 40, 48, 64 and 70 hrs p.i. in Ripa buffer. Protein 
amounts were determined by BCA protein assay. In each lane 50µg of protein was loaded. 
C-mock infected control; W- infected with wtHAdV-5; R- infected with RL-07.
Figure 5.5 Trypan blue-based survival assay. U251 and SNB19 cultures were infected 
with wtHAdV-5 or RL-07 with a MOI of 100. Cell death in the cultures was determined 
by trypan blue as described by Tollefson and colleagues [64]. Error bars represent the 
SD (n=3) * - statistical significance; unpaired, two sided t-test, p<0.01. ® - wtHAdV-5 
infected and Δ - RL-07 infected
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Table 5.3 Characteristics primary glioma cell cultures
Tumor specimen Male/Female Age Histology
EMC-1 M 44 Anaplas. Astrocytoma
EMC-3 M 48 Glioblastoma multiform
EMC-9 M 66 Glioblastoma multiform
EMC-24 M 50 Glioblastoma multiform
EMC-26 F 42 Anaplas. Astrocytoma
EMC-29 F 53 Anaplas. Astrocytoma
Figure 5.6 Relative survival of infected cells as determined by WST-1 assay. 
Cytopathic activity of RL-07 (grey bar) compared to wtHAdV-5 (black bar) is higher on 
primary high grade glioma cell cultures. Error bars represent SD (n = 4). * -statistical 
significance; paired, two sided t-test, p < 0.01. Cells were seeded in 96-well plates 1 
day prior infection with RL-07 and wtHAdV-5 (MOI range 0-100 pfu/cell). Viability of the 
cultures was determined by WST-1 assay 7 days p.i.. 
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 So far our results demonstrate that the i-leader mutation in RL-07 accelerates 
virus release and enhances spread in established glioma cell lines. However, the 
potency of oncolytic HAdV can differ remarkably between established cell lines 
and cultures derived from resection material. To verify the cytopathic activity 
of RL-07 in human gliomas, cultures established from resection material of high 
grade gliomas were used for cytolysis assays. The characteristics of the cultures 
used in this study are summarized in table 5.3. The cytopathic activities of the 
viruses were evaluated 7 days p.i. by WST-1 assay. The results are presented 
in figure 5.6. At MOI=10 and MOI=100 all RL-07-infected cultures showed a 
significantly increased cytopathic activity in comparison to wtHAdV-5. In three 
of the cultures, EMC-1, EMC-9 and EMC-24, a significant effect could already 
observed at MOI=1.
DISCUSSION 
In our long term efforts of developing efficacious adenoviruses for gene therapy 
in glioma [50,60,65-69], we studied the effect of a truncating mutation in the 
i-leader open reading frame on adenovirus cytopathic activity in glioma cell 
lines and cell cultures. Our data show that this mutation results in more rapid 
release of progeny viruses into the culture medium and enhanced spread of 
the virus in plaque assays. While the precise mechanism for this effect remains 
to be elucidated, the improved cytopathic activity may be employed in new 
oncolytic adenoviruses. Our data confirm and extend the results described by 
Yan et al. [57]. These authors isolated the ONYX-201 and ONYX-203 viruses by 
bioselection on HT29 cells. These viruses harbor several mutations, and share 
four mutations including the i-leader truncating C8350T mutation. Subsequently 
these authors generated the ONYX-234 virus that only harbors the C8350T 
mutation, and show that this mutation enhances the adenovirus’s capacity to 
kill HT29 cells. We confirm and extend these observations and demonstrate that 
truncation of the open reading frame enhances the adenovirus’s cytopatogenicity 
in glioma cells.
 Similar to Subramanian et al. [56], we found that the i-leader mutation did not 
affect virus yield and production kinetics. In addition, no consistent differences 
in particle to pfu ratios were observed in batches produced in parallel. In a 
side by side comparison we demonstrated that RL-07 is more cytopathic on 
A549 and the glioma cell lines U251 and SNB19 than the isogenic wtHAdV-5. 
The increased cytopathic activity observed on these cell lines is similar to the 
observations of Yan et al. with ONYX-234 on HT29 [57]. 
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 Enhanced spread was observed on U251 figure 5.2 with a 7-fold increase 
in plaque surface. This is in line with published data of the other i-leader 
mutants [56,57]. There is a broad variation in plaque surfaces for both viruses. 
As discussed by Subramanian et al. this may be attributable to stochastic 
fluctuations in virus infection and replication [56]. The enhanced spread on U251 
can be explained by the more rapid release of RL-07 from the cells. This is not 
caused by enhanced DNA replication (data not shown) confirming observations 
of Soloway and Shenk [59] and Subramanian [56], nor by a changed kinetics 
of protein synthesis of fiber, E1A and ADP figure 5.3. These results are similar 
to the results of Subramanian and co-workers, who also demonstrated that the 
improved viral spread is independent of ADP expression [56]. In contrast to 
the data of Yan et al. [57], we found no evidence that the truncating i-leader 
mutation affects virus replication, viral gene expression, or viral yields. The 
reason for this discrepancy is unclear but may relate to differences in the cell 
system used (glioma cells vs. colorectal carcinoma cells). It is also conceivable 
that any of the other six mutations in the ONYX-201 and ONYX-203 viruses have 
contributed to the differences between the results of the Yan study and ours [57]. 
 Our data provide clear evidence for enhanced cytopathicy of the RL-07 virus 
in glioma cell cultures. To test whether this is caused by more rapid cell death 
upon infection or to enhanced virus spread we used several assays to assess 
cell viability. The WST-1 assay measures the metabolic activity of the residual 
viable cells in a culture, and is unable to distinguish these two components. The 
involvement of ADP in early cell death is unlikely since there is no difference 
between ADP expression in RL-07 and HAdV-5 infected cells. A more direct 
viability assays is the colony-formation survival assay which yielded very similar 
results with RL-07 and wtHAdV-5. Also a more direct assessment of cell killing 
on a per-cell basis is the assay by trypanblue exclusion. This assay revealed that 
there was no difference in cell death between the two viruses in U251 cells. On 
SNB19 cells a slightly more rapid cell death was observed in cultures infected 
with RL-07 compared to wtHAdV-5. The reason for the difference between the 
U251 cells and the SNB19 cells is unclear. Nevertheless, our data imply that 
although metabolic viability of U251 cultures infected with RL-07 decreases 
faster than in wtHAdV-5 infected cultures, this is not reflected in a more rapid 
cell killing by RL-07. In both cell types there is a strong increase in the release 
of infectious viral particles early after infection figure 5.3. 
 In the last set of experiments the cytopathic activity of RL-07 was determined 
on primary glioma cell cultures. Primary cell cultures resemble the original tumor 
more than established tumor cell lines. Also in these cultures, we observed 
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significant increased cytotoxic activity of RL-07 in all the cell lines tested. These 
results confirm that RL-07 exhibits an increased cytopathic activity in low 
passage cultures of resected glioma cells. 
 To enhance the potency and reduce the toxicity of adenovirus vectors the 
replication of HAdV-5 vectors for glioma therapy has been restricted by using 
promoters that are preferentially expressed in tumor cells for driving expression 
of key viral genes such as E1A. Also the tropism of the viruses has been 
modified by fiber modifications to increase the transduction of tumor cells and/
or to decrease the transduction in non-target cells. New mutations such at the 
mutation that truncates the i-leader open reading frame may prove very useful 
for optimizing such vectors by increasing their the spread. With the fiber-swap 
mutations [50] and the optimized glial fibrillary acidic protein promoter [60,67], 
the mutation truncating the i-leader open reading frame protein constitutes a 
new addition to our arsenal of validated modules for inclusion in new replicating 
glioma-targeted adenoviruses.
CONCLUSION 
In conclusion, truncating the i-leader of HAdV-5 by a single point mutation will 
give increased cytopathic activity in glioma cells. Introducing this mutation in 
an oncolytic adenovirus may enhance the antitumor cytopathic efficacy in the 
treatment of glioblastoma. 
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SUPPLEMENTARY FIGURES 
Supplementary figure 5.1 Identification of RL-07 by PCR analyses. PCR analyses 
were performed on small freeze-thaw-lysate samples of the viral batches. Samples were 
heat inactivated and treated with proteinase K prior to PCR analysis. The i-leader region 
was amplified with the following primer set: Fwd primer 5’-AGACGCTCGGTGCGAGGATGCG; 
Rev primer 3’-GTCGTCTTCACGCAGAGGCGC. The PCR product was purified according to 
the SureClean protocol (Bioline, London, UK) and the product was digested using XhoI and 
loaded on 2% agarose gel. The picture represents the photo-negative image.
Supplementary figure 5.2 Alignment i-leader region. Sequencing analyses were 
performed on PCR products of freeze-thaw samples of virus batches (described by 
identification RL-07). PCR products were first cleaned with Sureclean (Bioline, London, 
UK), according to the manual, before direct sequencing. Sequencing was performed at the 
Leiden Genome Technology Center (LGTC, Leiden, The Netherlands). The sequences of 
nucleotide 8300-8400 of the parental plasmid pTG3602 and the sequences of the HAdV-5 
and RL-07 viruses are represented. The C8350T changes, as well as the XhoI site created 
in the RL-07 virus, are boxed.
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ABSTRACT 
Human orthoreovirus Type 3 Dearing is not pathogenic to humans and has 
been evaluated clinically as oncolytic agent. Its transduction efficiency and the 
tumor-cell selectivity may be enhanced by incorporating ligands for alternative 
receptors. However, genetic modification of reoviruses has been difficult and 
genetic targeting of reoviruses has not been reported so far. Here we describe 
a technique for generating genetically targeted reoviruses. The propagation 
of wild-type reoviruses on cells expressing a modified s1-encoding segment 
embedded in a conventional RNA polymerase II transcript leads to substitution 
of the wild-type genome segment by the modified version. This technique was 
used for generating reoviruses which are genetically targeted to an artificial 
receptor expressed on U118MG cells. These cells lack the junction adhesion 
molecule-A and therefore resist infection by wild-type reoviruses. The targeted 
reoviruses were engineered to carry the ligand for this receptor at the C-terminus 
of the s1 spike protein. This demonstrates that the C-terminus of the s1 protein 
is a suitable locale for the insertion of oligopeptides ligands and that targeting of 
reoviruses is feasible. The genetically targeted viruses can be propagated using 
the modified U118MG cells as helper cells. This technique may be applicable for 
the improvement of human reoviruses as oncolytic agent.
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INTRODUCTION
Orthoreovirus Type 3 Dearing (T3D) has been evaluated clinically as oncolytic 
agent [1,2]. The impetus for these studies has been the observation that reovirus 
T3D preferentially lyses tumor cells, especially those with an activated Ras 
signaling pathway [3-7]. The Reoviridae (Respiratory Enteric Orphan viruses) 
constitute a family of non-enveloped viruses with segmented double-strand (ds) 
RNA genomes. The three types of human reoviruses have 10 genome segments 
and are classified in the genus orthoreovirus. These viruses are not associated 
with disease in humans. In newborn mice, however, these viruses can cause 
lethal infections [8]. T3D is often studied and serves as a model for the family. 
Reovirus T3D enters the host cell through the interaction of the spike protein s1 
with its cognate receptor, the junction adhesion molecule (JAM-A). In addition, 
sialic-acid groups at the cell surface can act as receptors [9-13]. The JAM-A-
binding amino acids are located in the C-terminal head domain of σ1 [12,14-16]. 
After cell attachment, integrin-binding motifs in the capsid protein λ2, which 
forms the structural base for σ1, bind β1-integrins and mediate endocytosis 
[17]. Following endosomal escape viral replication ensues. Capped plus-strand 
RNA molecules are formed by transcription of the genome segments by the 
viral RNA-dependent RNA-polymerase. Plus-strand RNA molecules are used for 
translation and also associates with viral core proteins in special virus-induced 
cellular compartments, the so-called “viral factories” [18]. The packaging of 
the 10 genomic segments must be well orchestrated, as each viral core must 
contain a single copy of each of the plus-strand transcripts. Recent studies 
suggest that sequences contained within the 130 nucleotides (nt) at the 5’ 
terminus serve as identity label for each of the segments [19]. Negative-strand 
synthesis takes place within the newly-formed core, yielding dsRNA segments. 
These can be further transcribed, or included in maturing virions to be released 
by the infected cell [20-22]. The plus-strand RNAs contain the tetranucleotide 
sequence ‘GCUA’ at the 5’ end and the pentanucleotide sequence ‘UCAUC’ at the 
3’ end, which may have a role in the encapsidation process [23]. 
 The efficiency of reovirus-based oncolytic therapies is most likely 
compromised by the scarcity of reovirus receptors on the surface of tumor cells. 
Freshly isolated colorectal tumor cells resist T3D infection, probably due a lack 
of JAM-A on their surface [24]. The transduction efficiency and the tumor cell 
selectivity of oncolytic viruses, such as adenoviruses, has been enhanced by 
genetically incorporating ligands for alternative receptors [25]. However, genetic 
modification of reoviruses has been notoriously difficult. A few reports have 
been published on the genetic modification of member of the Reoviridae family 
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[21,26]. However, these systems are arduous and rather inefficient. Recently, 
a reverse genetics method has been described that relies on transfection of 
10 different expression plasmids encoding all of the viral segments [27]. With 
this method, a heterologous transgene was engineered into one of the genome 
segments. However, the genetic modification of capsid components to amend 
viral tropism was not reported.
 Here we describe a new technique for genetically modifying reoviruses. The 
technique was used for generating targeted T3D variants carrying (His)6 tags 
at exposed positions in the head domain of the s1 spike. Reoviruses carrying 
the s1-(His)6 spikes, but not wild-type T3D, can infect genetically engineered 
U118MG glioblastoma cells displaying a single-chain antibody fragment (scFv-
His), recognizing the (His)6 tag as an artificial receptor on their surface. The 
(His)6-tagged reoviruses, in combination with the scFv-His-expressing U118MG 
cells, can serve as a basis for developing tumor-targeted reoviruses. 
MATERIALS AND METHODS
Cell lines 
The cell line 911 is adenovirus type 5 early region 1-transformed human embryonic 
retinoblasts [28]. U118MG human glioblastoma cells were obtained from Dr. B. 
de Leeuw (Erasmus Medical Center, Rotterdam, The Netherlands). All cell lines 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Breda, 
The Netherlands) supplemented with penicillin, streptomycin, glucose, and 8% 
fetal bovine serum (FBS; Invitrogen), unless otherwise specified. Cells were 
cultured in a 5% CO2 atmosphere at 37°C. 
Reovirus propagation
The cell line 911 was used to propagate wild-type T3D (American Type Culture 
Collection, VR-824) as described previously [29]. Briefly, cells were exposed 
to reovirus in DMEM/2% FBS for 2 hrs at 37°C, 5% CO2. Subsequently, the 
inoculum was replaced by DMEM containing 8% FBS. The virus was harvested 
48 hrs postinfection by resuspending the cells in phosphate-buffered saline 
(PBS) with 2% FBS and subjecting the suspension to three cycles of freezing 
and thawing. The sample was cleared by centrifugation for 10 min at 800x g. 
Where indicated, the virus was further purified by CsCl equilibrium centrifugation 
essentially as described [28]. In some experiments the R124 clonal isolate was 
used. This isolate was purified from the VR-824 stock obtained from the ATCC by 
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two rounds of plaque purification on 911 cells. The infectious reovirus titer was 
determined by plaque assay on 911 cells.
Cell viability assay
WST-1 reagent (Roche, Woerden, The Netherlands) was used to assay the 
viability of cells after reovirus infections. Cells were infected with different 
amounts of reovirus in 96-well plates and WST-1 reagent was added, according 
to the manufacturer’s instructions, at various time points post infection. 
Cloning of T3D S1 from infected 911 cells
Cultures of 911 cells were infected with to wild-type reovirus T3D at an MOI 
of ~2 plaque-forming units (pfu)/cell. Total cellular RNA was extracted 24 hrs 
postinfection using the Absolutely RNA miniprep kit (Stratagene, Huissen, The 
Netherlands). First-strand cDNA synthesis employed the ReoS1 Rev primer, using 
SuperScript II reverse transcriptase (Invitrogen). Pfu polymerase (Promega, 
Leiden, The Netherlands) was used for template amplification. See table 6.1 
for details about the primers and the PCR fragments. The PCR product was 
purified from a 1% agarose gel using the JetSorb kit (Genomed, ITK Diagnostics, 
Uithoorn, The Netherlands). The product was digested using HindIII and NotI, 
and cloned into the plasmid pCDNA3.1+ (Invitrogen) digested with the same 
enzymes, yielding plasmid pRT3S1. The sequence of the insert was verified at 
the Leiden Genome Technology Center.
 To insert the codons for the (His)6 tag at the C-terminus of σ1, the σ1-coding 
region was PCR amplified with primers HisReoS1_Rev and ReoS1_For table 6.1. 
The PCR product was digested with HindIII and ligated to HindIII-and EcoRV-
digested pCDNA3.1+. The resulting plasmid was used as template for PCR 
amplification with primers SigmaEnd_Rev and ReoS1_For and, after digestion 
with HindIII, ligated into HindIII and EcoRV-digested plasmid pCDNA3.1+, 
generating plasmid pRT3S1His. 
 The sequences of all the constructs described in this study are available on 
request.
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Table 6.1 Primers used in this study
Method Primer name 
Primer 
number Sequence
Primer 
combi
Fragment 
length 
(bp)
JAM 
detection
hJAM
For
1 5’-TGGGGACAAAGGCGCAAGTC-3’
hJAM_RT 
Rev
2 5’-CACCAGGAATGACGAGGTC-3’ 1+2 928
S1 cloning ReoS1 
For
3 5’-CCAAGCTTGCTATTGGTCGGATG
GATCCTCG-3’
ReoS1 Rev 4 5’-ATTGCGGCCGCGATGAAATGCCCC
AGTGCCG-3’
3+4 1435
His-tag 
addition
HisReoS1 
Rev
5 5’-GCAGGGTGGTCTGATCCTCAGTGATGGT
GATGGTGATGCGTGAAACTACGCGGGTA-3’
3+5 1423
SigmaEnd 
Rev
6 5’- GATGAAATGCCCCAGTGCCGCGGGG
TGGTCTGATCCTCA-3’  
3+5 1442
S1His RT-
PCR
S1endR 7 5’-GATGAAATGCCCCAGTGC-3’ 3+7 1442
His-Rev 8 5’-GTGATGGTGATGGTGATG-3’ 3+8 1403
β-actin 
RT-PCR
Hum_β-
actin For
9 5’-CAAGAGATGGCCACGGCTGCT-3’
Hum_β 
actin Rev
10 5’-TCCTTCTGCATCCTGTCGGGCA-3’ 9+10 275
JAM-ECD 
cloning
JamDP For 11 5’-TGTACTGCAGTGCACTCTTCTGAACC
TGAAGT-3’
JamDP Rev 12 5’-TATGCTGCAGGACCCCCACATTCCGCT-3’ 11+12 755
Reverse transcription-PCR
Primers used for the RT-PCR procedures are listed in table 6.1. For the detection 
of human JAM-A RNA , 911 cells and U118MG cells were seeded on 5 cm 
dishes and total cellular RNA was isolated using the Absolutely RNA miniprep 
kit (Stratagene). In all cases, SuperScript II was used to generate first-strand 
cDNA. For the characterization of the 911S1His cell line, total cellular RNA 
was extracted from confluent cultures of 911 and 911S1His cells, as described 
above. For the detection of S1His in reovirus batches, infections of 911 cells 
were performed. RNA was isolated 24 hrs after infection and used for RT-PCR 
amplification. The resulting PCR products were cloned into plasmid pTOPO-TA 
(Invitrogen) and their DNA sequences were determined.
Production of lentiviral vectors
All lentiviral constructs used in this study were based on the pLV-CMV-x-IRES-
Neo vector [30] figure 6.3. The S1His region of plasmid pRT3S1His was released 
by Eco105I and XbaI digestion and inserted in the same restriction sites of pLV-
CMV-x-IRES-Neo. To generate the HA-JAM lentiviral expression vector, plasmid 
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pCDNA-HA-JAM [31] (kindly provided by Dr. U.P Naik, Delaware, Newark) was 
digested with Eco105I and XbaI and inserted in pLV-CMV-BC-Neo. Plasmid pLV-
JAM-ECD-IRES-Neo was made by first inserting the codons for the extracellular 
domain (ECD) of JAM into pDisplay (Invitrogen) and cloning the Eco105I-XhoI 
fragment into the same sites of the pLV vector. pCDNA-HA-JAM was used as 
template to amplify the JAM-ECD (see table 6.1) . To generate pLV-scFvHis-
IRES-Neo, encoding the anti-His tag single-chain antibody fragment, pHissFv.
rec [32] (a kind gift from Dr. D.T. Curiel, Univ. of Alabama) was digested with 
Eco105I and XhoI and inserted in the pLV vector. Production of the lentiviral 
vectors and transduction of the cells were performed as described previously 
[30,33]. The LV-S1His vector was used for transducing cultures of 911 cells 
at an estimated MOI of 0.5. The polyclonal, G418-restistant cell population, 
referred to as 911S1His cells were used for further studies.
Generation of modified reoviruses carrying the S1His segment
Wild-type reoviruses were used to infect 911S1His cells according to routine 
procedures. After three rounds of propagation, the resulting σ1-His containing 
viruses were harvested by freeze thawing and used to infect U118scFvHis cells. 
The virus produced in U118scFvHis cells was harvested at the first signs of CPE, 
and serially passaged several times in U118scFvHis cells. 
[35S]Methionine labeling
Infected or mock-infected cells were incubated with Redivue [35S]methionine 
Pro-mix (200 µCi/ml; Amersham, Roosendaal, the Netherlands) for 4 hrs at 
various time points post infection. Cells were washed once with PBS and lysed in 
Giordano Lysis Buffer (50 mM Tris-Cl (pH=7.4), 250 mM NaCl, 0.1% Triton, 5 mM 
EDTA) containing protease inhibitors (Complete mini tablets, Roche Diagnostics, 
Almere, The Netherlands). All labeling assays were performed in 24-wells plates 
with 5 µl Pro-mix per well. The cells were lysed with 100 µl lysis buffer per 
well. Fifty µl of the lysates was loaded on a 10% SDS-polyacrylamide gel after 
addition of sample buffer. Gels were dried and exposed to a radiographic film to 
visualize the labeled proteins. 
Immunofluorescence assay 
For immunofluorescence assays, cells were grown on round glass cover slips 
in 24-well plates, fixed with methanol, washed with PBS containing 0.05% 
Tween-20, and incubated with a primary antibody against the oligo (His) tag 
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primary antibody (Sigma Aldrich, Zwijndrecht, The Netherlands). The coverslips 
were washed and incubated with secondary fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse serum for 30 min at room temperature. The 
mounting solution consisted of glycerol containing 0.02 M Tris-HCl (pH=8.0), 
2.3% 1,4-diazabicyclo-[2.2.2]-octane and 0,5 μg/ml 4’,6-diamidino-2-
phenylindole (DAPI) to visualize the nuclei. 
Western blot analysis
Cell lysates were made in Giordano lysis buffer supplemented with protease 
inhibitors. Reovirus lysates were prepared by adding 15 ml of cleared reovirus to 
5 ml of Western sample buffer (final concentrations: 10% glycerol, 2% SDS, 60 
mM Tris-Cl (pH 6.7), 2.5% b-mercaptoethanol, and 2.5% bromophenol blue). 
After incubation for 3 min at 100°C, the samples were analyzed on SDS 10% 
polyacrylamide gels. The proteins were transferred to Immobilon-P (Millipore, 
Etten-Leur, The Netherlands) and visualized using standard protocols. Primary 
antibodies used were the Penta-His antibody (Qiagen, The Netherlands) for 
detection of the (His)6 tag and 7F4 directed against reovirus protein λ2 [34] 
(kindly provide by Dr. K. Tyler, University of Colorado Health Science Center, 
Denver, Colorado). The secondary antibody used was horseradish peroxidase-
conjugated Goat anti-Mouse IgG (Santa Cruz Biotechnology, Santa Cruz, USA). 
Selective eradication assay
U118MG cells were transduced with a lentiviral vector encoding the eGFP gene 
[33]. The resulting U118eGFP cells were mixed with U118scFvHis cells and 
seeded in six-well plates. The mixed cultures were either mock infected, or 
infected with R124-S1His (MOI of ~1 pfu/cell). At the indicated time points after 
the infection, the cocultures were trypsinized and the cells were collected in PBS. 
These cell suspensions were analyzed for eGFP activity using a BD LSRII flow 
cytometer and BD FACSDiva software (BD Bioscience, Breda, The Netherlands).
RESULTS
The efficacy and specificity of oncolytic-virus approaches can be enhanced by 
targeting infection to tumor cells. The development of targeted reoviruses has 
been hampered by the difficulties in applying reverse genetics procedures to the 
segmented dsRNA genomes of these viruses. Therefore we set out to develop a 
novel technique for generating such genetically targeted reoviruses (figure 6.1). 
A cell line was selected that supports reovirus replication but resists infection 
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due to the absence of reovirus receptors. This cell line was endowed with a 
cell-surface protein that can function as an artificial receptor. The codons for 
the peptide ligand were engineered in a suitable position in one of the reovirus 
capsid proteins. Finally, the genomic segment encoding this modified capsid 
protein was introduced in the reovirus genome. 
Figure 6.1 Schematic representation of the selection system for a targeted 
reovirus. The lentivirus vector LV-S1His was used to transfer a reovirus S1-expression 
cassette into 911 cells. The resulting 911S1His cells produce the σ1 protein carrying the 
(His)6 tag at its C-terminus. On infection of the 911S1His cells with wild-type T3D, the 
progeny viruses may carry a mixture of σ1-His and σ1 spike proteins in their capsid. As 
a consequence, these viruses can infect the U118scFvHis cells that display an anti-His-
tag single chain-antibody on their cell surface which can serve as an artificial receptor. 
Unmodified U118MG cells resist reovirus infection. Sequential passaging of virus in 
U118scFvHis cells selects for viruses in which the wild-type S1 segment has been replaced 
by the heterologous S1His segment during replication in the 911S1His cells.
JAM-A deficiency underlies U118MG resistance to reovirus 
infection.
A cell line lacking reovirus receptors and, as a result, resistant to infection, is 
crucial in the development of genetically retargeted reoviruses. On the basis of 
published data [35], the human glioblastoma cell line U118MG was selected as a 
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candidate. To confirm its resistance to reovirus infection, cultures of U118MG cells 
were exposed to T3D and assayed for cell viability (figure 6.2 A). The viability of 
U118MG cells was not affected by T3D, up to a multiplicity of infection (MOI) of 
100. In contrast, survival of the control cell line 911 declined significantly after 
infection at a MOI of 0.001. The viability of the cells, as measured by WST-1 assay, 
strongly correlated with the induction of cytopathic effect (CPE) (data not shown).
Figure 6.2 U118MG cells resist reovirus infection due to a lack of JAM-A expression. 
(A) U118MG cells survive reovirus infection. The viability of cultures of U118MG cells 
( • ) and cultures of 911 cells ( ◊ ) infected with increasing amounts of reovirus T3D was 
measured two days post-infection by WST-1 assay. (B) hJAM-1 RNA is absent in U118MG 
cells. RNA from U118MG cells (U118) and 911 cells was isolated and used for cDNA 
synthesis with primer hJAM_RT rev (see table 6.1). As a positive control (+), a small 
amount of the pCDNA-HA-JAM plasmid was included in a PCR reaction (product length 
see table 6.1). A β-actin-specific RT-PCR assay was performed to confirm the integrity of 
the RNA. (C) Schematic representation of the HA-JAM and JAM-ECD proteins displayed at 
the cell membrane. (D) Display of JAM-A or its extracellular domain-sensitized U118MG 
cells to reovirus T3D. Reovirus T3D-infected cells and mock-infected cells were labeled 
with [35S]-methionine once CPE became apparent, and protein samples were analyzed by 
SDS-PAGE. The positions of the reoviral σ, μ, and λ proteins are indicated. JAM-A, junction 
adhesion molecule-A; RT-PCR, reverse transcription-PCR
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 To determine whether the resistance of U118MG cells to T3D is due to the 
absence of the reovirus receptor JAM-A [9,36,37], RNA isolated from U118MG 
cells and 911 cells was assayed for the presence of JAM-A mRNA by reverse 
transcription-PCR (RT-PCR) using a JAM-A-specific primer set. The RNA from 
U118MG cells yielded no detectable PCR product (figure 6.2 B), confirming 
the absence of JAM-A. This was further corroborated by immunofluorescence 
microscopy with JAM-A-specific antisera (data not shown). In contrast, JAM-A 
mRNA was readily detectable in 911 cell-derived RNA (figure 6.2 B).
 To study whether the absence of JAM-A is the sole factor contributing to the 
resistance of U118MG cells to T3D infection, U118MG cells were transduced 
with a lentiviral vector encoding hemagglutinin (HA)-tagged JAM-A (figure 6.3). 
In another vector (LV-JAM-ECD), the extracellular domain (ECD) of JAM-A was 
linked to a heterologous transmembrane domain to formally rule out JAM-A-
mediated signaling (figure 6.2 C). Parental U118MG cells and HA-JAM- or JAM-
ECD-expressing U118MG cells were exposed to T3D and metabolically labeled 
with [35S]-methionine to assess reovirus-protein synthesis, as an indicator 
for viral replication. No synthesis of reovirus proteins was observed up to 7 
days postinfection in U118MG. In contrast, synthesis of the reovirus proteins 
was detectable in the HA-JAM- and JAM-ECD-expressing U118MG derivatives 
(figure 6.2 D). Note that host-protein synthesis is not fully shut off by reovirus 
in U118MG cells. Taken together, these data show that the absence of JAM-A on 
the surface of U118MG is the only reason for its resistance to reovirus T3D.
Expression of an artificial receptor on the surface of U118MG 
cells 
As an artificial receptor that could be utilized by targeted reoviruses, we exploited 
a single-chain antibody fragment specific for stretch of six C-terminal histidine 
residues (scFv-His) [38] as an artificial receptor for the reovirus T3D. This scFv 
is expressed on the surface of mammalian cells, if linked to a transmembrane 
domain and has been previously used as an artificial receptor for propagation 
of recombinant adenoviruses [32]. The codons for scFv-His, linked to the 
transmembrane domain of the human platelet-derived growth factor receptor 
and an HA tag, were inserted in the vector pLV-CMV-x-IRES-Neo (Figure 6.3), 
and the resulting vector was used to transduce U118MG cells. Immunochemical 
staining confirmed homogeneous expression of the artificial receptor in the 
transduced U118MG cell population (data not shown). 
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Figure 6.3 Lentiviral vectors used in this study. The scheme represents the integrated 
lentiviral vectors. The vectors are derived from a self-inactivating third-generation HIV-
1 vector. Upon integration, the vector loses its capacity to produce mRNA other than 
the mRNA derived from the transgene expression cassette. The positions of the Rev-
responsive Element (RRE), the central polypurine tract (cPPT), and the post-transcriptional 
regulatory element (PRE) are indicated. The transgenes were inserted upstream of the 
internal ribosome entry site (IRES) and the neomycin phosphotransferase (Neo) selection 
marker. JAM is the cDNA encoding human junction adhesion molecule. JAM-ECD encodes 
the extracellular domain of JAM-A fused to the PDGF transmembrane domain. scFvHis 
represents the single-chain antibody directed against the (His)6 tag. S1His is a modified 
cDNA of the reovirus T3D S1 segment in which the (His)6 tag is fused with σ1. PDGF, 
platelet-derived growth factor. 
Modification of σ1 by adding a (His)6 tag to its C-terminus
To produce σ1 variants, we opted to using a trans-complementation approach 
in which reovirus was propagated on a cell line producing one of the capsid 
components. The virus may incorporate the modified component in its capsid 
during virus generation. To generate reoviruses with modified σ1 variants in 
its capsid, 911 cells were generated that stably express a modified S1 gene 
segments. The S1 genome segment was cloned from wild-type reovirus T3D-
infected 911 cells, using primers chosen on the basis of the published S1 sequence 
[39]. The deduced σ1 amino-acid sequence of the S1 genome segment cloned 
from the ATCC VR-824 T3D reovirus batch was found to differ from the published 
S1 sequence at two positions, Ile246 to Thr and Thr249 to Ile. These mutations are 
known to abolish a trypsin-sensitive site in the σ1 shaft [40]. 
 The codons for (His)6 tag were inserted by mutation PCR downstream of the 
triplet encoding the C-terminal Thr of σ1. The resulting recombinant S1 genome 
segment encoding (His)6-tagged σ1 (S1His) was inserted into a lentiviral vector 
(figure 6.3). This vector was used to generate 911 cells, which stably express 
S1His. The synthesis of the (His)6-tagged σ1 (σ1-His) in the polyclonal 911S1His 
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cell lines was verified by immunofluorescence (figure 6.4 A), RT-PCR (figure 6.4 
B and C, and table 6.1), and Western-blot analysis (figure 6.4 D). The staining 
pattern of σ1-His (figure 6.4 A) is reminiscent of the morphology of the viral 
factory [8,41]. These data led us to conclude that σ1-His protein was produced 
in the transduced cells.
Figure 6.4 Characterization of the 911S1His cell line. (A) Immunofluorescence 
assay demonstrating the presence of the s-His protein in 911S1His cells. The mouse a-His 
antibody and FITC-coupled Goat-anti-Mouse sera (green) were used to detect the s1-His 
protein in the LV-S1His-transduced 911 cells. The nucleus is stained with DAPI (blue). 
(B) Schematic representation of S1His expression cassette after lentivirus-mediated gene 
transfer. The region coding for s1 is indicated by the open box. The primers used in the 
PCR assay and the expected PCR products are indicted. H represents the position of the 
(His)6 tag (see Table 6.1 for the sequence of the primers). (C) RT-PCR to detect S1 RNA 
in 911S1His cells. Reverse transcription of 911S1His and 911 cell RNA was performed 
using primer S1endR. The plasmid pRT3S1His was used as a positive control for the PCR 
analysis which used the primers indicated in (B). The positions of the primers in the S1 
segment, as well as the expected PCR products S1F-E and S1F-His, are indicated in (B). 
(D) Western analysis demonstrating the presence of the s1-His protein in 911S1His cell 
lysates. s1-His protein was detected with the Penta-His antibody. DAPI, 4’,6-diamidino-2-
phenylindole; FITC, fluorescein isothiocyabate; RT-PCR, reverse transcription-PCR.
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Reovirus pseudotyping by modification of sigma-1
To evaluate whether the σ1-His protein was incorporated in the capsid, the 
911S1His cells were infected with wild-type T3D, and the virus was passaged 
three times on the 911S1His cells. If σ1-His is incorporated it could amend the 
tropism. To test the tropism, U118MG, U118HA-JAM and U118scFvHis cells were 
infected with either wild-type T3D or T3D from the third passage on 911S1His 
cells. T3D harvested from 911S1His cells, but not wild-type T3D virus, could 
infect and lyse U118scFvHis cells (figure 6.5 A). The cell-viability assay confirmed 
that U118MG cells resist the σ1-His-containing T3D and showed survival of 10% 
of the U118HA-JAM cells at 3 days after exposure to the 911S1His-cell derived 
T3D. U118scFvHis cells exposed to the σ1-pseudotyped T3D showed a drop 
of 55% in viability (figure 6.5 B). These data demonstrate that the 911S1His-
derived reovirus can infect U118MG cells that express the scFvHis as an artificial 
receptor. From these results, we conclude that σ1-His is incorporated in the 
reovirus capsid, that the (His)6 tag is accessible to the artificial receptor and that 
interaction of this tag with its receptor leads to productive infection.
Selecting a genetically modified reovirus
Recent data suggest that the sequence motifs that facilitate assortment and 
packaging of the reovirus segments are contained within a 130 nt region at the 
5’ end of reoviral RNAs [19]. This region is also present in the heterologous 
transcripts produced in 911S1His cells. If the reoviral signals in the LV-S1His-
derived σ1-His-encoding transcripts are functional, these transcripts should 
associate with newly formed cores and replace the wild-type S1 segment in the 
progeny virus. 
 To test this hypothesis, we harvested the virus progeny from the U118scFvHis 
cells that were infected with s1-pseudotyped T3D. If the particles contain the 
S1His genome segment, it should be possible to propagate them on U118scFvHis 
cells. Indeed, a metabolic labeling experiment performed at 3 days postinfection 
showed that the reovirus particles produced in U118scFvHis cells could again 
infect U118scFvHis, in contrast to unmodified T3D (figure 6.6 A). The propagated 
virus, which was named T3D-S1His, was passaged 11 times and maintained the 
s1-His protein as assayed by Western blotting (figure 6.6 B). The presence 
of the (His)6-tag was also confirmed by sequence analysis of cloned RT-PCR 
products (figure 6.7). These data suggest that S1His segment is incorporated as 
a genome segment in T3D and expanded its tropism. 
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Figure 6.5 Pseudotyping of T3D reovirus after propagation in 911S1His cells. (A) 
CPE induction in cultures of U118scFvHis and U118HA-JAM cells, but not U118MG cells, 
infected with reovirus T3D harvested from 911S1His cells. Photos of CPE were taken 3 
days post-infection. (B) Cell viability of U118MG, U118HA-JAM and U118scFvHis cells, 
as measured by WST-1 assay, 3 days after infection with reovirus T3D harvested from 
911S1His cells. The relative survival is depicted normalized to mock-infected U118MG 
cells (mean of three measurements).
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Figure 6.6 Selection of genetically stable T3D-S1His reovirus stock on 
U118scFvHis cells. (A) U118scFvHis cells synthesize reovirus proteins upon infection 
with T3D-S1His. [35S]-methionine-incorporation assays were performed 3 days post-
infection on U118scFvHis and U118HA-JAM cells infected with wild-type reovirus T3D 
(wt), T3D-S1His 740 (SH) reoviruses or mock-infected (m), respectively. (B) σ1-His is 
present in S1His reovirus batches as evidenced by Western analysis of reovirus-containing 
lysates. Western analyses were performed on different viral lysates for the presence of the 
(His)6-modified s1 using the anti-His tag serum. T3D depicts a lysate of the unmodified 
reovirus T3D. Sel9-11 represents T3D reovirus lysates propagated for 9-11 passages 
on U118scFvHis cells. Loading controls using the antibody 7F4 against reovirus λ2 are 
depicted in the upper panel. (His)6-tagged σ1 detected with Penta-His antibody is shown 
in the lower panel.
Selection for the (His)6 tag co-select other alterations in 
genome segment S1
So far we have demonstrated that the (His)6 tag of the S1 segment is incorporated 
in the reovirus. To test wether selection for the presence of the (His)6 tag could be 
used for selecting other mutations in the same segment, we repeated the selection 
experiment with the T3D laboratory strain R124. The nucleotides sequence of S1 
from R124 differs in two nucleotides from that used to construct LV-S1His (figure 
6.7). This allows distinguishing the origin of the S1 sequences in the resulting 
T3D-S1His independent of the His tag sequences. After three passages of R124 
on 911S1His cells, the virus was harvested and used to infect U118MG, U118HA-
JAM and U118scFvHis cells. CPE was observed in U118HA-JAM and U118scFvHis 
cell cultures but not in the infected U118MG cultures. In contrast, non-
speudotyped R124 only induced cell death in U118HA-JAM cells (data not shown).
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Figure 6.7 Amino-acid sequence of different σ1 and σ1-His proteins. The amino-
acid sequence alignment of σ1 (455 aa) and σ1His (461 aa) is shown. The upper sequence 
(s1[pub]) is the published sequence of σ1 (accession number gi|333742|gb|M10262.1). 
R124 is our lab strain of reovirus T3D. The isolate was purified from the VR-824 stock 
obtained from the ATCC by two rounds of plaque purification on 911 cells. σ1His (cloned) 
is the sequence in pRT3S1His. σ1His RT1 and -2 are two RT-PCR amplified clones from the 
ATCC-T3D-derived T3D-S1His viruses. σ1His RT3 and -4 are amplified clones from the R124-
S1His virus. The amino-acid changes are color-coded. RT-PCR, reverse transcription-PCR.
 The virus produced in the U118scFvHis cells was passaged for six times 
on this cell line. The resulting virus, named R124-S1His, was used again to 
infect U118scFvHis cells. After confirming the presence of the (His)6-tagged σ1 
(figure 6.8 A), RNA was isolated from infected cells and the S1 segments were 
cloned after RT-PCR amplification. Sequence analysis confirmed the presence of 
the (His)6-tag encoding sequence. All clones have a sequence identical to the 
cloned S1His, rather than the R124-S1, at the positions which differ between 
isolates (figure 6.8 B en C). These data suggest that selection for the presence 
of the (His)6 tag leads to incorporation of the entire S1 segment into reovirus 
particles. A few additional changes were found in the s1 encoded by the S1 
of R124-S1His (figure 6.7). This can be attributed to the RNA-dependent RNA 
polymerase’s relative lack of fidelity [42]. The fact that all the clones contained 
a S325Y mutation suggest that this mutation occurred early during passaging 
on U118scFvHis cells. Taken together, our data are consistent with a mechanism 
in which the entire S1 genome segment is replaced by the S1His segment.
Selective infection of cells in a mixed population by a 
targeted reovirus
To verify that genetically targeted reoviruses could be used to selectively 
eradicate specific cells in a mixed population, U118scFvHis cells were plated with 
U118-eGFP cells to represent target and non-target cells, respectively. A number 
of these mixed cultures were exposed to the R124-S1His virus at an MOI of 1.5. 
At various time points after infection the relative number of eGFP-positive cells 
was determined by flow-cytometry (figure 6.8 D). The relative number of eGFP-
positive cells increased more than 5.4-fold in comparison with mock-infected 
cultures at 96 hrs post infection. These data demonstrate selective eradication 
of sensitized cells by a genetically targeted reovirus.
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Figure 6.8 Selection of R124-S1His reoviruses on U118scFvHis cells. (A) The s1-
His protein is present in lysates of R124-S1His reoviruses serially passaged on U118scFvHis 
cells. R124 is a lysate of the plaque-purified T3D reovirus. Sel4-6 depict R124-S1His 
reovirus lysates isolated after the indicated number of passages on U118scFvHis cells. 
Upper panel: Western blot analysis for l2. The presence of λ2 was confirmed by western 
blotting using the 7F4 specific for λ2. Lower panel: Western blotting demonstrates the 
presence of (His)6-tagged σ1 with the Penta-His antibody in the R124-S1His virus. (B) 
Nucleotide differences distinguish the cloned S1His sequence and the R124 S1 sequence. 
The amino acids coded by codons at positions 749 and 758 of the R124-S1 create a 
trypsin-cleavable site in σ1 (“). (C) Sequence analyses depict the differences at nucleotides 
747-760 of RT-PCR clone R124-S1His RT4 and R124. Arrows represent the nucleotide 
differences at position 749 and 758. (D) The R124-S1His reovirus specifically eradicates 
the U118scFvHis cells from a mixed population. A mixture of U118scFvHis and U118-eGFP 
cells were infected with R124-S1His reovirus at an MOI of 2, and samples were taken for 
flow-cytometric analyses at the indicated times after the infection. Represented is relative 
frequency of GFP-positive cells in the virus-infected cultures relative to mock-infected 
cultures. These data show that the relative frequency of the R124-S1His-resitant eGFP-
positive cells increased more than 10-fold upon selective eradication of the cells which 
are sensitive to the targeted reovirus. GFP, green fluorescent protein; MOI, multiplicity of 
infection; RT-PCR, reverse transcription-PCR.
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DISCUSSION
Reverse genetics in RNA viruses with segmented genomes has been technically 
challenging. For Reoviridae, this is due, at least in part, to the difficulties in 
achieving sufficient quantities of non-polyadenylated plus-strand reovirus RNAs 
in the cytoplasm of mammalian cells. The previously described methods to 
manipulate reovirus genomes either involve transfection of RNA synthesized in 
vitro or employ T7 polymerase-driven expression cassettes [21,26,27]. In these 
techniques, ribozymes generate transcripts with 3’ ends, which are identical to 
normal segment termini. In general, such transcripts are unstable since they 
lack a poly-A tract [21,26,27]. Here we show that also polyadenylated transcripts 
generated with a conventional RNA polymerase II expression cassette can be 
used to replace a genome segment. A transcript containing a modified copy of 
the reovirus T3D S1 segment, encoding a (His)6-tagged version of the spike 
protein σ1, was stably expressed. This protein was capable of binding a single-
chain antibody fragment for oligo (His) tags. Propagation of wild-type T3D on 
cells producing s1-His led to its incorporation into reovirus capsids. A similar 
strategy has been previously used for other capsid proteins of reoviruses [43] 
and other non-enveloped viruses such as adenoviruses [44,45]. However, if the 
genetic sequences encoding the modified capsid protein are not encapsidated, 
the altered targeting specificity would be lost after a single round of replication. 
 The transcripts encoded by the lentivirus vector LV-S1HIS contain all genetic 
information and most likely also the structural information contained within 
the S1 segment, for example the motifs regulating plus- and minus-strand 
synthesis. We hypothesized that these transcripts would be targeted to the 
‘viral factories’and here associate with newly formed viral cores. Furthermore, 
if the signals for minus-strand synthesis [22,46] are functional, the S1 part of 
the lentiviral transcript should be converted in dsRNA. Secondary transcription 
of this dsRNA would lead to S1 segments with authentic termini. Our results 
propagating the T3D-S1His variant support these hypotheses. 
 Based on our hypothesis, we anticipated that the entire LV-S1His-derived 
genome segment, rather than only the region encoding the (His)6 tag, would 
become incorporated into the virion. This was confirmed using the R124 strain in 
the selection. The reovirus selected after infection of the U118scFvHis with the 
R124 strain propagated in 911S1His cells contained the sequence of the (His)6-
tagged s1-encoding segment instead of the S1 from R124 at the isolate-specific 
positions. These findings are consistent with the model that the entire S1His 
segment is derived from the transcript specified by LV-S1His. 
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 This approach may prove useful for improving reoviruses as oncolytic agents. 
To date, only wild-type T3D has been used in clinical trials [2,6,47]. The results 
of this approach are encouraging and the procedure is well tolerated. However, 
the scarcity or inaccessibility of reovirus receptors on the surface of tumor cells 
may limit the efficacy of wild-type reoviruses as oncolytic agents. We recently 
reported that cultures of colorectal tumor cells isolated from resected tumor 
material resist reovirus infection, despite the presence of JAM-A [48]. This is 
likely attributable to the insufficient expression of reovirus receptors at their 
plasma membranes since T3D-derived infectious subviral particles, which are 
known to enter cells independent of JAM-A and sialic acid, efficiently infect and 
lyse these cells. Further development of the approach presented here should 
allow modification of reoviruses to enhance tumor cell transduction and reduce 
the infection of non-target cells. This will increased the safety and efficacy of 
anticancer strategies using reoviruses as oncolytic agents.
 We have developed a simple technique to genetically modify reoviruses, and 
identified the C-terminus of σ1 as a good location for insertion of a targeting 
oligopeptides. Moreover, the (His)6 tag at the C-terminus of σ1, in combination 
with the U118scFvHis cells allowed the construction of reoviruses that do not 
depend on JAM-A for attachment and cell entry. Furthermore, the development 
of tumor-targeted reoviruses can benefit from the experience with targeted 
adenoviruses, especially as the spatial structure of the reovirus spike is 
remarkably similar to the adenovirus fiber [49].
 This reovirus genetic-modification technique developed in this study may 
be widely applicable. It may be adapted for other reovirus genome segments 
[50]. This would allow generation of defined mutants for gaining insight in the 
intricate interactions between the reoviruses and their hosts, and to address 
questions about virus structure, function, and pathogenesis. The strategy may 
be amendable for use in other Reoviridae. Although from the family name one 
may get the impression that all its members are ‘orphan’ viruses, some of them 
cause severe diseases and have considerable economic impact. Members of its 
genera Orbivirus and Coltivirus cause diseases of humans, for example Colorado 
tick fever, and of domestic livestock, for example African horse sickness and 
blue-tongue disease [51]. Moreover, members of the genus Rotaviruses are the 
major etiologic agents of serious diarrhea in children under 2 years of age [52]. 
In these genera, too, this reverse genetics technique may be very useful.
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ABSTRACT 
Mammalian Reovirus is a double-stranded RNA virus with a distinctive preference 
to replicate in and lyse transformed cells. On that account, Reovirus type 3 
Dearing (T3D) is clinically evaluated as oncolytic agent. The therapeutic efficacy 
of this approach depends in part on the accessibility of the reovirus receptor 
junction adhesion molecule-A (JAM-A) on the target cells. Here, we describe the 
isolation and characterization of reovirus T3D mutants that can infect human 
tumor cells independent of JAM-A. The JAM-A-independent (jin) mutants were 
isolated on human U118MG glioblastoma cells, which do not express JAM-A. 
All jin mutants harbour mutations in the S1 segments close to the region that 
encodes the sialic acid-binding pocket in the shaft of the spike protein. In 
addition, two of the jin mutants encode spike proteins with a Q336R substitution 
in their head domain. The jin mutants can productively infect a wide range 
of cell lines that resist wt reovirus T3D infection, including chicken LMH cells, 
hamster CHO cells, murine endothelioma cells, human U2OS and STA-ET2.1 
cells, but not primary human fibroblasts. The jin mutants rely on the presence 
of sialic-acid residues on the cell surface for productive infection, as is evident 
from wheat germ agglutinin (WGA) inhibition experiments, and from the jin-
reovirus resistance of CHO-Lec2 cells, which have a deficiency of sialic-acids on 
their glycoproteins. The jin mutants may be useful as oncolytic agents for use in 
tumors in which JAM-A is absent or inaccessible. 
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INTRODUCTION 
The Reoviridae constitute a family of viruses with a non-enveloped icosahedral 
capsid and a segmented double-stranded RNA genome. Prototypes of the 
mammalian orthoreoviruses were isolated from the human respiratory and 
enteric tracts and have not been associated with serious human disease. The 
human reovirus type 3 Dearing (T3D) is frequently studied and often serves 
as a model for the family. The reoviruses have a lytic replication cycle and 
preferentially induce cell death and apoptosis in tumor cells but not in diploid, 
non-transformed cells [2,3,53]. In transformed cells reovirus uncoating and 
replication are stimulated [7,8,54-56]. In addition, Ras signalling sensitizes the 
cells to reovirus-induced apoptosis [57]. Based on these observations, reovirus 
T3D is a promising candidate for use as oncolytic agent, and is currently 
evaluated in a variety of clinical cancer therapy trials [1,58-60]. 
 Reovirus attachment to cells is a multi-step process. The reovirus spike protein 
σ1 binds with a region of its shaft domain to cell surface-bound sialic acids with 
low-affinity, before the head domain of σ1 engages the high affinity receptor 
junction adhesion molecule-A (JAM-A, also known as JAM-1) [10,61]. Following 
receptor binding, virions become internalized by a mechanism involving the 
capsid protein λ2 binding to β1 integrins [17,62]. An alternative entry pathway 
can be employed upon proteolytic removal of the reovirus outer capsid protein σ3 
and cleavage of μ1/μ1C, yielding intermediate (or infectious) subviral particles 
(ISVPs). The ISVPs can directly penetrate the cellular membrane independent 
of the presence of JAM-A [63,64]. The ISVPs are similar to the disassembly 
intermediates formed during cellular entry via the endocytosis pathway. 
 The reovirus receptor JAM-A is expressed in epithelial and endothelial cells 
of several tissues including lung, kidney, pancreas, heart, brain, intestine 
and lymph nodes [65] but some tumor cells have down-regulated the JAM-A 
receptors on their cell surface, thereby limiting the susceptibility to reovirus 
T3D. JAM-A expression was found significantly down-regulated in clear-cell renal 
carcinoma cells [66]. Also, cells grown from freshly isolated colorectal tumor 
metastases resist reovirus infection. Immunohistochemistry demonstrated that 
JAM-A is not accessible at the cell surface, although JAM-A is detectable intra-
cellularly [67]. Furthermore, there is an inverse correlation of JAM-A expression 
in breast cancer cells and their ability to migrate. JAM-A is expressed in normal 
human mammary epithelial cells but in metastatic breast cancer tumors the 
expression is down-regulated [68]. 
 Here we describe the isolation and characterization of reovirus T3D mutants 
that are adapted to propagation in JAM-A negative, reovirus-T3D resistant cell 
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lines. The first was identified as a spontaneously occurring mutant in one of our 
batches genetically retargeted reovirus [69]. Subsequently two other mutants 
were isolated by selection on JAM-A negative human glioblastoma cells. We 
demonstrate that these JAM-A-independent (jin) mutants employ an as yet 
unidentified, but apparently ubiquitous receptor, which is present on a wide 
variety of cell types. Their potential use as novel oncolytic tools against tumor 
cells in which JAM-A is absent or inaccessible is discussed. 
MATERIALS AND METHODS 
Cell lines 
Cell lines 911 (generated previously in our lab, see reference [28]), U118MG 
(obtained from ATCC), U2OS (obtained from ATCC, see reference [70]), CHO 
(obtained from ATCC), Eoma (obtained from ATCC, see reference [71]) and VH10 
(primary human foreskin fibroblasts, provided by B. Klein [72]) were cultured in 
Dulbeco’s Modified Eagle Medium (DMEM) containing high glucose (Invitrogen, 
Breda, The Netherlands), supplemented with penicillin, streptomycin (pen-
strep) and 8% fetal bovine serum (FBS) (Invitrogen, Breda, The Netherlands). 
The U118-HAJAM cells were cultured in DMEM plus 8% FBS and pen-strep, 
supplemented with 200 μg/ml G418. LMH cells (obtained from ATCC, see 
reference [73]) were grown on collagen I coated dishes (Rat Tail collagen, 2.5 
μg/cm2, Invitrogen, Breda, The Netherlands) in DMEM plus 8%FBS and pen-
strep. STAET2.1 cells were grown on collagen I coated dishes (5.0 μg/cm2) in 
RPMI 1640 medium (Invitrogen, Breda, The Netherlands), supplemented with 
pen-strep and 10% FBS. Lec2 cells (derived from ATCC, see reference [74]) 
were cultured in alpha-MEM (Invitrogen, Breda, The Netherlands) with 8% FBS. 
All cells are cultured in an atmosphere of 5% CO2 at 37°C. 
Reovirus propagation 
The wild-type T3D virus strain R124 (see accession numbers) was isolated 
from a reovirus T3D stock obtained from the American Type Culture Collection 
(stock VR-824) by two rounds of plaque purification on 911 cells. The 911 cells 
were used to propagate R124 (referred to as wt T3D in the text) as described 
previously [29]. Briefly, cells were exposed to reovirus in DMEM plus 2% 
FBS for 2 hrs at 37°C, 5% CO2. Subsequently, the inoculum was replaced by 
DMEM containing 8% FBS. The virus was harvested 48 hrs post infection by 
resuspending the cells in phosphate-buffered saline (PBS) with 2% FBS and 
subjecting the suspension to three cycles of freezing and thawing. The sample 
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was cleared by centrifugation for 10 min at 800x g. For the mutant jin viruses, 
U118MG cells were used to propagate the viruses after one round of plaque 
purification on 911 cells. The jin viruses were routinely harvested from U118MG 
cells 72 hrs post infection. The experiments were done with virus-containing 
freeze-thaw lysates, unless otherwise indicated. The infectious reovirus titers of 
the strains were determined by plaque assay on 911 cells. 
Origin of the jin-mutants 
jin-1 is derived from U118scFvHis cells during our experiments on genetically 
modifying reovirus [69]. The jin-1 virus was first grown on U118scFvHis cells 
for two propagations, before three passages on U118MG cells (first point of S1-
sequence analysis). The virus was subjected to one round of plaque purification 
on 911 cells to obtain a homogenous population. This was further propagated on 
U118MG cells for 11 rounds before analysis of the complete genome sequence 
(table 7.1).
 jin-2 was isolated from U118scFvHis cells infected with wt T3D reovirus 
and passaged twice in these cells. The S1 segment was sequenced from this 
passage. Subsequently it was passaged 10 times on U118MG cells. After plaque 
purification, the complete genome sequence was determined (table 7.1). 
 jin-3 was isolated from U118MG cells exposed to wt T3D virus followed by 
blindly passaging the virus for 6 rounds. From the resulted preparation a virus 
was isolated by plaque purification and following by 10 additional passages on 
the U118MG cells (table 7.1). 
Yield determinations 
To determine the replication of wt T3D, jin-1, jin-2 and jin-3 in U118MG and 
VH10 cells (figure 7.3), cells were seeded in 24-well plate with a cell density of 
1x105 cells/well. Viruses (in DMEM plus 2% FBS) were added to the cells with 
an MOI of 10, two wells per virus. After an exposure of one hr in incubator 
(37°C, 5% CO2) the inoculum was removed and the cells were washed once 
with PBS and fed by fresh DMEM plus 2% FBS. Reoviruses were harvested from 
medium and cells by 3 cycles of freeze-thawing, 72 hrs after infection. Yields 
were determined by plaque assays on 911 cells. 
 For the replication of wt T3D or jin-1 in 911, U118MG, LMH, U2OS, CHO and 
Lec2 cells (figure 7.7 B and figure 7.8 B), cells were seeded in 6 well plates with 
a density of 1.5x106 cells/well. Wild-type T3D or jin-1 was added to 4 wells in 
case of 911 cells and 3 wells for the other cell lines with an MOI of 10 (in DMEM 
plus 2% FBS). After one hr of exposure in incubator, the viruses were washed 
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from cells and medium was replaced. From one well, immediately after washing 
once with PBS, cells in medium were collected and subjected to freeze-thaw 
cycles (1 hr time point). 32 Hrs (911 cells only), 48 and 72 hrs after infection 
cells and medium were collected and subjected to freeze-thaw cycles. Viral 
yields were determined by plaque assays on 911 cells.
Table 7.1 Amino acid differences in reovirus proteins of the jin mutants and the 
wt T3D reovirus strains
RNA 
segment 
(protein)
AA position wt jin-1 jin-2 jin-3
S1 (σ1) 187 Gly Arg
193 Thr Met
196 Gly Arg
336 Gln Arg Arg
S2 (σ2) 254 Ser Phe
S3 (σNS) No changes
S4 (σ3) 177 Ser Phe
198 Gly Glu
357 Met Thr
M1 (μ2) No changes
M2 (μ1) 388 Lys Arg
530 Thr Ala
M3 (μNS) 705 Ala Val
706 Asp Ala
708 Val Ala
L1 (λ3) 413 Ile Ser
L2 (λ2) 1101 Met Ile
L3 (λ1) 201 Thr Ala
703 Arg Gly
1164 Ser Phe
Cell viability assay 
WST-1 reagent (Roche, Almere, The Netherlands) was used to assay the viability of 
cells after reovirus infections. U118MG and 911 cells in 96-well plate were mock-
infected or infected with wt T3D or jin-1 with an MOI of 10, in triplo. Six days post 
infection WST-1 reagent was added, according to the manufacturer’s manual. 
The viability measurements in mock-infected cell cultures, were set to 100%. 
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[35S]Methionine labelling 
Infected cells (911 cells infected at MOI=1; U118MG and U118-HAJAM with 
MOI=5) or mock-infected cells were incubated with TRAN35S -LABELTM (10mCi/
ml; MP Biomedicals, Eindhoven, The Netherlands) for 4 h; one day (911 cells) 
or two days (U118MG and U118HA-JAM cells) post infection. Cells were washed 
once with phosphate-buffered saline and lysed in Giordano Lysis Buffer (50 mM 
Tris HCl pH 7.4, 250 mM NaCl, 0.1% Triton, 5 mM EDTA) containing protease 
inhibitors (Complete mini tablets, Roche Diagnostics, Almere, The Netherlands). 
The labelling assays were performed in 24-well plates with 5 ml (50 μCi) 
TRAN35S -LABELTM per well. The cells were lysed with 100 μl lysis buffer. After 
addition of sample buffer, 50 μl per lysate was loaded in the wells of a 10% 
SDS-polyacrylamide gel. Gels were dried and exposed to a radiographic film to 
visualize the labeled proteins. 
Immunofluorescence assay 
For immunofluorescence assays, U118MG and 911 cells were grown on glass 
coverslips in 24-well plates before infection with wt T3D or jin-1 with an MOI of 
5 or no virus. One day post infection the cells were fixed with cold methanol (15 
min, 4°C), washed with PBS containing 0.05% Tween-20, and incubated with 
antibody 4F2 directed against reovirus σ3 (monoclonal antibody developed by 
T.S. Dermody [34]; obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the NICHD and maintained by The University 
of Iowa, Department of Biology, Iowa City, IA 52242), diluted in PBS containing 
3% BSA. After incubation at room temperature the cells were washed (PBS, 
0.05% Tween-20) and incubated with secondary fluorescein isothiocyanate 
(FITC)-conjugated goat antimouse serum for 30 min at room temperature. The 
mounting solution consisted of glycerol containing 0.02 M Tris HCl pH8.0, 2.3% 
1,4-diazabicyclo-[2.2.2]-octane and 0,5 μg/ml 49,6-diamidino-2-phenylindole 
(DAPI) to visualize the nuclei. 
RT-PCR and sequencing 
Total RNA was isolated (Absolutely RNA miniprep kit; Stratagene, Agilent 
Technologies, Amstelveen, The Netherlands) from U118MG cells infected with 
the different reovirus mutants (jin-1 or jin-3), one day post infection. For wt 
T3D total RNA was isolated from infected 911 cells. Primers used for the RT-
PCR procedures are listed in Supplementary_table 7.1. DNA synthesis of all the 
segments started with the unique endR primer designed for every segment, 
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using SuperScript III (Invitrogen, Woerden, The Netherlands) for the reverse 
transcription process. For the PCR, Pfu polymerase (Promega, Leiden, The 
Netherlands) was used with the primer combinations unique for every segment. 
PCR products were first cleaned with Sureclean (Bioline, London, UK), according 
to the manual, before direct analysis of the sequence. In some cases the 
resulting PCR products were cloned into plasmid pJet1 (GeneJet, PCR cloning 
kit; Stratagene, Agilent Technologies, Amstelveen, The Netherlands) and their 
DNA sequences were determined. All sequence data were generated by The 
Leiden Genome Center (LGTC, Leiden, The Netherlands). 
In vitro transcription-translation and trimerization assay 
All primer sequences can be found in Supplementary_table 7.1. With DualSHFor 
and DualSHRev primers, S1 PCR product was generated from plasmid 
pCDNART3S1 [69], according to manual of the pDual-GC vector (Stratagene, 
Agilent Technologies, Amstelveen, The Netherlands). The resulting construct 
(pDualS1His) contained no stop codon, meaning that the Myc-His tag was present 
behind S1. To introduce a stop codon behind the S1 ORF in pDualS1His, the 
DualS1st for and rev primers were used in a mutation PCR, with EXL polymerase 
(Stratagene, Agilent Technologies, Amstelveen, The Netherlands). This resulted 
in the plasmid pDGC-S1delTag, which was used for the trimerization assay and 
as start to generate the pDGC-S1QR and pDGC-S1Y313A (with S1-QRmut2Rev 
and For combi or S1Y313AmRev and For combi, respectively) also with EXL 
polymerase. For the in vitro transcription-translation (ITT) part, TNT® T7 Quick 
Coupled Transcription/Translation kit (Promega, Leiden, The Netherlands) was 
used. Input for the ITT assays were the plasmids pDGC-S1delTag, pDGC-S1QR 
and pDGCS1Y313A. The total reaction volume was 15 μl, scaled according to the 
manual (in the presence of 6 μCi TRAN35S-LABELTM; MP Biomedicals, Eindhoven, 
The Netherlands). For the trimerization Assay, one fifth of every ITT reaction 
per construct was used and incubated with Sample buffer (final concentrations: 
10% glycerol, 2% SDS, 60 mM Tris HCl pH 6.7, 2.5% β-mercaptoethanol and 
2.5% bromophenol blue) for 30 min at 37°C to stabilize the trimers or boiled 
for 5 min 96°C to disrupt the trimers. After incubation the samples were loaded 
on a 10% SDS-polyacrylamide gel, which was kept at 4°C during the run. Gels 
were dried and exposed to a radiographic film to visualize the labeled proteins. 
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Plaque assay and size measurements 
Plaque assays were performed in a standard assay as previous described for 
adenoviruses [28] with minor modifications. Briefly, virus stocks were serial 
diluted in DMEM containing 2% FBS. The dilutions were added to near-confluent 
911 cells in six-well plates. Four hrs after infection, medium was replaced with 
agar-medium. Agar-medium consists of (final concentrations) 0.5% agarose 
(UltrapureTM, Invitrogen, The Netherlands), 16 minimal essential medium 
(MEM), 2% FBS, 12.5 mM MgCl2, 2 mM GlutaMAXTM (Invitrogen, Almere, The 
Netherlands) and 1x pen-strep antibiotic mixture (Invitrogen, Almere,The 
Netherlands). Plaques are counted six days post infection. Plaques sizes were 
measured four days post infection. For the measurements a CKX41 Olympus 
microscope was used and the plaque area was measured with the software of 
Olympus: Olympus DP-soft. 
Western analysis 
Cell lysates were made in Giordano Lysis Buffer supplemented with protease 
inhibitors (Complete mini tablets, Roche Diagnosics, Almere, The Netherlands). 
Total amount of protein in the lysates was measured (Bradford, Biorad, 
Veenendaal, The Netherlands) and the same amount of lysate (30 μg) was 
loaded into the wells of a 10% SDS-polyacrylamide gel after addition of western 
sample buffer (final concentrations: 10% glycerol, 2% SDS, 50 mM Tris HCl pH 
6.8, 2.5% β-mercaptoethanol and 0.025% bromophenol blue). The proteins 
were transferred to Immobilon-P (Millipore, Etten-Leur, The Netherlands) 
and visualized using standard protocols. Antibodies used in this study: 4F2 
directed against reovirus σ3; β-Actin antibody: ImmunO anti-Actin clone C4 (MP 
Biomedicals, Eindhoven, The Netherlands). 
E64d inhibition 
E64d (Sigma Aldrich, Zwijndrecht The Netherlands) was dissolved in DMSO 
before use. U118MG and 911 cells were seeded in 24 well plates; half of the cells 
were exposed to 100 μM E64d at 37°C, 5% CO2 for one hr. Purified wt T3D or 
jin-1 virus and ISVPs (approximately 2x103 particles per cell) were added to the 
cells and left for one hr at 4°C; cells were washed with PBS and transferred back 
to 37°C, 5% CO2 in the absence or presence of E64d, for 36 hrs. Lysates were 
made as described in Western analysis. For the immunodetection the anti-σ3 
antibody (4F2) and β-Actin antibody were used. 
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Generatio n of ISVPs 
Wild-type T3D or jin-1 virus ISVPs are freshly prepared by treating CsCl purified 
virions [29] with chymotrypsin. Purified viruses were diluted to a concentration 
of 1011 pfu/ml in Reovirus Storage Buffer (10 mM Tris HCl pH 7.5, 150 mM 
NaCl, 10 mM MgCl2) and treated with 200 μg/ml Chymotrypsin (TLCK treated, 
Sigma Aldrich, Zwijndrecht The Netherlands; C3142) at 37°C for 1 hr. Reaction 
was stopped by adding 5 mM phenylmethyl-sulfonyl fluoride (Sigma Aldrich, 
Zwijndrecht The Netherlands). 
Wheat germ agglutinin (WGA) binding and competition 
experiment 
For the detection of sialic acids in the different cell lines, FITC labeled WGA 
(Sigma Aldrich, Zwijndrecht The Netherlands) was used. Cells (grown on round 
glass coverslips in 24-well plate) were fixed with ice-cold Methanol (15 min, 4°C) 
and washed with PBS containing 0.05% Tween-20. WGA-FITC was added to the 
cells at a concentration of 5 μg/ml in PBS containing 3% BSA and incubated for 
1 hr at room temperature. Excess of unbound WGA-FITC was washed away with 
PBS containing 0.05% Tween-20. Nuclei were visualized by DAPI in the same 
mounting solution as is described for the immunofluorescence assay. 
 WGA competition experiment was done by exposing cells (in 24-well plate 
wells) to WGA at a concentration of 100 μg/ml in culture medium for one hr in 
CO2 incubator at 37°C. The preincubation medium was removed and wt T3D 
or jin-1 virus was added to the cells with an MOI of 10 in DMEM containing 
2% FBS at 4°C for one hr. Cells were washed with ice-cold PBS and normal 
culture medium was added to the cells. Cells were left for 32 hr in CO2 incubator 
(37°C) before lysates were made as described in Western analysis. For the 
immunodetection the anti-σ3 antibody (4F2) and β-Actin antibody were used.
RESULTS 
Isolation of a JAM-A independent reovirus mutant 
Previously we described a system for generating genetically modified reoviruses. 
The modification strategy relies on the exchange of a genome segment encoding 
the spike protein σ1 by a segment encoding a his-tagged spike. The modified 
viruses can be selected and propagated on U118scFvHis cells. This cell line is 
a derivative of the JAM-A negative human glioblastoma cell line U118MG and 
expresses a single-chain Fv (scFv) on its surface that is capable of binding the His-
tag. The scFv serves as an artificial receptor for the σ1-His containing viruses [69]. 
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Figure 7.1 Reovirus mutant jin-1 is able to infect the JAM-A negative cell line 
U118MG. (A) Viability assay (WST-1) on 911 and U118MG cells. Cells were mock infected 
(black bar) or infected with wt T3D (white bar) or jin-1 virus (grey bar) with an MOI of 10, 
six days post infection. Means (± standard deviation) from three wells. (B) Detection of 
outer capsid protein σ3 in 911 and U118MG cells after addition of wt T3D or jin-1 virus with 
an MOI of 5. 40 hrs post infection cells were stained with a monoclonal antibody directed 
against σ3 (4F2) and visualized with a fluorescein isothiocyanate (FITC)-conjugated 
goat-anti-mouse secondary antibody. The nuclei are visualized with 49,6-diamidino-2-
phenylindole (DAPI). (C) Assessment of reoviral protein synthesis in jin-1 or wt T3D 
infected cells. Indicated cells were infected with wt T3D or jin-1 virus and labeled with 
[35S]methionine once CPE became apparent. 911 cells were infected with an MOI of 1 and 
U118MG or U118HAJAM cells with MOI of 5. Indicated are the positions of the reoviral λ, 
μ and σ proteins. m represents mock infected cells; wt: wt T3D infected cells and jin-1: 
jin-1 infected cells. 
 In one of the batches of σ1-His modified reoviruses, we noted that a 
cytopathic effect (CPE) was not only induced in the U118scFvHis cells, but also 
in the parental U118MG cells. This suggested that this batch contains viruses 
that are capable of infecting cells independent of the presence of JAM-A and 
independent of the artificial scFv-His receptor. 
 The first mutant virus isolated, which was called jin-1 (JAM-A independent), 
was further propagated on U118MG cells. The jin-1 mutant virus was compared 
to our lab reference wt T3D reovirus. In contrast to the wt T3D reovirus, the 
jin-1 virus induces CPE in U118MG cells as is evident from a WST-1 cell viability 
assay (figure 7.1 A). Both viruses are equally cytolytic to 911 cells which do 
contain JAM-A [69]. Immunofluorescence assays using an antibody against 
the major capsid protein σ3 confirmed the presence of σ3 in U118MG cells 
infected with jin-1, but not with wt T3D (figure 7.1 B). To further verify that 
U118MG cells support the replication of the jin-1 mutant, a metabolic labelling 
with [35S]methionine was performed. As a positive control the U118HA-JAM cell 
line was included. This U118MG-derived cell line had been transduced with a 
lentivirus to overexpress an HA-tagged version of the JAM-A receptor. In U118-
HAJAM and in 911 cells, exposure to the wt T3D as well as to jin-1 reoviruses 
established infection as is evident from the synthesis of reovirus proteins. In 
contrast, in U118MG cells the reoviral protein synthesis was only detectable 
upon infection with the jin-1 virus but not with our wt T3D (figure 7.1 C). These 
data demonstrate that the jin-1 reovirus, in contrast to wt T3D, is capable of 
infecting and replicating in the JAM-A negative cell line U118MG.
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Sequence analysis of the reovirus mutants 
The jin-1 mutant originated from the U118scFvHis cell line. Since this mutant can 
infect JAM-A negative U118MG cells, we speculated that the attachment protein 
σ1 was altered. After one round of plaque purification and further propagation 
for eleven passages on U118MG cells, the complete genome was sequenced. 
The primers used (for this) are listed in Supplementary_table 7.1. The PCR 
products were purified and used for sequence analysis. In the S1 segment two 
mutations occurred. The mutation led to a threonine-to-methionine change at 
position 193 (T193M) and a glutamine-to-arginine change at position 336 of the 
protein (Q336R). Also in other segments mutations were found (table 7.1). 
 To expand the pool of mutants, we repeated the procedure and exposed the 
U118scFvHis cells with our wild-type virus before further expansion on U118MG 
cells. After the first selection rounds in the U118scFvHis cells, we again found 
the Q336R mutation in the σ1 head domain. Upon prolonged propagation (10 
passages) on U118MG cells an additional mutation was found in S1, resulting in 
a G187R change. This mutant strain, carrying mutations resulting in a Q336R 
and G187R change was named jin-2. Based on the findings in jin-2 S1 in the 
earlier passage, we analyzed S1 of an earlier passage of jin-1 as well (prior to 
plaque purification) and also in this S1 segment the only mutation present was 
the one resulting in the Q336R change in σ1.
Figure 7.2 Schematic representation of mutations in Sigma-1. Model of the σ1 
protein (adapted from Chappel et al., 1997 [75]). Arrows indicate the positions of the 
mutations.
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 Another mutant reovirus (jin-3) was obtained after direct exposure of U118MG 
cells at very high MOI to wt T3D reovirus. This virus was blindly passaged (i.e. 
the cells were lysed without signs of overt CPE at the time of virus harvest) for 6 
rounds on U118MG cells. After 6 rounds in U118MG cells, CPE became apparent. 
After plaque purification on 911 cells and 10 additional passages on U118MG 
the complete genome of the jin-3 mutant was sequenced. Only one mutation 
was found in the S1 segment, resulting in a G196R alteration. Table 7.1 gives 
a summary of all the amino acid changes found in the mutants, compared to 
our wt T3D. A schematic overview of the amino acid changes in σ1 is depicted 
in figure 7.2. In all jin mutants the amino-acid alterations in the shaft of σ1 are 
located close to the sialic acid (SA) binding motif [10,55,75,76]. 
Primary human fibroblasts (VH10 Cells) do not support 
replication of the jin mutants or wt T3D 
To study whether the jin mutants acquired the capacity to replicate in normal, 
non-transformed human cells, we exposed diploid human foreskin fibroblasts 
(VH10 cells) to wt T3D and to the jin-mutants. The skin fibroblasts were chosen 
because primary human fibroblasts do not express JAM-A [77]. We studied the 
yields of the jin viruses and compared these with the yields of wt T3D on VH10 
fibroblasts and on U118MG cells. As expected U118MG cells yielded high titers 
of the jin reoviruses, while wt T3D virus yields were below the amounts of virus 
added to the cells (figure 7.3 A). On VH10 fibroblasts, neither the wt T3D reovirus 
nor the three jin-mutants yielded significant titers (figure 7.3 B). Furthermore in 
the VH10 cell cultures no apparent signs of cell death were observed (data not 
shown). These data suggest that, like wt T3D our jin mutants do not replicate in 
normal non-transformed diploid fibroblasts. 
 During the plaque assays on 911 cells for the determination of viral yields, 
we noted that the plaques formed by the jin-1 virus and jin-3 virus were 
consistently smaller than those of the wt T3D virus; the plaque surface area of 
the initial jin-1 virus and jin-3 virus is approximately 10-fold lower (figure 7.3 
C), suggesting reduced cell-to-cell spread of the mutants. 
 The jin-2 virus also has a reduced plaque size compared with the wt virus, 
but the variation within the population is larger, which suggests heterogeneity in 
the population. Sequence analysis of the S1 segment of both the smaller and the 
larger jin-2 plaques revealed that the smaller plaques contained the mutations 
for the G187R and Q336R change, while the larger plaques only contained the 
mutation that yield the Q336R alteration in σ1 (data not shown). 
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Figure 7.3 Comparison of wt T3D with jin-viruses in terms of plaque size, yield in 
U118MG cells and primary human fibroblasts (VH10 cells). (A) Yield of wt T3D and 
jin-1, jin-2 and jin-3 mutants from U118MG cells infected with MOI 10 per virus. Yields 
were determined 72 hours post infection by plaque assays on 911 cells. The graph shows 
yields (Log10 pfu) of two independent U118MG cell infections: first one is shown as a white 
bar and second as a grey bar. The dashed line represents the input amount of the initial 
infection. (B) Yield of wt T3D and jin-1, jin-2 and jin-3 mutants from VH10 cells infected 
with MOI 10 per virus. Yields were determined 72 hours post infection by plaque assays 
on 911 cells. The graph shows yields (Log10 pfu) of two independent VH10 cell infections: 
first one is shown as a white bar and second as a grey bar. The dashed line represents the 
input amount of the initial infection. (C) Plaque sizes of wt T3D and jin-1, jin-2 and jin-3 
mutants in 911 cells. Surface areas of 10 plaques per virus were measured four days post 
infection with Olympus DP-software.
Protease inhibitor E64d blocks entry of jin-1 virus 
Reoviruses enter cells by receptor-mediated endocytosis after attachment of the 
σ1 protein to the JAM-A receptor [9,63]. Subsequently, the viral λ2 protein binds 
cellular integrins leading to endocytosis. In the endosomes the particle undergoes 
conformational changes by partial proteolysis, leading to intermediate subviral 
particles (ISVPs). The outer capsid proteins σ3 and μ1/μ1C are cleaved by cellular 
proteases and σ1 undergoes a conformational change. In vitro, this process can 
be mimicked by proteolytic treatment of complete virions. The generated ISVPs 
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are capable to enter cells independent of the JAM-A receptor by penetration of 
the cytoplasmic membrane [63,64,78]. One possible explanation for the JAM-A 
independent entry of the jin-1 virus could be a premature transition to ISVPs 
prior to entry into the cell. To test whether the jin-1 virus is still dependent on 
cellular proteases the protease inhibitor E64d was used. If cells are exposed to 
E64d prior to infection, intact virions are trapped in the endosome while ISVPs 
can complete the replication cycle [79,80]. To confirm that wt ISVPs are JAM-A 
independent we exposed the U118MG cells to wt T3D ISVPs and to intact T3D 
virions (figure 7.4 A). As expected, only in the cells exposed to the ISVPs, 
viral protein σ3 synthesis is detected, evidencing virus entry and viral virus are 
inhibited by E64d (figure 7.4 B), while σ3 was detected in both the jin-1 and wt 
ISVP infected cells. Also in the U118MG cells, the jin-1 virus entry is blocked by 
the presence of E64d, but not the jin-1 ISVP entry. These data demonstrate that 
like wt T3D reovirus, the reovirus mutant jin-1 exploits the endocytotic pathway 
to enter U118MG cells. 
Figure 7.4 Effect of the cysteine protease inhibitor E64d on jin-1, wt T3D virus, 
and ISVP entry into cells. (A) U118MG cells were exposed to purified wt T3D virus and 
wt T3D ISVP (2*103 particles per cell). Lysates were made 24 hours post-infection and 
analyzed by SDS-PAGE and western-blotting. The reovirus σ3 proteins were detected by 
the anti-reovirus σ3 antibody 4F2 and an anti-Actin serum was used to detect actin as a 
loading control. (B) Effect of 100 μM E64d on the entry of particles compared to entry 
of ISVPs. Cells, treated (+) or untreated (-) with 100 μM E64d, were exposed to jin-1 
(U118MG and 911 cells) or wt T3D (911 cells) virus or ISVPs (2*103 particles per cell). 
Lysates were made 24 hours post-infection. Equal amounts of protein were loaded on 10% 
SDS-polyacrylamide gel and detected with anti-reovirus σ3 antibody (4F2), and anti-Actin 
as a loading control. 
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jin-1 σ1 forms trimers 
The change at amino-acid position 336 is located close to the domain that has 
been implicated in trimerization of σ1 [81]. Although the Q336R alteration is 
located at the outward surface-exposed side of every monomer in the trimeric 
conformation (figure 7.5 A, R336 is shown in red) it is essential to confirm that 
the Q336R alteration does not interfere with trimer formation. To this end an in 
vitro trimerization assay was performed as described by Leone et al. [74]. For this 
wt σ1, σ1-Q336R and σ1-Y313A proteins were synthesized in vitro. The Y313A 
change abolishes the capacity of σ1 to form trimers [81]. The σ1 products were 
analysed by mild PAGE at 4°C (figure 7.5 B). Whereas the σ1-Y313A protein does 
not form mature trimers, both the wt T3D σ1 and σ1-Q336R do. Intermediate 
trimers, which consist of σ1 molecules in which only the shaft is trimerized 
while the head domain is in a monomeric configuration, are detectable in all σ1 
variants tested. Our data show that the Q336R alteration that occurs in the jin-
1 and jin-2 viruses does not affect the formation of mature σ1-trimers in vitro. 
jin-1 and jin-2 have selective advantages over wt reovirus in 
U118MG cells 
To confirm that jin-1 and jin-2 viruses have a selective advantage over wt T3D 
in U118MG cells, we mixed jin-1 or jin-2 with a 100-fold excess of wt T3D prior 
to infection of cells. Cultures of 911 cells were infected at an MOI 10 with the 
mixtures to allow reassortment of genome segments to take place. Two days 
post-infection, the virus was harvested by three freeze-thaw cycles and used to 
infect U118MG cells. While no CPE for jin-1/wt T3D mixtures was observed at 7 
days post-infection in the U118MG cells, the cells were freeze-thawed and the 
lysate was used to infect fresh U118MG cultures. In U118MG cells infected with 
jin-2/wt T3D mixture the virus was harvested after 4 days, with visible signs of 
CPE. This procedure was repeated for two more times. At passage 3 clear CPE 
was observed four days post infection in both jin-1/wt and jin-2/wt selections. 
Sequencing of PCR products after reverse transcription PCR of the S1 segment 
after the third selection on U118MG cells were compared with the S1 sequences 
of wt T3D, jin-1 and jin-2 (figure 7.6). S1 of the jin-1/wt end population contains 
a T at nucleotide position 590 and a G at position 1019, identical to the jin-1 S1 
segment. Sequence results for S1 of the jin-2/wt end population revealed an A at 
position 571 and a G at position 1019 and this is identical to jin-2 S1 sequence. 
From these findings we conclude that in U118MG cells σ1 proteins from jin-1 or 
jin-2 provide a strong selective advantage over wt T3D σ1. These data provide 
evidence that the amino-acid alterations in σ1 provide the jin mutants with the 
capacity to infect and replicate in JAM-A-negative cells. 
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Figure 7.5 Analysis of Sigma-1 trimers synthesized in vitro. (A) Top view of σ1-
trimer, with colored monomer units (green, turquoise, orange). Position of the Q336R 
mutation in each monomer is indicated as red CPK symbol [86] PDB ID: 1KKE. The 
software used for the 3D graphs is Viewerlite 5.0 from Accelrys. (B) [35S] methionine 
labelled in vitro transcribed and translated products of plasmids pDGC-S1wt (S1wt), 
pDGC-S1Q336R (S1Q336R) and pDGCS1Y313A (S1Y313A) were incubated for 30 minutes 
at 37°C (to stabilize the mature trimers) or boiled for 5 minutes (to disrupt the trimers), 
before loading on a 10% SDS-polyacrylamide gel at 4°C. The position of the three different 
conformations is indicated.
jin-1 reoviruses infect cells that are non-permissive for wt T3D 
To study whether the jin-1 mutant has expanded its tropism beyond the 
U118MG cell line, we evaluated whether this virus can replicate in a panel of 
cell lines that resists infection with wt T3D virus. These cell lines include chicken 
hepatoma cell line LMH [73] murine endothelioma cell line Eoma [71], human 
bone osteosarcoma cell line U2OS [70] and human Ewing sarcoma cell line 
STA-ET2.1 [82]. In parallel the cell lines 911 and U118HA-JAM were included as 
positive controls for infection. Each of the cell lines were exposed to wt T3D or 
jin-1 viruses with an amount of virus corresponding to 8 PFU/cell as determined 
in 911 cells. While no major capsid protein σ3 was detected in the wt T3D-
resistant cell lines exposed to wt T3D, exposure of these cells to jin-1 resulted 
in the detection of the σ3 protein at 36 hr post infection (figure 7.7 A). In 911 
and U118HA-JAM cells, the σ3 protein is present in wt T3D infected cells as well 
as in the jin-1 infected cells. 
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Figure 7.6 S1-sequence analysis of the jin-1/wt T3D and jin-2/wt T3D selection 
assay on U118 MG cells. The jin-1 or jin-2 viruses were mixed with a 100-fold excess 
of wt T3D virus with regards to MOI. 911 cells were exposed to the mixtures first, before 
propagation on U118MG cells for three more passages. Reovirus RNA was isolated from 
the virus derived from the third passage on U118MG cells and subjected to RT-PCR to 
obtain the S1 products from the total population (jin-1/wt end or jin-2/wt end). Sequence 
histograms of the indicated regions were compared to the S1 sequences of the input 
reoviruses. Arrows indicate the nucleotide differences between the wt T3D and jin-1 or 
jin-2. (S1 nucleotide positions 571, 590 and 1019). 
 To verify that wt T3D resistant cells could support replication of the jin-1 
virus, the virus yields were determined in some of these cell lines (figure 7.7 
B). In 911 cells both viruses give a similar yield, but in three other cell lines 
(U118MG, U2OS and LMH) more progeny virus was produced with the jin-1 
virus than with wt virus. The amount of wt T3D produced per cell did not rise 
above the amount added to the cells (MOI of 10, dashed lines). From these data 
we conclude that the jin-1 virus is able to productively infect our panel of wt T3D 
resistant cells. 
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Figure 7.7 Reovirus mutant jin-1 can infect cell lines that resist wt T3D reovirus 
infection. (A) Several cell lines were infected with wt T3D or jin-1 and 32 hr post-infection 
cells were lysed. Protein samples (30 μg) were analyzed by 10% SDS-polyacrylamide gel 
electrophoresis. For the immunodetection anti-reovirus σ3 (4F2) was used. The cell lines 
911 and U118-HAJAM are included to serve as positive controls for the infectivity of wt 
T3D. The cells were mock-infected (m); wt T3D infected, or jin-1 infected. (B) Virus 
production of wt T3D and jin-1 in the different cell lines. Cells were exposed to virus at 
MOI of 10 for one hr, washed with PBS and immediately lysed (1 hour time point) or left 
for 48 or 72 hrs. For 911 cells an additional harvest point at 32 hrs post-infection was 
included. The viral titers in the samples were determined by plaque assays on 911 cells. 
The graph shows a representative example of the assay. Open circles: wt T3D (o), crosses: 
jin-1 (x). The dashed line represents the input amount of the initial infection (10 pfu/cell). 
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Cell entry of reovirus jin-1 and jin-3 relies on sialic acids 
Apart from the Q336R mutation, the other mutations found in the S1 segments 
of the jin mutants are located close to the region involved in SA binding [10,55]. 
Recently the crystal structure of the sialic acid-σ1 complex was elucidated [76]. 
There is a remarkable heterogeneity in the amino acid sequence of the SA-
binding domains of different T3D and T1L strains. Some isolates cannot bind 
SA as determined on JAM-A negative murine erythroleukemia (MEL) cells. The 
forced selection of such strains yielded mutants that could infect MEL cells 
probably via the interaction with SA [83]. 
 The wt T3D that was used in our studies has an amino-acid sequence of the 
sialic-acid binding pocket that is identical to strains capable of binding sialic acid. 
The S1 mutations found in the jin mutants are not located in the region coding 
for the SA-binding pocket of σ1 (viz. amino acids 198–204; ref [10,76]), but are 
located in close proximity of this region.
Figure 7.8 Lec2 cells are poorly infected by reovirus mutant jin-1 and jin-3. (A) 
CMP-sialic acid transporter defective Lec2 cells and parental cell line, CHO, were exposed to 
wt T3D, jin-1, and jin-3 at MOI of 10. Protein lysates were made 32 hrs post-infection and 
analyzed by SDS-polyacrylamide gel electrophoresis. For the immunodetection of σ3 the 
anti-reovirus σ3 antserum 4F2 was used, and anti-actin (human) was used to detect actin 
as a loading control. (B) Virus production of wt T3D and jin-1 in CHO and Lec2 cells. Cells 
were exposed for one hour to the viruses at MOI of 10, washed with PBS and immediately 
lyzed (1 hour time point), or incubated at 37°C for 48 hrs and 72 hrs. Virus yields were 
determined by plaque assays on 911 cells. The graph shows a representative example of 
the assay. Open circles: wt T3D(o), crosses: jin-1(x). The dashed line represents input 
amount of virus used at the initial infection (10 pfu/cell).
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Figure 7.9 WGA inhibits binding of reovirus to cells. (A) Detection of sialic acids in 
cell lines (911, CHO, U118MG and Lec2) by FITC-labeled WGA immunofluorescence. (B) 
WGA inhibition of reovirus infection. Prior to exposure of reovirus jin-1, the cells (U118MG, 
CHO, and Lec2) were mock-treated (-) or treated with 100 μg/ml WGA for 1 hr. at 37°C 
(+). After exposure of the cells to the virus at 4°C the cells were washed with PBS and 
incubated for an additional 32 hours in a CO2 incubator before protein lysates were made. 
For the immunodetection of the σ3 protein the anti-reovirus σ3 (4F2) was used and anti-
actin was used as a loading control. (C) WGA inhibition of wt T3D and jin-1 reovirus 
infection in 911 cells. 
Nevertheless, it is conceivable that the amino acid alterations in the jin mutants 
affect the affinity or avidity of SA binding. To investigate the involvement of SA 
in binding of our mutant viruses we used Lec2 cells. Lec2 cells have a strongly 
reduced (by about 90%) amount of sialic acids on their cell surface [84,85]. 
Lec2 cells are mutants derived from Chinese Hamster ovary (CHO) cells, which 
are poorly infected by wt T3D reovirus [11,36]. In contrast, both the jin-1 and 
jin-3 mutants efficiently infect CHO cells (figure 7.8 A). The wt T3D nor jin-1 
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and jin-3 infect Lec2 cells, as is evidenced by lack of detectable σ3 in the cells 
exposed to these viruses (figure 7.8 A). Also the replication of jin-1 in the Lec2 
cells is markedly reduced compared with the yields obtained in the parental 
CHO cells (figure 7.8 B). This suggests that the expanded tropism of jin is 
dependent on the presence of SA on the cell surface. To support the utilization 
of SA by the jin-1 mutant, we shielded the SA on the surface of the cells by 
pre-incubating the cells with wheat germ agglutinin (WGA). WGA is a lectin 
with a strong affinity to a broad range of sialoconjugates. To confirm that WGA 
effectively binds to the cell lines 911, U118MG and CHO, but not to Lec2, we 
employed FITC-labeled WGA on fixed cells grown on cover slips (figure 7.9 A). 
For the competition experiments we blocked the sialic acids with WGA prior to 
the binding of jin-1 to the cells. The addition of WGA to the cells inhibited entry 
of jin-1 in U118MG and CHO cells (figure 7.9 B). Also in 911 cells, jin-1 and wt 
T3D infection are inhibited (figure 7.9 C). This confirms the dependency of wt 
T3D on SA for cell binding and entry. Our data demonstrate that also the jin-1 
mutant relies on SA binding for cellular entry.
DISCUSSION 
The use of tumor-selective oncolytic viruses for killing tumor cells that resist 
conventional therapeutic approaches is conceptually attractive. Human reoviruses 
are one of the promising candidates for use as replicating oncolytic agent 
[6,56,87]. Reoviruses preferentially induce cell death and apoptosis in tumor 
cells, but not in diploid, non-transformed cells [2,3,53]. However, in some tumor 
cells expression of the JAM-A receptors is down-regulated and absent on the cell 
surface, thereby limiting the susceptibility of the cells to reovirus T3D infection. 
 Here we report the isolation of JAM-A independent T3D reoviruses with 
an expanded tropism. These mutants, designated as jin mutants, may be 
considered as oncolytic agents in those tumor types that lack accessible JAM-A 
on their surface [66-68,88] Although we encountered the first jin mutant in a 
batch of S1-His modified reovirus after selection in the U118MG-scFvHis cell line 
[69], the jin mutants are not genetically modified viruses in the formal sense 
since they resulted from spontaneous mutations in T3D viruses. 
 In three independent virus batches we identified jin mutants. Two of these 
(jin-1 and jin-2) carried an identical mutation in the head domain of the spike 
protein σ1. The mutation replaces the glutamine (Q) residue at position 336 by 
an arginine (R). The amino acid 336 is located at a surface exposed position, 
close to the region involved in the trimerization of the σ1 spikes [81]. The 
alteration renders the area more positively charged. This could potentially result 
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in conformational changes that may disturb the formation of σ1-trimers. However, 
the results of a trimerization assay (depicted in figure 7.3) revealed that altered 
σ1of jin-1 still forms mature trimers, showing that the Q336R alteration in S1 
of the jin-1 and jin-2 viruses does not affect trimer formation of this domain. 
 While the jin mutants were isolated on human glioblastoma cell line U118MG, 
we found that the jin-1 mutant efficiently infects a variety of reovirus T3D 
resistant cell lines, including the chicken hepatoma cell line LMH, but not non-
transformed primary human skin fibroblasts (VH10) This expanded tropism, 
together with the small-plaque phenotype observed in the JAM-A positive cell 
line 911, is reminiscent of changes observed in other virus families. Adaptation 
to cell culture conditions can result in selection of viruses that acquired the 
capacity to bind heparan sulfates [89-91]. Variants of foot-and-mouth disease 
virus (FMDV) which bind strongly to heparan sulfate in vitro, show small plaques 
on BHK cells and these variants are attenuated in cattle. Furthermore, they have 
a decreased ability to spread from the site of inoculation [91]. Alternatively, 
mutants of Sindbis Virus that exhibit a reduced binding to heparan sulfate 
give rise to larger plaques in vitro and are more virulent in vivo with slower 
clearance from the circulation [89]. However, the Q336R change in jin-1 and 
jin-2 does not yield a typical linear heparin-binding domain consensus -X-B-B-
X-B-X-and -X-B-B-B-X-X-B-X-in which B is a basic residue (mainly K or R) and X 
a hydropathic residue [92-94]. It should be noted that the presence of a linear 
consensus sequence is not a strict prerequisite for glycosaminoglycan binding. 
Some of Venezuelan equine encephalitis virus (VEE) mutants bind heparan 
sulfates (HS) through a conformational domain and do not contain the linear 
HS-binding domain [95]. Our observation that reovirus jin-1 entry into U118MG 
cells cannot be inhibited by incubation with heparin or heparan sulphate (data 
not shown) suggests that binding to glycosaminoglycans is not responsible for 
the broadened tropism of jin-1 and jin-2. It therefore remains to be established 
if and how the Q336R change contributes to the expanded tropism. Also with 
respect to sialic acid binding, in some DNA viruses mutations in the SA-binding 
pocket resulted in changes in plaque morphology [96,97]. 
 Upon continued serial passaging of jin mutants in U118MG cells, additional 
amino acid alterations accumulated in spike protein σ1, T193M in jin-1 and 
G187R in jin-2. For the jin-3 mutant, a single mutation in S1 resulted in G196R 
substitution in σ1. Those changes are located in close proximity of the region 
implicated in sialic acid binding [10,55,75,76]. This is in line with the previous 
observation that passaging of reoviruses incapable of binding SA on mouse 
erythroleukemia cells yielded mutants capable of binding sialic acids [83]. In 
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co-crystalization experiments of σ1 in complex with SA it was shown that the 
changes were mapped in the σ1 region between amino acids 198 and 204 [76]. 
 Also outer capsid protein σ3 plays an important role in the process of 
reoviral entry [62,63,98,99]. A mutation found in so-called persistent-infection 
reoviruses leads to an amino acid change Y354H in the σ3 protein. This alteration 
has been linked to the reoviral resistance to the protease inhibitor E64d [100]. A 
mutation in jin-1 results in M357T in σ3, which is in close proximity of position 
354. However, no such mutations are found in jin-2 and jin-3. Moreover, jin-1 
is sensitive to E64d, demonstrating that the jin-1 virus still depends on cysteine 
proteases for uncoating and infection. This suggests that the jin-1 virus enters 
JAM-A negative cells via the endocytic pathway, like wt T3D in JAM-A expressing 
cells. 
 So far, we have evaluated the jin mutants in in vitro studies only and it 
remains to be elucidated what the effect will be in vivo, both with regards to 
safety, as well as to their oncolytic efficacy. 
 While we cannot exclude the possibility of the recruitment of secondary 
receptors, our data suggest that the jin mutants rely on sialic acid binding for 
internalization. It is tempting to speculate that a changed affinity for sialic acids 
underlies the changed tropism of our jin viruses, since they show a decreased 
ability to spread in cultured cells, exhibit a small plaque phenotype, and shielding 
SA moieties with WGA prevents the jin viruses to enter cells. It remains to be 
established if the mutation in S1 affects reovirus pathology in mice. In this 
respect, it is noteworthy that the pathology of reoviruses is, in part, dependent 
on the σ1 protein [101]. 
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SUPPLEMENTARY TABLE 
Supplementing table 7.1 List of primers used in this study. 
RT-PCR primers Sequence (5’-3’) Length
S1for GCTATTGGTCGGATGGATCCTCG 23
S1end R GATGAAATGCCCCAGTGC 18
S2for GCTATTCGCTGGTCAGTTATGGC 23
S2endR GATGAATGTGTGGTCAGTCGTGAGG 25
S3for GCTAAAGTCACGCCTGTCGTC 21
S3endR GATGATTAGGCGTCACCCACCACCAAG 27
S4for GCTATTTTTGCCTCTTCCCAG 21
S4endR GATGAATGAAGCCTGTCCCACGTCA 25
M1for GCTATTCGCGGTCATGGCTTA 21
M1endR GATGAAGCGCGTACGTAGTCTTAG 24
M2for GCTAATCTGCTGACCGTTACTC 22
M2endR GATGATTTGCCTGCATCCCTTAAC 24
M3for GCTAAAGTGACCGTGGTCATGGCT 24
M3endR GATGAATGGGGGTCGGGAAGGCTTA 25
L1for GCTACACGTTCCACGACAATG 21
L1endR GATGAGTTGACGCACCACGACCCATG 26
L2for GCTAAATGGCGCGATGGCGA 20
L2endR GATGAATTAGGCGCGCTCACGAGGGA 26
L3for GCTAATCGTCAGGATGAAGCGG 22
L3endR GATGAATCGGCCCAACTAGCATTG 24
Additional sequence primers
L1midSQ1 For GCTAGCTCAAGTTATTCATGGTTTA 25
L1midSQ2 Rev GCTATGTCATATTTCCATCCGAATTC 26
L1midSQ3 For GTGAAACTATTCAGAACGATCTAG 24
L1seq3 For GTCTGGACGAGCGGCCCCT 19
L1seq4 Rev CGCGCTTTCTTATCATTGG 19
L1seq5 For GTCTGGTAGTGCGGTCATTGAG 22
L2midFor GAACAGAAGATCTTGCCCAA 20
L2midRev GTCTCGATACCAGTCACGGA 20
L2seq2 Rev TGGTATAGATTCCTGCGTCG 20
L2seq3 For TGGACGCATGACTCTTCAGC 20
L2seq4Rev CTGAGGAAGTTCCGATGAAAGCA 23
L2sq6For CTCTAGTGGGATCTAATGCT 20
L3mdSQ6_REV CGTTCTGCCATTGTACTGCTG 21
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Supplementing table 7.1 Continued
Additional sequence primers
L3mdSQ7_FOR GGACTTCACCAATGAGTTAAC 21
L3midSQ1 For GTTCAAGTTTCGGCTGATGTCG 22
L3midSQ2 Rev CGTGGCCACGTGTGAGGCGTTG 22
L3seq4 For ATGACCCTAGCCAACATG 18
L3seq5 Rev TGCAGATACATTGGTGTC 18
L3seq8Rev CAAATGTGTCGACTGAACACG 21
M1midSQ1_For AATCTTGTTATATGCTCC 18
M1midSQ2_Rev TGAGCGAATGTTAGCAATC 19
M1midSQ3_Rev CATGATTTGGATTCCTAAT 19
M2midFor GGAACTAATTGGCATCTCAA 20
M2midRev TTGCCGTTTGGATCCCAGCT 20
M3midSQ1 For GATCCTGAAATCTATAACGAG 21
M3midSQ2 Rev CTGCTGCAACACAGGACATTC 21
M3midSQ3_For TTGCTTGACGCTGTGCGTGTCG 22
S4midFor AGCCTTAAACCTGATGATCG 20
S4midRev AGAATTGGGTTTGACGAGCA 20
Dual-GC primers
DualS1st rev AGCGCGGCCGCAGTGTTTAAACTTCACGTGAAACTACGCGGGT 43
DualS1st for ACCCGCGTAGTTTCACGTGAAGTTTAAACACTGCGGCCGCGCT 43
DualSH rev GCCTCTTCTAAGCGTGAAACTACGCGG 27
DualSH for GCCTCTTCCATGGATCCTCGCCTACGT 27
S1-QRmut2Rev AATGTCGGAGTTCACCCGTACCCTCCAATTCAGC 34
S1-QRmut2For GCTGAATTGGAGGGTACGGGTGAACTCCGACATT 34
Y313A S1mrev GCTCTGCCTAAACCTAGCATTTGGACTCATTCCGATA 37
Y313A S1mfor TATCGGAATGAGTCCAAATGCTAGGTTTAGGCAGAGC 37
First part of the table contains the primers used for the Reverse Transcription PCR 
experiments. Middle part contains the additional primers used to sequence the different 
segments. The last part contains the primers used to clone the S1 and S1mutants in the 
Dual-GC system for the trimerization experiments
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ABSTRACT
Glioblastoma (GB) is a devastating disease for which new treatment modalities 
are needed. Efficacious therapy requires the removal of stem-cell like cells, 
these cells drive tumor progression because of their ability to self-renew 
and differentiate. In glioblastoma, the GB stem-like cells (GSC) form a small 
population of tumor cells and possess high resistance to chemo and radiation 
therapies. To assess the sensitivity of GSC to reovirus-mediated cytolysis, a panel 
of GSC cultures was exposed to wild-type reovirus Type 3 Dearing (T3D) and 
its junction adhesion molecule-A (JAM-A)-independent mutant, jin-1. Several 
parameters were evaluated, including the fraction of cells expressing the JAM-A 
reovirus receptor, the fraction of cells synthesizing reovirus proteins, the number 
of infectious reovirus particles required to reduce cell viability, the amount of 
infectious progeny reovirus produced and the capacity of the reoviruses to infect 
the GSC in 3-dimensional (3D) tumor cell spheroids. Our data demonstrate a 
marked heterogeneity in the susceptibility of the cultures to reovirus-induced 
cytolysis. While in monolayer cultures the jin-1 reovirus was generally more 
cytolytic than the wild-type reovirus T3D, in the 3D GSC spheroids, these viruses 
were equally effective. Despite the variation in reovirus sensitivity between the 
different GSC cultures, our data support the use of reovirus as an oncolytic agent. 
It remains to be established whether the variation in the reovirus sensitivity 
correlates with a patient’s response to reovirus therapy. Moreover, our data 
show that the expression of the JAM-A receptor is not a major determinant of 
reovirus sensitivity in 3D GSC cultures.
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INTRODUCTION
Treatment of glioblastoma (GB) remains a significant clinical challenge. Despite 
intensive treatment, which includes surgical resection, followed by chemo-
irradiation therapy, the prognosis remains infaust. This is largely due to the high 
tumor recurrence rate caused by the highly infiltrative and aggressive nature of 
these tumors. Despite the extensive research in the past decades, the patient 
survival rates have only incrementally improved [102]. An important role in 
the recurrence of GBs has been assigned to a small population of cells, the GB 
stem-like cells (GSC) [102-104]. These cells possess high resistance to radio-
and chemotherapy [105-107] and can self-renew and differentiate into the 
heterogeneous cell types that drive tumorigenesis [103,108,109]. Additionally, 
genotypic and phenotypic analyses of cultured GSC revealed that they retain 
the molecular characteristics of the parental tumors better than cells cultured in 
conventional serum-containing media [108,109].
 The notion that GSCs are relatively resistant to the conventional radiation and 
chemotherapies stresses the importance of exploring other means of eliminating 
these cells. An approach that has gained much interest for cancer treatment 
over the past decades is virotherapy. So far, at least fifteen different viruses 
have been evaluated in preclinical studies. Of these, at least four, that is, herpes 
simplex virus, human adenovirus, Newcastle disease virus and mammalian 
reovirus, have been evaluated in clinical studies for the treatment of GB. The 
results demonstrated that the approach is safe and well tolerated, and provided 
anecdotal evidence of anti-tumor efficacy (as reviewed in Wollman et al. [110] 
and Zemp et al. [111]) Nevertheless, these studies revealed that the therapeutic 
efficacy needs further improvement. One way to accomplish this is to focus the 
treatment modalities by identifying those tumors and patients who are more 
likely than others to respond to a specific therapy. 
 Here we evaluated the susceptibility of a panel of cultured GSCs, isolated 
from tumor resections of GB patients, to mammalian reovirus Type 3. Reovirus 
Type 3 Dearing (T3D) has been evaluated extensively as oncolytic agent. It has 
a segmented double-stranded RNA genome. Reovirus attachment and entry are 
mediated by the junction adhesion molecule-A (JAM-A), which is an integral 
tight junction protein [9,36]. Research indicates that the absence or incorrect 
expression of JAM-A on colorectal tumor cells inhibits reovirus infection [112]. 
In addition, upon infection, reoviruses preferentially lyse cells with an activated 
RAS/RalGEF/p38 pathway [7,29,53]. This tumor cell preference leads to the 
initiation of at least 30 clinical studies involving the use of wild-type (wt) T3D 
as oncolytic agent [113]. So far, one phase-I clinical trial involving intratumoral 
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administration of reovirus to patients with recurrent malignant glioma was 
completed. This study showed that this approach is safe and well tolerated, but 
anti-tumor efficacy has been limited [1]. 
 To evaluate the capacity of reovirus to establish a lytic infection in brain tumor 
stem cells, we assessed the cytolytic capacity of reoviruses in GSC cultures. 
First, the expression of the canonical mammalian reovirus receptor, JAM-A [9] 
was analyzed by flow cytometry. A wide heterogeneity in JAM-A expression 
between the GSC cultures was observed. Therefore, the susceptibility to wt T3D 
was compared with the susceptibility to the T3D mutant jin-1. This mutant, in 
contrast to wt T3D, can infect cells independent of JAM-A expression [114]. To 
evaluate the susceptibility of the GSCs, early viral protein synthesis, the virus-
induced cytopathic effect and progeny virus yields were determined. Progeny 
virus yields are relevant, as virus spread and amplification are dependent on 
progeny production. Moreover, virus penetration and spread in 3-dimensional 
(3D) GSC spheroid cultures were determined. The 3D cultures serve as an 
intermediate between monolayer cultures and animal model systems, and these 
3D cultures may mimic the intratumoral environment more than monolayer 
cultures [115,116]. Moreover, distribution, spread and oncolysis can be studied 
in 3D spheroid models [117]. Our data reveal a wide heterogeneity in reovirus 
susceptibility among the different GSC cultures and that the reovirus replication 
can be hampered at various stages of infection. In addition, we demonstrate 
that the jin-1 mutant infects cells more efficient in GSCs in monolayer cultures, 
is more cytolytic and produces more progeny virus upon GSC infection. However, 
in 3D GSC spheroid cultures, the pattern of viral spread and infection of jin-1 
was similar to wt T3D.
MATERIALS AND METHODS
Cell lines 
The established cell lines 911 and U118MG were cultured in high glucose 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Breda, The 
Netherlands), supplemented with penicillin, streptomycin (pen-strep) and 
8% fetal bovine serum (Invitrogen, Bleiswijk, The Netherlands). A detailed 
protocol for establishment of GSC cultures from glioma resection specimens is 
described elsewhere [118]. In brief, GSCs were grown on growth factor-reduced 
extracellular matrix-(Cultrex BME Reduced Growth Factor, R&D systems, 
Abingdon, UK) coated dishes and cultured in DMEM/F12 supplemented with 
1% pen-strep, B27 (Invitrogen), human EGF (5 μg/ml), human basic FGF (5 
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μg/ml) (both Tebu-Bio, Heerhugowaard, The Netherlands) and heparin (5 mg/
ml) (Sigma-Aldrich, Zwijndrecht, The Netherlands). The tumor material was 
acquired with informed consent from patients as approved by the Institutional 
Review Board of the Erasmus Medical Center, Rotterdam. All cell cultures were 
cultured in humidified atmosphere of 5% CO2 at 37°C. 
Reovirus 
The wt mammalian reovirus Type 3 Dearing strain R124 (referred in the text 
as wt T3D), and the jin-1 mutant were propagated as described before [114]. 
Cultures of 911 cells were exposed to wt T3D in DMEM 2% fetal bovine serum. 
At 4 hrs post infection, the medium was replaced with DMEM 8% fetal bovine 
serum. The wt T3D virus was harvested 48 hrs after infection by collecting the 
cells in 2% fetal bovine serum/phosphate-buffered saline and the virus was 
released by three cycles of freeze-thawing. The jin-1 virus was propagated 
on the JAM-A-deficient cell line, U118MG, and was harvested at 72 hrs post 
infection. Infectious titers of both viruses were determined by plaque assay on 
911 cell cultures. 
Cell viability assay 
Cells were infected in suspension with wt T3D or jin-1 at a multiplicity of infection 
(MOI) range 0-100 pfu911 per cell. Subsequently cells were transferred to an EMC 
growth factor-reduced pre-coated 96-well plate in which 1x104 cells per well 
were seeded. The viability of the cultures was measured 72 hrs post infection 
by CellTiter-Glo Luminescent Cell Viability assay, according to manufacturer’s 
instructions (Promega, Leiden, The Netherlands). Briefly, the reagent was added 
to the cell cultures and incubated at room temperature in the dark for 10 min. 
Next, samples were transferred to black 96-well plates and luminescence was 
measured by a plate reader (Tecan Infinite M200, Tecan Group Ltd, Männedorf, 
Switzerland). Luminescence count data of the plate reader were transferred to 
Microsoft office Excel and half maximal effective concentration (EC50) values were 
calculated from the mean residual luminescence from three independent samples. 
Flow cytometry analysis 
Anti-JAM-A immunostaining. GSC cultures, 911 cells and U118MG cells, in 
suspension as single cells, were incubated with mouse monoclonal anti-JAM-A 
antibody (clone M.Ab.F11, Cat. No. ab17261, Abcam, Cambridge, UK) for 1 hr 
on ice. Subsequently, the cells were incubated in the dark with PE fluorochrome-
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conjugated rat anti-mouse serum (Cat. No. 340270, BD Bioscience, 
Erembodegem, Belgium) for 30 min on ice. After washing, the samples were 
taken up in FACS buffer (phosphate-buffered saline, 0.5% BSA, 2 mM EDTA) 
and assayed on a BD LSRII flow cytometer. Data were analyzed with FACSdiva 
software (BD Bioscience). 
 Anti-Sigma 3 immunostaining. Cells were infected in suspension with wt T3D 
or jin-1 at an MOI 3 pfu911 per cell and transferred to a 6-well plate at 2x104 cells 
per well. After 30 hr, the cells were harvested and fixed in 4% formaldehyde for 
10 min. Subsequently, cells were washed and permeabilized with Perm/Wash 
buffer (Cat. No. 554714, BD Cytofix/Cytoperm Fixation Permeabilization kit, 
BD Bioscience) followed by incubation with the anti-Sigma 3 mouse antibody 
(4F2, monoclonal antibody, Developmental Studies Hybridoma Bank (DSHB), 
University of Iowa, Iowa, IA, US) for 1 hr at 4°C. After washing twice with Perm/
Wash buffer, the samples were incubated in the dark with the PE fluorochrome-
conjugated rat anti-mouse serum (Cat. No. 340269, BD Bioscience) for 30 min. 
Subsequently, the samples were washed extensively, resuspended in FACS 
buffer and assayed on a BD LSRII flow cytometer and data of a gated population 
of 1x104 cells were analyzed with FACSDiva software (BD Bioscience). 
Viral progeny 
Cells were exposed in suspension at 37°C for 1 hr with wt T3D or jin-1, MOI 3 
pfu911 per cell. Next, unbound virus was removed by centrifugation, removal of 
the medium and plating the cells in fresh medium in 24-well plates. After 72 hrs, 
cells and media were collected and freeze-thawed three times to release virus 
from the cells. Viral titers were determined by plaque assays on 911 cells as 
described [28]. The plaque titration conditions used have an inter-experimental 
variation of <15%. The virus production by the cell cultures was expressed as 
the fold-increase and calculated by dividing the total yield by the amount of 
virus used to infect the culture. 
Spheroid 3D cultures 
Multicellular spheroids were generated by seeding 1x104 cells per well in a non-
adherent 96-well round-bottom plate in culture media supplemented with 2.4% 
methylcellulose (Sigma-Aldrich). After 1 day, the multicellular spheroids were 
washed three times and placed in fresh media. Two days later, the spheroids were 
mock infected or exposed to wt T3D or jin-1 at a MOI 10 pfu911 per cell. Three 
days after infection, the spheroids were fixed overnight with 4% formaldehyde 
and embedded in paraffin. Analyses of 6 mm paraffin sections were performed 
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by 3,3’-Diaminobenzidine immunocytochemistry. First, sections were incubated 
overnight with the primary antibody against Sigma 3 (4F2, DSHB) followed by 
a wash and subsequent incubation with the secondary horse radish peroxidase-
conjugated antibody (Cat. no. P0447, Dako, Glostrup, Denmark). 
RESULTS
The aim of our research is to develop an oncolytic virus-based therapy for 
glioblastoma. To assess the susceptibility, we defined the sensitivity of GSCs 
to reovirus by measuring five parameters. A panel of seven independent 
serum-free GSC cultures [118] was evaluated in parallel to the highly reovirus-
susceptible human embryonic retinoblast cell line 911 [28,114] and the JAM-A 
negative U118MG cell line [114]. All of the serum-free GSC cultures are 
derived from GB resections, five from primary tumor specimens, and two from 
recurrent disease cases. The characteristics of the patients from whom the GSC 
cultures were derived are summarized in table 8.1. The expression of the JAM-A 
reovirus receptor was assessed in each of these cultures by flow cytometry. 
The expression is heterogeneous and could be categorized in four groups. The 
GS187 and GS249 cultures were JAM-A negative whereas the GS184 and GS186 
have only a low-level of JAM-A expression. Moderate JAM-A expression was 
measured in GS79 and GS245 cultures, respectively, with between 30 and 50% 
of the cell population expressing JAM-A. The highest expression was observed 
in GS224, in which almost the entire population expressed JAM-A (figure 8.1and 
table 8.2). The latter closely resembled the JAM-A expression of the control cell 
line 911. The high variation in JAM-A expression prompted us to include in our 
studies the T3D reovirus jin-1. In contrast to the wt T3D, the jin-1 mutants can 
infect cells independent of JAM-A expression [114]. 
Table 8.1 Patient Characteristics of Glial Stem-like Cells cultures
GSC Cultures Male/Female Age Type
GS79 F 74 GB
GS184 M 50 GB
GS186 F 48 GB
GS187 F 63 GB recurrent
GS224 M 49 GB recurrent
GS245 M 70 GB
GS249 M 43 GB
Abbreviations: F, female; GB, glioblastoma; M, male
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Figure 8.1 Flow cytometry analyses of JAM-A expression on GSC cultures and 
911 and U118MG cells. Staining was performed with an anti-JAM-A mouse monoclonal 
antibody followed by a secondary rat anti-mouse PE-conjugated antibody (light grey 
histograms). The dark grey histograms represent the incubation with secondary antibody 
only. The analysis was performed on a gated population of 10,000 cells. The percentages 
represent the JAM-A positive population in respect to only secondary antibody treated cells.
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 Within the GSC cultures, a highly variable sensitivity to wt T3D reovirus 
infection was observed (table 8.2). In five out of seven GSC cultures, the fraction 
of reovirus-positive cells did not exceed 1%. This indicates that virus entry in 
these cultures is inhibited or that the infection is blocked prior to the initiation 
of reovirus protein synthesis. In contrast, upon wt T3D reovirus exposure, 
approximately 20% of the GS79 cells were positive for σ3, whereas in GS224, 
more than 50% of the cells synthesized σ3 (table 8.2). 
 To establish the EC50, each culture was exposed to serial dilutions of the wt T3D 
reovirus stocks and the viability was determined. No clear cytopathic effects were 
observed in four GSC cultures. The viability assay demonstrated that GS187 and 
GS249 are fully resistant to wt T3D. The GS184 and the GS245 cultures exhibited 
a minimal reduction in viability at the highest MOI used and therefore their EC50 
values were scored as >100 pfu911 per cell. Infection of wt T3D was clearly 
discernible in GS79, GS186 and GS224 cultures (table 8.2). In GS186 cultures, 
the reovirus cytolysis was not accompanied by reovirus protein synthesis. 
 To study whether GSC infection results in the production of infectious progeny 
reovirus, the viral yields were determined at 72 hr post infection. From these 
data, the fold-increase in progeny was calculated (table 8.2). Significant amounts 
of progeny virus particles were obtained in six out of the seven GSC cultures. 
Only from the GS184 culture the amount of reovirus recovered was below the 
amount used to infect the cultures. The highest yields were collected from GS79 
and GS186, with a 20-fold-increase in infectious titer. A 10-fold-increase was 
produced by GS224. The cultures of GS245 and GS249 both yielded almost four 
times more virus particles. A doubling of the infectious virus particle number 
was achieved by GS187. From these data we conclude that several of the GSC 
cultures are productively infected with wt T3D, albeit with highly variable yields. 
 In order to determine the virus production per cell, the data of the σ3-positive 
population was combined with the virus yields (table 8.2). The viral yield per 
cell obtained from GS79, GS184 and GS224 was low, and does not exceed the 
300 pfu911 per cell. The production per cell from GS187, GS245 and GS249 
cultures ranged from 1.5 x103 to3 x103 pfu911 per cell. The highest yields were 
produced by GS186 with approximately 104 pfu911 per cell. These data show 
that, whereas some cultures are susceptible to reovirus infection, they do not 
replicate reoviruses to high titers. 
 The GSC cultures were grown as spheroids to study the reovirus spread in 3D 
cultures that mimic the tumor structure more faithfully than monolayer cultures 
[116,119]. Immunocytochemistry revealed the presence of reovirus-infected 
cells in all GSC spheroid cultures. The distribution and the abundance of the 
reovirus-infected cells differed within the GSC spheroids (figure 8.2). In GS184, 
Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures
195
8
only a few reovirus-positive cells were detected throughout the spheroid. In GS79 
and GS245, the entire outer rim of the spheroids was infected. Already at visual 
inspection of the spheroid cultures cellular debris was observed surrounding 
the spheroids. These detached cells were lost during sample processing prior to 
analysis. In GS187 and GS249, the wt T3D infected cells were concentrated at a 
single side of the spheroids, suggesting that the virus infection was initiated at a 
single point near the outer rim, and then spread inward from there. Additionally, 
visual inspection of GS187 spheroids revealed abnormal blown-up cell structures 
on the edge of the spheroid, indicative of reovirus infection. The GS224 spheroids 
showed a mixed pattern of infection with the entire outer layer being reovirus 
infected in combination with inward spread on one side of the spheroids. On 
GS186 spheroids, the σ3 staining revealed that all cells of the spheroids were 
infected with the exception of the core cells in a few spheroids. Taken together, 
these data show that there is a high variation in the extent of reovirus infection 
and pattern of spreading in the different GSC spheroid cultures. 
 To study whether the jin-1 mutant is more effective in the GSC cultures, we 
repeated the experiments described above with this mutant virus. Overall, the 
fraction of positive cells exceeded the fraction of reovirus positive cells after 
infection with wt T3D. The cultures with the lowest number of reovirus σ3-
positive cells included GS184 and GS245. In the GS186, GS187 and GS249 
cultures, more than 60% of the cell population stained positive for σ3 reovirus 
protein. Most susceptible to jin-1 were GS79 and GS224 with, respectively, 99 
and 89% of the cells being reovirus positive (table 8.2). 
 Similar to the experiments with wt T3D reovirus, the EC50 values were 
determined (table 8.2). All values of jin-1 infection were found to be lower than 
after infection with wt T3D. On GS249, a moderate cytopathic effect of jin-1 was 
seen at MOI=100. In all the other six cultures, cytopathic effects were clearly 
seen in higher dilution ranges. The EC50 determined on GS245 and GS184 was 
40 and 26 pfu911 per cell, respectively. The remaining four cultures scored an 
EC50 below 10 pfu911 per cell. The culture most sensitive to jin-1 was GS186, in 
which an effect was already observed at MOI=0.1. 
 The lowest effective viral progeny yield was obtained from GS79, GS184 and 
GS224 with less than a hundred-fold-increase in virus titer. Higher yields were 
obtained in GS245 and GS187 with a 200 and 500-fold amplification, whereas 
in the GS186 and GS249 cultures the yields exceeded the input dose by three 
orders of magnitude (table 8.2). Moreover, the calculated yield per infected 
cell in four of the seven cultures was similar for the jin-1 and wt T3D viruses. 
In three cultures, the yields per cell were different from those of wt T3D and 
jin-1. In GS79 and GS186, the yield of progeny virus is higher for wt T3D than 
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for jin-1, whereas in GS184 the yield of the jin-1 was 45-fold higher than in wt 
T3D-exposed cultures. 
Figure 8.2 wt T3D and jin-1 reovirus infection pattern in GSC spheroids. GSC 
spheroids generated of 10,000 cells were incubated with wt T3D or jin-1 at MOI =10. After 
72 hrs, the spheroids were fixed and processed into paraffin sections. To analyze the σ3 
pattern, sections were incubated with the monoclonal antibody 4F2 against σ3 followed 
by secondary antibody horse radish peroxidase (HRP)-conjugated polyclonal Goat anti-
Mouse immunoglobulins. HRP activity was visualized by 3,3’-Diaminobenzidine staining. 
The brown color indicates the presence of σ3 protein indicative of reovirus infection.
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 To study the distribution and abundance of reovirus-infected cells in 3D 
cultures, GSC spheroids were exposed to jin-1 (figure 8.2). Similar to wt T3D, 
variable results were obtained upon exposure to jin-1. In four GSC spheroids, the 
cells at the outer rim stained positive for σ3, although at varying levels. GS187 
and GS249 were more effectively infected than GS79 and GS245. Viral spread 
into the core of the spheroids was seen in GS184, GS186 and GS224. In GS184 
and GS224, only some isolated reovirus-infected cells were seen, whereas in 
GS186 spheroids, σ3-stained cells were found throughout the spheroid. 
DISCUSSION
The identification of GSCs, their role in tumor recurrence, metastases and 
therapy resistance, stresses their importance in brain cancer research. 
Treatment procedures aiming at eliminating these cells may improve brain 
cancer outcomes [102,120]. The aim of this study was to test the susceptibility 
of GSC cultures to the wt mammalian reovirus T3D and the JAM-A-independent 
jin-1 mutant. In previous studies, the susceptibility to reovirus was tested in 
tumor cells in serum-supplemented cultures [35,121], which lose their parental 
tumor characteristics during culturing [108,109] and therefore may be less 
representative for the clinical situation. 
 In this study, we measured the GSC cultures on four parameters - reoviral 
protein synthesis, the induction of cytopathic effects, the production of progeny 
virus and the spread and penetration of the virus in a 3D spheroid culture of the 
GSC. These parameters are all independently evaluated in addition to cell lysis, 
production and spread. Moreover, because the expression of the high-affinity 
reovirus receptor JAM-A varied on the GSC cells, we evaluated if jin-1 was more 
potent in this regard than wt T3D. 
 From this study we conclude that there is marked heterogeneity between the 
GSC cultures in their sensitivity to reovirus-mediated cytolysis. The differences in 
reoviral σ3 protein synthesis may reflect variation differences in reovirus binding 
to the cells, reovirus egress from endosomes or differences in positive-strand 
messenger RNA generation [122,123]. The efficiency of reovirus σ3 protein 
synthesis does not correlate with the sensitivity to reovirus-mediated cytolysis. 
While GS186 is poorly susceptible to wt T3D reovirus synthesis, as evidenced 
by the fraction of cells that produces σ3 proteins, it is relatively sensitive to 
reovirus-induced cytolysis. In contrast, GS79 synthesizes σ3-proteins in 
a relatively high percentage of the cells, while it is relatively insensitive and 
requires a high MOI for induction of cytopathic effects by wt T3D. Similarly, we 
see a highly variable capacity to support reovirus propagation. The amount of 
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progeny reovirus produced per productively infected cells varies over 2 orders 
of magnitude with the GS186 culture being the most effective wt T3D producer, 
and the GS224 being least effective. With the use of the jin-1 reovirus, we see 
a similar heterogeneity. Whereas minor variation is seen in fraction of reovirus-
infected cells in the different GSC cultures, the sensitivity to reovirus-induced 
cytolysis, as well as the capacity to produce progeny reovirus is much more 
heterogeneous. 
 The infection efficiency, the reovirus-induced cytolysis and the virus 
production in the monolayer cultures are more efficient with jin-1 than with wt 
T3D. In contrast, the distribution and abundance of σ3-positive cells in spheroid 
cultures is similar with these viruses. This suggests that the JAM-A receptor 
expression is not a prime determinant of the reoviruses’ capacity to spread 
in spheroid cultures. Although this was unexpected, it is not unprecedented. 
Recently it was established that wt T3D infects and spreads efficiently in 3D 
tumor spheroids established from JAM-A-deficient U118MG cells. In contrast, 
wt T3D infection of U118MG cells in monolayer cultures is dependent on JAM-A 
expression [124]. This demonstrates that the canonical T3D entry route, which 
starts by the reovirus σ1 protein’s engagement of JAM-A, is not essential in 3D 
cultures, and that under these growth conditions alternative entry routes can be 
used by the reovirus. 
 Spread of the oncolytic viruses within the tumor is essential for anti-tumor 
efficacy. The compartmentalization brought about by depositions of extracellular 
matrix presents itself as a physical barrier [125]. Also, the vasculature and 
the tumor-stroma may impose limitations to viral spread [126]. An appealing 
option for enhancing the spread of the oncolytic viruses is the use of carrier 
cells loaded with oncolytic viruses [127-129]. The carrier cells need to possess 
the capacity to home to tumors. Several cell types have been identified that 
can home to tumors, such as dendritic cells, T cells, macrophages and several 
types of stem cells. After loading, the virus should hitchhike on these cells and 
be released in the tumor [128,129]. If the viruses are associating with the 
cells in a manner that shields them from neutralizing antibodies, the approach 
may also be effective in those patients with pre-existing neutralizing immunity 
against reovirus. That this strategy can be applied for reovirus delivery was 
shown by Ilett et al. [130,131], who showed that reovirus can hitchhike onto 
dendritic cells and T cells. Additionally, internalization of reovirus by dendritic 
cells protected the virus from neutralizing antibodies [131].
 So far, only single GSC cultures were established and studied from the 
individual patients. It therefore remains to be established whether the 
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heterogeneity observed between different cultures faithfully reflects phenotypic 
inter-patient or inter-tumor variations, or whether the heterogeneity is the 
result of intratumor heterogeneity [132] or even phenotypic drift in the cultures. 
The latter could result from the preferential outgrowth of specific populations of 
cells in the tumor cell cultures. Such culture bias could limit the predictive value 
as model for the clinical tumors in situ. It would therefore be extremely useful 
if clinical studies on the efficacy of oncolytic reovirus therapy were paralleled 
with in vitro studies on reovirus sensitivity in cultures of tumor cells derived 
from the same patients. Such studies may eventually reveal which of the in vitro 
parameters would best predict the efficiency of therapeutic reovirus replication 
in vivo. 
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ABSTRACT
Virus neutralization and scavenging by non-target tissues are major hurdles for 
effective systemic virotherapy. The use of carrier cells for delivery of oncolytic 
viruses may overcome these limitations. Here we evaluated the feasibility of 
using human bone-marrow-derived mesenchymal stromal cells (MSC) for 
delivery of reovirus Type 3 Dearing (T3D). In this study the efficiency of loading 
the wild-type (wt) reovirus T3D and reovirus mutant jin-1 was evaluated. The 
mutant jin-1 has gained the capacity to infect cells independent of junction 
adhesion molecule-A (JAM-A). Most of the MSC lack expression of the reovirus 
receptor (JAM-A), but the MSC were poorly susceptible both to wt T3D and to jin-
1 reoviruses. Nevertheless, the wt T3D and jin-1 exposed-MSC could efficiently 
hand-off the virus to reovirus-sensitive 911 cells. Exposing 911 cultures to 
reovirus-exposed MSC resulted in reovirus-induced cytopathology in these 
cultures. Reovirus hand-off was not blocked by incubating the reovirus-exposed 
MSC with neutralizing human immunoglobulin concentrates, demonstrating that 
at least part of the reoviruses were associated with the MSC in a neutralization-
resistant form. In addition, the reovirus-loaded MSC could also hand-off 
reoviruses to cells in 3-dimensional spheroid cultures. These results support 
the development of human MSC as cellular vehicles for the delivery of oncolytic 
reoviruses and warrant further animal studies on the feasibility of this approach.
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INTRODUCTION
A promising oncolytic agent for the treatment of a variety of cancer types 
is the mammalian orthoreovirus type 3 Dearing (T3D) [8]. The mammalian 
orthoreoviruses were first isolated from the respiratory and enteric tract. 
Infections proceed usually asymptomatically and the majority of the human 
population possess neutralizing antibodies against reovirus [133,134]. Already 
in the late 1970’s, the human reoviruses’ preference for lytic replication in 
transformed cells was noted [47,135,136]. Strong and coworkers were the 
first to implicate activation of the RAS signaling pathway in the sensitization of 
cells to reovirus replication and cytolysis [53]. Subsequently, more details were 
unraveled and the sensitivity of cells to reovirus mediated cytolysis was related 
to an activated RAS/RalGEF/p38 signaling pathway [7,47,57]. This pathway is 
constitutively activated in many human tumors [8,47,137]. The virus’ preference 
for transformed cells, together with the absence of reovirus-associated clinical 
pathology, led to studies on the feasibility of using wild-type (wt) reovirus T3D 
as oncolytic agent.
 Phase I and II clinical trials involving the use of reovirus T3D have been 
initiated for a variety of tumor types [113]. These studies demonstrated 
that reovirus-administration to humans is generally safe and well tolerated 
[1,58,59,138]. Despite evidence of antitumor efficacy, the overall effect of 
reovirus as single therapeutic agent has been limited. Currently the use of 
reoviruses in combination with conventional therapies is being explored in phase 
I-III clinical trials [113,138,139]. The first results of these combination trials 
demonstrate that also this strategy is safe and well tolerated [138,140-142], 
and there is evidence for anti-tumor efficacy [143]. Although these data are 
encouraging, the deposition of the reovirus into the tumor upon systemic virus 
delivery is limited and should be improved to enhance therapeutic efficacy.
 The presence of neutralizing antibodies reduces the transduction of tumor 
cells, especially upon systemic administration [128,138]. In addition, other 
soluble factors, including complement and pre-immune IgM, as well as non-
specific binding of the viruses to blood cells, and uptake by non-target tissues, 
hamper therapeutic virus delivery [144]. To enhance oncolytic virus therapy 
efficacy, various virus-shielding strategies to improve the viral transfer to the 
tumors have been explored [113]. One of these strategies involves the use of 
cellular delivery vehicles. Migration of cells to tumors may facilitate chaperoning 
and delivery of the viruses to the tumor site. In addition, during transport the 
carrier cells may shield the virus from neutralizing antibodies [128,145-147]. 
There are a number of cell types which have been investigated as oncolytic-virus 
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delivery vehicles including cytokine induced-killer cells, tumor-antigen-specific T 
cells, dendritic cells, macrophages, and various stem cells [129,148]. 
 In this study we explored the possibility of loading human bone marrow-
derived mesenchymal stromal cells (MSC) with reovirus with the prospect of using 
them as delivery vehicles for therapeutic viruses. The procedure of isolating MSC 
is relatively straightforward and the cells can be cultured and expanded in vitro. 
Studeny and coworkers [149] were the first to show that MSC could be used as 
a delivery vehicle for tumor targeting. They transduced MSC with an adenoviral 
vector expressing IFN-β and administered these cells to tumor bearing mice. 
Although the therapeutic effect was transient, tumor growth was significantly 
delayed compared to human IFN-β administration [149]. Subsequent studies 
explored the delivery of oncolytic viruses such as adenovirus and measles virus 
to both immune-deficient as well as in immune-competent tumor bearing-
mice [147,150,151]. These studies further encouraged exploration of MSC for 
reovirus delivery.
 Here, we evaluated loading of MSC with wt T3D and with the mutant reovirus 
jin-1, which can infect cells independent of the expression of the junction 
adhesion molecule-A (JAM-A) [114]. Our data demonstrate that human MSC 
could be successfully loaded with wt T3D and with jin-1, and that loaded MSC 
could successfully hand-off virus to both monolayer as well as in 3-dimensional 
tumor cell spheroids. In addition, the reoviruses could also be handed off to 
JAM-A negative U118MG cells in spheroid cultures, consistent with our earlier 
observations that reovirus infections in tumor cells spheroids do not depend on 
JAM-A expression [124]. Taken together these data warrant further exploration 
of MSC-mediated oncolytic reovirus delivery in experimental tumor models. 
MATERIAL AND METHODS
Cell lines 
The human adenovirus type 5 (HAdV-5) E1 transformed human embryonic 
retinoblast cell lines 911 and the malignant glioma cell lines U118MG and U87MG 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco-BRL, Breda, 
the Netherlands) supplemented with 10% fetal bovine serum (FBS, Gibco-BRL). 
Human bone-marrow derived Mesenchymal Stromal Cells (MSC) (a kind gift 
from H. Roelofs, LUMC) were cultured in DMEM supplemented with 10% FBS 
and penicillin-streptomycin. All cell lines were maintained at 37°C in humidified 
atmosphere with 5% CO2. 
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 MSC expressing eGFP were generated by lentivirus-mediated transfer of 
the eGFP expression cassette. Production of the lentiviral vector containing 
the human Cytomegalovirus immediate early enhancer/promoter driven eGFP-
cassette, and the transduction of MSC were performed as described previously 
[30,33].
Reoviruses
The isolation and propagation methods of the wt T3D and jin-1 reoviruses 
were performed as described before [69,114]. In brief, propagation of wt T3D 
performed on 911 cultures. Cells were exposed to the virus in DMEM with 2% 
FBS and after 4 hrs, the infection medium was replaced by DMEM with 8% 
FBS. The wt T3D was harvested 48 hrs after infection by collecting the cells in 
PBS/2% FBS and released by freeze-thawing the cells three times [69]. The 
jin-1 was routinely propagated on the JAM-A-negative cell line U118MG as 
previously described [114]. The final production was performed on 911 cells and 
the virus was harvested 72 hrs post-infection. Infectious titers of both viruses 
were determined by plaque assays on 911-cell cultures and expressed as pfu911/
ml [69]. 
Reverse transcription PCR
Total cellular RNA was isolated from MSC with the Absolutely RNA miniprep 
kit (Stratagene, Agilent Technologies, Amstelveen, The Netherlands). Copy 
DNA synthesis of JAM-A or GAPDH RNA was started with the synthetic 
primers hJAM_RT Rev 5’-CACCAGGAATCACGAGGTC-3’ or GAPDH Rv 
5’-AATGAAGGGGTCATTGATGG-3’ using SuperScript III (Invitrogen, Woerden, 
The Netherlands) for reverse transcription. For the PCR Pfu polymerse 
(Promega, Leiden, the Netherlands) was used with the primer combination 
unique for hJAM-A forward hJAM For 5’-ATGGGGACAAAGGCGCAAGTC-3’ 
and hJAM_RT Rev 5’-CACCAGGAATGACGAGGTC-3’or unique for GAPDH Fw 
5’-ACAGTCAGCCGCATCTTCTT-3’, GAPDH Rv 5’-AATGAAGGGGTCATTGATGG-3’. 
The plasmid pLV-JAM-ECD-IRES-Neo [69] encoding huJAM was used as positive 
control. 
Flow cytometry analysis
Anti-JAM-A immunostaining
MSC cultures, as single cells in suspension, were incubated for one hr on ice with 
mouse monoclonal anti-JAM-A antibody (clone M.Ab.F11, Cat. No. ab17261, 
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Abcam, Cambridge, UK). Subsequently, the cells were incubated in the dark 
with PE fluorochrome-conjugated rat anti-mouse serum (Cat. No. 340270, 
BD Bioscience, Erembodegem, Belgium) for 30 min on ice. After washing, the 
samples were taken up in FACS buffer (PBS, 0.5% BSA, 2 mM EDTA) and assayed 
on a BD LSRII flow cytometer. Data was analyzed with FACSdiva software (BD 
Bioscience). 
Anti-sigma-3 immunostaining
Adhered MSC cultures of 105 cells were infected with wt T3D or jin-1 at a 
multiplicity of infection (MOI) 10 pfu911/cell, or mock infected. After 72 hrs the 
MSC were harvested and fixed in 4% formaldehyde (FA) for 10 min. Subsequently, 
cells were washed and permeabilized with Perm/Wash buffer (Cat. No. 554714, 
BD Cytofix/Cytoperm, Fixation Permeabilization kit, BD Bioscience) followed 
by incubation with the anti-sigma3 (σ3) mouse antibody (4F2, monoclonal 
antibody, Developmental Studies Hybridoma Bank (DSHB), University of Iowa, 
Iowa, US) for one hr at 4°C. After washing twice with Perm/Wash buffer the 
samples were incubated in the dark with the PE fluorochrome conjugated rat 
anti-mouse serum (Cat. No. 340269, BD Bioscience) for 30 min. Subsequently, 
the samples were washed extensively, resuspended in FACS buffer and assayed 
on a BD LSRII flow cytometer and data of a gated population of 1x104 cells were 
analyzed with FACSDiva software (BD Bioscience). 
Immunofluorescence
MSC were plated in 24-well plates on glass coverslips at a concentration of 
105 cells/well. The next day cells were exposed to MOI=10 wt T3D or jin-1 
per cell. The MSC were fixed 72 hrs post infection (pi) in ice-cold methanol 
and subsequently washed with phosphate-buffered saline containing 0.05% 
Tween-20. The fixed cells were incubated with the primary antibody against 
reovirus capsid protein σ3 (4F2). After thoroughly washing, the cells were 
incubated with a goat anti-mouse fluorescein isothiocyanate (FITC)-conjugated 
serum. After 30 min incubation at RT, the secondary antibody was removed 
and the nuclei were stained with Hoechst 33342 (Molecular Probes, Leiden, The 
Netherlands). After washing the coverslips were mounted in Vectashield (Vector 
Laboratories, Inc. Burlingame, US).
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Virus yield determination
MSC (105 cells) were exposed to reoviruses at a MOI=10 with wt T3D or jin-1. 
After 4 hrs the medium was replaced by fresh medium. At 72 hrs pi conditioned 
media and cells were harvested and the virus was released from the cells by 
three cycles of freeze-thawing. The reovirus titers were determined by plaque 
assays on 911-cell cultures. 
Neutralization of wt T3D by IVIg
A monolayer of 911-cells was infected with wt T3D, MOI=3, or Mock. The infection 
media was supplemented with human intravenous immunoglobulin (IVIg), 10 
ng/ml, 1 ng/ml or 0 ng/ml. 48 hrs after infection the viability of the cultures 
was assayed by adding WST-1 reagent (Roche, Woerden, The Netherlands) 
according to the manufacturer’s instructions. 
Virus release assay - monolayer
MSC were exposed to MOI=3 of either wt T3D or jin-1. At 72 hrs pi the MSC 
cultures were harvested by brief trypsinization, washed and incubated in 
DMEM containing 10% FBS with or without 60 mg/ml IVIg for 30 min at 37°C. 
Subsequently, the MSC were washed in DMEM containing 10% FBS and counted 
before they were mixed in increasing concentrations with 911 cultures. The 
cytopathic effects (CPE) in these mix cultures were scored at day 7 post mixing.
Real-time imaging 
In an experimental set up similar to the hand-off assay, the mixed cultures of 
reovirus-exposed MSC.eGFP and 911-indicator cells were analyzed by bright-
field and fluorescence microscopy every hr up to 64 hrs after initiation of the co-
culture by IncuCyte life-cell microscopy (Bucher Biotech AG, Basel, Switzerland).
Virus release assay - spheroid cultures
Spheroids cultures of 911, U118MG, and U87MG cells were generated by 
seeding 104 cells/well in a non-adherent 96-well round-bottom plate in DMEM 
containing 10% FBS supplemented with 2.4% methylcellulose (MC) (Sigma-
Aldrich). Two days post seeding, the spheroids were washed three times with 
media to remove the MC. At day three the spheroids were treated with one 
of the following conditions; 1) Mock infection; 2) exposed to wt T3D at 2500 
pfu911/well; 3) exposed to jin-1 at 2500 pfu911/well, 4) addition of 500-mock 
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infected MSC.eGFP; 5) addition of 500 wt T3D-infected MSC.eGFP; 6) addition 
of 500 jin-1 infected MSC.eGFP. The MSC.eGFP had been mock infected or were 
exposed to MOI=10 wt T3D or jin-1, three days earlier. Three days after mixing 
the spheroids were fixed in 4% formaldehyde (FA), and embedded in paraffin. 
Microtome sections of 6 µm thickness were deparaffinized, rehydrated, and 
incubated overnight with the primary antibodies against σ3 (4F2) or against GFP 
(Cat. No. A11122, rabbit polyclonal, Invitrogen, Eugene, Oregon, USA). After 
thoroughly washing, the secondary Horse Radish Peroxidase (HRP) conjugated 
antibody (Dako Netherlands bv. Belgium) signals was used to visualize the 
antigens by 3,3′-diaminobenzidine (DAB) immunohistochemistry. 
RESULTS
To assess the ability of reovirus to hitch-hike on MSC to target cells, we studied 
the reovirus loading onto MSC and the efficiency of MSC-mediated reovirus 
delivery in different culture systems. In these studies we evaluated loading of wt 
T3D and of the jin-1 mutant, which is capable of infecting cells independent of 
the presence of the high-affinity reovirus receptor junction adhesion molecule-A 
(JAM-A) [114]. 
Oncolytic reovirus infection of MSC
An essential cell property for productive infection in monolayer is the expression 
of JAM-A on the cell surface [9,114,152]. JAM-A expression on MSC was 
determined by reverse-transcription PCR on total cellular RNA and anti-JAM flow 
cytometric analysis of the MSC population. No JAM-A cDNA could be amplified 
(figure 9.1 A) and flow cytometry detected only a small subpopulation (3.3%) 
of MSC expressing JAM-A (figure 9.1 B). Next, the MSC cultures were exposed 
to wt T3D or jin-1 at multiplicity of infection (MOI) 1, 10 and 100 to determine 
the sensitivity to both reovirus isolates. Three-days post-infection the cells were 
visually inspected. No overt cytopathic effects (CPE) were apparent in the virus-
exposed MSC cultures of MOI=1 and 10. Cultures exposed to MOI=100 clearly 
suffered from the high virus dose. Immune fluorescence microscopy with an 
antiserum directed against the reovirus capsid protein σ3 did not detect this 
protein in MSC exposed to MOI=1, and only very few cells exposed to MOI=10 
were positive for σ3. Additionally only a slightly higher percentage of cells 
displayed σ3 proteins upon jin-1 exposure than upon wt T3D exposure, 0.8% 
and 0.2% respectively. 
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Figure 9.1 A small population of MSC express junction adhesion molecule-A (A) 
rtPCR analysis was performed on total RNA extract of MSC. Copy DNA (cDNA) synthesis 
and PCR amplification was performed with specific synthetic oligonucleotides directed 
against human JAM-A or, as control, GAPDH. A plasmid encoding human JAM-A was 
used as positive control for the PCR reaction. (B) Flow cytometric analyzes of JAM-A 
expression on MSC – 3.3% of the MSC expressed JAM-A. U118MG, negative for JAM-A, 
and U118hJAM, 99.1% of the cells expressed JAM-A, were implemented as respectively 
negative and positive control for the JAM-A staining. Staining was performed with an anti-
JAM-A mouse monoclonal antibody followed by a secondary rat anti-mouse PE-conjugated 
antibody shown in the black histograms. The percentages represent the JAM-A positive 
population in respect to secondary antibody treated cells only, represented in the grey 
histograms. Analysis was performed on a gated population of 10,000 cells. 
Infectious reovirus particles obtained from MSC
Infected cells were harvested and subjected to several freeze-thaw cycles 
before total viral progeny yields were determined by plaque assay. No significant 
differences in the viral production were seen between wt T3D and jin-1 (figure 
9.2). In addition, of both viruses the total yields did not exceed the input titer. 
Previously similar yields of both viruses were obtained from diploid human 
skin fibroblasts (VH10 cells), which are also non-transformed cells [114]. This 
confirmed the poor permissiveness of MSC for wt T3D and jin-1 reoviruses.
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Figure 9.2 The reovirus yield of wt T3D in a MSC culture is comparable to the 
jin-1 yield. A total of 105 MSC were incubated with reovirus, wt T3D or jin-1, MOI=10 
pfu911/cell. After 72 hrs cells and medium were harvested and freeze-thawed three times 
to release the virus. Virus titers were determined by plaque assays on 911-cell cultures. 
Grey bar - wt T3D, Black bar - jin-1, dashed line - the input titer of the initial infection. 
The experiments were performed in triplicate.
MSC hand-off oncolytic reovirus
Viruses can use several mechanisms when hitch-hiking with cellular vehicles 
[129]. The first is that the virus productively infects the carrier cell and produces 
progeny viruses, which are released at the target site. Alternatively, the viruses 
may associate non-productively with the cells and be released at the destination 
site. Either way, the viruses must be released by their cellular vehicle to infect 
the target cells. To determine the ability of MSC to hand-off reoviruses to 
sensitive cells, a co-culture experiment was set-up. MSC were exposed for 72 
hrs to reovirus either wt T3D or jin-1 before the loaded MSC were added to 
reovirus-sensitive 911-cell cultures. Already 48 hrs after mixing the first signs 
of CPE were observed and over time the CPE became apparent in the higher 
dilutions as well. At day seven the CPE per mix culture was scored visually, from 
0 (no CPE) to 4 (full CPE) (figure 9.3 A). Total CPE was discernible in the 911-
cell cultures to which 104 and 103 wt T3D-loaded MSC were added. If 100 wt 
T3D-loaded MSC were added, only in one of three cultures full CPE was exhibited 
while in the other mix-cultures viable cells were still detectable. In the 911 cell 
cultures mixed with jin-1-loaded MSC total CPE was apparent after addition of 
as few as 10 and 100 loaded-MSC.
 The experiment was repeated using eGFP-marked MSC to allow tracking and 
monitoring of the reovirus-exposed MSC in the co-cultures. In this experiment 
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the reovirus-loaded eGFP-MSC were mixed with reovirus-sensitive 911 cells and 
imaged every hr by IncuCyte bright-field and fluorescence microscopy. While 
in many of the co-cultures the 911 cells exhibit clear CPE for both viruses, no 
apparent infection signs were seen in the cultures exposed to mock-infected 
eGFP-labeled MSC for the entire observation period of 64 hrs. Disintegration 
of eGFP-labeled MSC was regularly noticed. During this process eGFP-labeled 
vesicle-like fragments were released. Eventually some of these MSC collapsed 
and completely fragmented, usually between 48 and 60 hrs after initiation of 
the co-culture (figure 9.3 B). This process was more frequently seen in reovirus-
loaded MSC, but also sporadically by mock-loaded MSC.
 Viruses can associate with the MSC in several ways. Most straight-forward is 
that the viruses are associated at the outside of the MSC surface. In this case 
the viruses would be sensitive to neutralizing antibodies. Alternatively, the virus 
could be taken up by the MSC and associate with the cell in an internal location. 
This could be in a manner that allows the virus to replicate, or alternatively, the 
virus could be taken up in a vesicle, and subsequently released at the tumor 
site, without any viral replication. In either of the latter two models, the virus 
would be protected against neutralizing immunity. To discriminate between these 
models we performed a hand-off assay in which the reovirus-loaded MSC were 
incubated for 30 min in the presence of a high titer neutralizing antibodies. To 
this end we used a human intravenous immunoglobulin (IVIg) preparation. The 
IVIg is derived from blood from over 104 healthy donors, and as a consequence 
has a high titer of neutralizing activity to human reoviruses. The batch IVIg of 
1 µg/ml used in this study contains a neutralizing titer against human reovirus 
T3D as is shown in figure 9.3 C. IVIg treatment of reovirus loaded MSC delayed, 
but did not fully block, the induction of cytopathicity for wt T3D as well as jin-1 
(figure 9.3 D). At day seven post-mixing, IVIg treatment inhibited hand-off of 
the virus in comparison to the untreated controls. These data demonstrate that, 
at least, part of the viruses carried by the MSC is physically shielded against the 
neutralizing activity of human immunoglobulins. 
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Figure 9.3 Reovirus-loaded MSC can transfer reoviruses to surrounding cells. 
Increasing amounts of reovirus-loaded MSC were mixed with reovirus-sensitive 911 cells. 
(A) Mean CPE score over 3 wells at 7 days post mixing. CPE was scored by microscopic 
inspection on a scale ranging from 0, indicating no CPE visible, 1 - one plaque visible per 
culture, 2 – several of plaques visible per culture, 3- all cells rounded but still attached 
to the bottom, and 4- almost all cells detached, the culture in total CPE. (B) Bright-field 
and fluorescent online imaging microscopy. Reovirus-loaded, eGFP expressing MSC were 
co-cultured with 911-cells. From the start of the experiment up to 64 hrs post mixing 
every hour photomicrographs were taken using an IncuCyte life-cell imaging system. 
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Figure represents jin-1-loaded MSC co-culture, at 24 hrs the jin-1 loaded MSC start to 
form vesicles. At 44 hrs and 48 hrs post mixture the MSC is fragmentized and the 911 
cells start to show signs of infection and at 58 hrs CPE of 911 cells is clearly visible. (C) 
Neutralization of wt T3D by IvIg. A monolayer of 911-cells was incubated with MOI=3 of 
wt T3D in IvIg supplemented media, as infection control no IVIg was added. 48 hrs after 
infection a viability assay was performed. The experiment was performed in triplicate. 
Black-bar – mock (no virus), Grey bar – wt T3D MOI=3. (D) Mean CPE score over 3 wells 
7 days post mixing. Reovirus-loaded MSC were washed with IVIg prior to their addition to 
the indicator cells. CPE was scored visually. 
Reovirus hand-off in 3-dimensional tumor cell spheroid models 
The data above demonstrated that MSC hand-off reoviruses to reovirus-sensitive 
911 indicator cells in monolayer. To investigate whether the MSC could also 
hand-off reovirus to cells in a 3-dimensional (3D) cell culture, reovirus delivery 
was evaluated in spheroids generated from 3 different cell lines. The cell lines 
included are the reovirus-sensitive JAM-A positive 911 cells, JAM-A-deficient 
U118MG cells, and the JAM-A positive U87MG cells.
 MSC expressing eGFP were loaded with wt T3D or with jin-1 at a MOI=10 and 
cultured for three days. Subsequently, 500 reovirus-loaded MSC were added to a 
preformed spheroid. As controls, spheroids were exposed directly to 2500 pfu911 wt 
T3D or jin-1 per spheroid. The viral titer used was equated to the viral load of 500 
MSC. The spheroids were fixed and embedded in paraffin three days after addition 
of the MSC. Subsequently sections were analyzed for reovirus-infected cells and 
MSC by antibody staining against reovirus σ3 and eGFP, respectively (figure 9.4). 
 MSC were detected throughout the spheroids in all cell lines (figure 9.4). The 
MSC were incorporated in the spheroids, as is evident from the eGFP signal at 
different depths within the spheroids. Mock-treated and reovirus-loaded MSC 
showed no differences in level and depth of incorporation, suggesting that the 
capacity of MSC to penetrate the spheroids is not affected by reovirus exposure. 
 Minimal infection was observed in the 911-cell spheroids exposed to the 
wt T3D and the jin-1 (figure 9.4, top panel). In contrast, significant infection 
occurred when these spheroids were co-cultured with reovirus-loaded MSC. 
Infection was evident throughout the spheroid, and also included the cores of 
the spheroids. The reovirus infection initiated by wt T3D-loaded MSC was more 
pronounced than with jin-1-loaded MSC. Since two consecutive sections were 
used for the analyses, overlay of the pictures allow assessing co-localization of 
MSC with reovirus infection. This revealed that there were areas in the spheroid 
that stained positive for reovirus σ3 as well as for eGFP. Taken together these 
data indicate that viral infection was initiated in the spheroids composed of 911 
cells by exposure to reovirus loaded MSC. 
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Figure 9.4 Distribution of reovirus infections in tumor-cell spheroids initiated by 
reovirus or reovirus-loaded MSC. Tumor-cell spheroids generated by 911, U118MG, 
and U87MG cells were incubated with 2500 pfu911 reovirus or 500 reovirus-loaded, 
eGFP-expressing MSC. 72 hrs post exposure, the spheroids were fixed, paraffinized, and 
sectioned. Analysis of the sections was performed by DAB-immunocytochemistry with 
antibody 4F2 against reovirus capsid protein σ3 or an antibody against eGFP, followed 
incubation with a Horse Radish Peroxidase (HRP)-conjugated antibody. HRP activity was 
visualized by DAB-staining. Representative spheroids are depicted. 
 No infection was observed in spheroids of U118MG cells exposed to only 
reovirus (figure 9.4, middle panel). When the spheroids were co-cultured with 
wt T3D-loaded MSC reovirus, σ3-positive cells were detected throughout the 
spheroid. In most areas there is no or limited eGFP signal, suggesting that the 
σ3-staining is derived from reovirus infected U118MG cells. The absence of eGFP 
signal can be explained by the fact that they are already lysed or fragmented in 
vesicle-like structures with a weaker eGFP signal. In spheroids incubated with 
jin-1-loaded MSC the σ3 signal was weaker, suggesting that jin-1 spreads less 
efficient in the spheroids than wt T3D reovirus. 
 No reovirus protein synthesis was observed when U87MG spheroids were 
infected with wt T3D or with jin-1 only. Spheroids co-cultured with reovirus-
loaded MSC demonstrated reovirus synthesis at various layers of the spheroid 
and the infection efficiency of wt T3D and jin-1 was similar. At the core of the 
spheroid the σ3 signal was weaker, and there was limited eGFP signal discernible 
suggesting that MSC did not reach the core of the spheroid. 
 Overall, the spread and penetration of reovirus into the spheroids upon 
exposure to reovirus-loaded MSC was higher than upon exposure to reovirus only. 
In these assays the efficiency of wt T3D was similar or higher than of the jin-1. 
DISCUSSION
In the last decade the concept of using carrier cells for delivery of oncolytic 
viruses to solid tumors has gained momentum [128,129,153,154]. Several cell 
types have been considered, including T cells, natural killer cells, macrophages, 
dendritic cells (DCs), neural stem cells, and mesenchymal stromal cells (MSC) 
[129,148]. Here we have evaluated MSC as carriers of oncolytic reovirus. MSC 
have been shown to be capable of homing to tumor sites [149], they can be 
employed in autologous as well as in allogeneic transplantations, and they have 
an excellent safety record in clinical transplantation [155]. This supports their 
use for oncolytic virus delivery. Here we demonstrate that MSC can be loaded 
with reoviruses and that these viruses can be efficiently handed-off to target 
cells in monolayer and 3D cultures. 
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 In the last decade much progress has been made in elucidating the molecular 
mechanisms of the reovirus infectious cycle. Reovirus can associate with cells 
via low-affinity binding to sialic-acid residues [75], internalization proceeds after 
engagement of the high-affinity receptor JAM-A. Absence of JAM-A on the cell 
surface provides resistance to reoviruses, as was seen by colorectal tumor cell 
cultures [156], chicken fibroblasts [9], and several tumor cell lines [114]. JAM-A 
independent entry into monolayer cultures can be achieved by the jin-mutants, 
which harbor mutations in the S1 segment encoding the viral spike protein 
[114]. Such mutants may have advantages over wt T3D reoviruses as oncolytic 
agent in tumors lacking JAM-A expression on their cell surface.
 While flow-cytometry analyses revealed slightly higher number of MSC with 
σ3 synthesis upon jin-1 infection compared to wt T3D, the viral yield of both 
viruses is lower than the amount required for infection, confirming the earlier 
results on human diploid skin fibroblasts [114]. These data are consistent with 
a mechanism that MSC inhibits reovirus replication at a post-entry level. While 
many of the mechanistic details involved in lytic reovirus replication are still 
enigmatic, the stimulating effects of activating the Ras/RalGEF/p38 signaling 
pathway [7,53] are well established. In addition, many other cellular factors 
have been implicated in various aspects of the lytic replication cycle (reviewed 
in [47,148]). 
 Although virus replication in carrier cells can be considered as advantage to 
increase the virus load however it is not a prerequisite for efficient cell-mediated 
delivery, as was demonstrated for reovirus loaded onto T cells, DCs, or blood 
cells [130,131,157]. These studies demonstrated efficient delivery to target 
cells in the absence of viral replication in the carrier cells. 
 In our studies the mechanism of reovirus MSC association and release need to 
be further elucidated. The real-time-imaging microscopy data demonstrated that 
reovirus-loaded MSC eventually fragment (figure 9.3 B), releasing the cellular 
matter to the cultures. The fragmentation was mostly seen in the reovirus-
exposed MSC co-cultures and at a much lower frequency, in mock-infected MSC 
co-cultured with indictor cells. The pathways leading to the fragmentation of the 
MSC have not yet been delineated. It is attractive to speculate that the vesicles 
released by the disintegrating reovirus-loaded MSC may facilitate reovirus 
dissemination to neighboring sensitive cells.
 Pre-existing immunity reduces the efficacy of oncolytic virus therapy after 
intravenously administration [158,159]. This is of relevance as the human 
population has been exposed to reovirus [134]. The presence of a strong 
reovirus neutralizing activity in patients was evident in a phase I clinical trial 
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where neutralizing anti-reovirus antibody titers were further increased upon 
intravenous reovirus administration [60]. Shielding the virus would prevent 
neutralization of the virus. Our data suggest that reoviruses loaded onto MSC 
are at least partially protected from neutralizing antibodies. Although we noted 
a small reduction in efficiency, reovirus hand-off is not blocked by high doses of 
intravenous immunoglobulins (IVIg). This suggests that the reoviruses associate 
with the MSC in a concealed environment, where they are protected from 
neutralizing immunity. Two mechanisms can be envisioned 1) the reoviruses 
productively infect the MSC and the progeny virus is released at the target site 
and infect the sensitive cells or 2) part of the viruses may be taken up by the 
cells in endosomes or other vesicles but do not establish a productive infection, 
but may still be subsequently released as infectious viruses. Such mechanism 
has been proposed for immature DCs [131]. In absence of efficient and specific 
inhibitors of reovirus replication, it is difficult to distinguish these mechanisms. 
  While the monolayer cultures are often used in the development of new 
anticancer agents, the cultures do not faithfully mimic the 3D cellular architecture 
of the tumor. Spheroid cultures composed of cancer cells are more similar to 
tumors [116,119]. Oncolytic viruses testing in spheroid models demonstrated 
that penetration and distribution of the viral anticancer agents can be easily 
monitored [117,160]. Our studies demonstrate that the reovirus-loaded MSC can 
associate and become incorporated within tumor cell spheroids. No difference 
in MSC incorporation was noted between reovirus-loaded MSC and mock-loaded 
MSC, demonstrating that the reovirus infection does not negatively affect the 
MSC capacity to integrate into the spheroids. The addition of the reovirus-loaded 
MSC to the tumor cell-spheroids led to efficient infection of the tumor cells 
within the spheroid. Almost no infection was observed when spheroids were 
incubated with 2500 pfu911 reovirus, which is comparable to the virus load of the 
reovirus pre-incubated MSC. Applying higher viral titers to the spheroids causes 
predominantly infections of the outer rim of the spheroids [124], while the 
addition of reovirus-loaded MSC to the spheroids resulted in reovirus infection 
deeper into the spheroids. Remarkably, efficient MSC-mediated infection wt T3D 
and jin-1 in 911-cell spheroids, U87MG-cell spheroids, as well as in U118MG-
cell spheroids was seen, even though the latter cells lack JAM-A expression. The 
infection of spheroids in absence of JAM-A can be attributed to secretion of active 
cellular proteases which convert the reovirus particles to infectious subviral 
particles [124]. This demonstrates that JAM-A expression can be dispensable 
for reovirus infection in 3D cultures. Taken together, these data suggest that the 
reoviruses do not depend on JAM-A for cell entry into 3-D cultures. The increased 
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efficiency of jin-1 in infecting JAM-A negative cells in monolayer culture does not 
correspond to an increased efficiency in 3D cell cultures. Therefore it remains to 
be established which mechanisms are employed by reoviruses to infect JAM-A 
negative cells in 3D cell cultures. 
 Taken together our data demonstrate that human MSC can be used for 
delivery of reovirus T3D. It was shown that reovirus loaded MSC can efficiently 
hand-off the virus to sensitive cells in monolayer and 3D cultures and that the 
reovirus does not inhibit the MSC’s capacity to become incorporated into tumor-
cell spheroids. In addition, the reoviruses associated with the MSC are partially 
protected from neutralizing immunoglobulins. Therefore, our data warrant 
further evaluation of MSC as carrier cells of oncolytic reoviruses in animal models 
for human cancer.
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The main aim of this thesis is to provide knowledge which can improve oncoltyic 
virus therapy with adenovirus and reovirus vectors. The concept of using viruses 
for the treatment of malignancies was already investigated in the 1950s. Due 
to the disappointing results, the interest in this approach faded away from the 
general public. Renewed interest was gained around the 90s when molecular 
techniques became more advanced. This allowed approaches to increase the 
potency and the safety of viral vectors. In addition this also provided researcher 
tools to modify virus genomes [1,2]. During this period oncolytic virus therapy 
was seen as promising treatment. Now more than two decades down the road 
it can be concluded that generating effective oncoltyic viruses has been more 
challenging than initially thought. Major bottlenecks are the efficiency and 
selectivity. In the recent years many research groups focused their research on 
improving oncolytic virus vectors.
 Adenovirus can infect quiescent and dividing cells and drive the cells into 
S-phase. This allows the virus to propagate efficiently. Although adenovirus 
does not have a natural preference for transformed cells it is still one of the 
best studied viruses for oncolytic virus therapy. A brief overview on the general 
virus biology and the modifications required for endowing the adenovirus with 
a tumor-cell preference can be found in chapter 2. In chapter 3 a similar 
overview is given for reovirus. In contrast to adenovirus the reovirus has an 
intrinsic preference for transformed cells. However, further modification of 
the genome of reovirus is challenging due to its segmented, double stranded 
RNA (dsRNA) genome. In part II and III different strategies for improving the 
oncolytic virus therapy with adenoviruses and reoviruses are discussed. In part III 
a section is dedicated to defining the susceptibility to reovirus of a cell type 
which has an important role in tumor genesis. 
ADENOVIRUS 
Adenovirus capsid protein modifications have been researched in depth to 
enhance the tumor cell specificity and decrease transfection of non-target tissue. 
The focus was to a large extent on fiber modifications, but also the other capsid 
proteins have been subjected to modification strategies to alter the tropism 
and shield the virus particle [3-6]. For instance protein IX turned out to be a 
useful anchor for small polypeptides to modify the cell tropism [7,8]. Protein IX 
is a minor capsid protein, and despite the much research to the functionality it 
remains enigmatic. Yet it is suggested that its function is important since the 
region is conserved in all primate adenoviruses [8]. Previous studies analyzing 
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the effect of the removal of protein IX already showed that the stability of the 
particles was negatively influenced [9]. In chapter 4 we show that removal 
of protein IX yields an adenovirus vector with enhanced transgene delivery in 
coxsackie and adenovirus receptor (CAR) negative cells. In addition protein IX 
deletion caused an enhanced activation of peripheral blood mononuclear cells 
(PBMC) and sequesters in the liver after intravenous delivery in a mouse model. 
These data give more insight in the function of protein IX in determining the cell 
tropism and the activation of the immune system. In addition this knowledge 
may be important for the development of future clinical oncolytic vectors.
 In the quest to improved adenovirus vectors for the use as oncolytic agents 
not only retargeting strategies are of interest but also modifications aiming at 
increasing the oncolytic efficiency and specificity are of concern. Since adenovirus 
has been popular as a model system in viral entry, transcription and replication 
studies and is well-investigated as an oncolytic vector, a lot of knowledge was 
gathered about gene functions and modification strategies. Therefore rational 
design was mainly the basis to the improved vectors that have been generated. 
However, literature exists showing that random approaches can also be effective 
for generating adenovirus vectors with improved cytopathic activity [10-13]. For 
example, two of these studies isolated mutants with mutations in the i-leader 
region after random mutagenesis and bioselection strategies [11,13].. The 
i-leader is present in the adenovirus major-late transcripts [14]. Unfortunately 
the exact function of this region is still unknown, partly because of that this 
region was not subjected earlier in modification studies. In the study of Yan et 
al. two mutants with multiple single-base-pair-mutations, including a shared 
mutation in the i-leader, were isolated after mutagenesis and bioselection on 
the human colorectal cancer cell line HT29. Further analysis confirmed that the 
shared i-leader truncating mutation was essential for the improved cytolytic 
activity [13]. The purpose of chapter 5 was to determine the cytopathic effect 
of an adenovirus vector with the i-leader mutation on glioma cells in comparison 
to wild-type adenovirus. A replication competent adenovirus vector containing 
the i-leader truncating mutation (RL-07) was constructed by site directed 
mutagenesis and homologous recombination. The comparison studies were 
performed on established cell lines and on primary high grade glioma cultures. 
These studies showed that RL-07 had a higher cytopathic effect on transformed 
cell cultures but not on non-transformed cell lines. The expression pattern of 
E1A, fiber and adenovirus death protein (ADP) was similar to wild-type, however 
RL-07 was released earlier from the cells enhancing, the spread in the cultures. 
Although further research has to confirm that the function of the i-leader protein 
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is related to early release of the virus from cells, this mutation may be useful in 
future vectors. 
REOVIRUS
Viral transduction of target cells may be hampered by the scarcity or 
inaccessibility of the viral receptors on the target cell. For reovirus is the 
junction adhesion molecule-A (JAM-A) receptor the high affinity receptor. The 
first genetic modification strategies in reovirus were published several years 
ago [15-17]. However retargeting of reovirus by genetic modifications is still a 
laborious and challenging process (see also chapter 1.3). The major challenges 
of modifying the reovirus genome is caused by the segmented double stranded 
RNA (dsRNA) genome. A description of one of the modification strategies, 
which may be applicable for the improvement of human reoviruses as oncolytic 
agents, is presented in chapter 6. The chapter focuses on the modification of 
the spike-encoding segment which anchors to the cognate receptor JAM-A. The 
generation of retargeted virus is performed on cells expressing a modified σ1-
encoding segment embedded in a conventional RNA polymerase II transcript. 
The wild-type σ-1 segment is replaced by the modified σ1-encoding segment 
upon propagation. This was shown by infection of a resistant cell line expressing 
the receptor for the modified σ1-protein. Further analysis confirmed that the 
modified σ-1 segment was also incorporated into the genome. From these data 
it can be concluded that 1) the modification strategy described is feasible for 
the modification of reovirus 2) the C-terminus of the spike-protein is a potential 
place to incorporate small polypeptides which can alter the cell tropism. However, 
additional experiments need to be performed to show which polypeptide would 
be suitable to introduce. 
 The lack of proofreading of the polymerase of RNA viruses, including reovirus, 
results in a high mutation rate [18]. Forcing reovirus propagation to resistant 
cell cultures which do not express the JAM-A receptor expands the cell tropism. 
This strategy is described in chapter 7. Briefly, wild-type reovirus was forced to 
propagate for several consecutive replication rounds on U118MG, a glioblastoma 
cell line which does not express JAM-A. Reovirus isolates which induce the 
cytopathic effect were further characterized. The isolated mutants, JAM-A 
independent (jin) mutants, could infect a wide range of cell lines that resisted 
wild-type, but infection on human fibroblasts was inhibited. Sequencing results 
of the S1 segment, encoding for the spike-protein, revealed that the jin mutants 
harbored mutations located close to the sialic-acid binding domain in the shaft 
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and two of the jin mutants also displayed a mutation in the head-domain, which 
is the JAM-A binding domain. Further analysis of the jin mutants indicated that 
infection relies on binding to sialic acid. Although these results indicate that 
the jin mutants may be useful as oncolytic vectors for the treatment of tumors 
which lack JAM-A on their surface, additional in vitro and in vivo studies need to 
confirm this. 
 The aim of chapter 8 was to evaluate reovirus susceptibility of glioblastoma 
stem-like cells (GSC). A GSC culture is established from a fresh surgical 
specimen of a glioblastoma (GB). GSC represent a small population of a GB 
which possess high resistance to radio- and chemotherapy. In addition, these 
cells acquire the capacity to self-renew and differentiate into heterogeneous 
cells types that drive tumorigenesis [19-24]. Further analysis revealed that 
cultures of GSC more closely mirror the clinical features of GB than cells cultured 
in conventional serum-containing media or established glioblastoma cell lines 
[22,24]. Flow cytometry analyses of seven GSC cultures showed large variation 
of JAM-A expression. For that reason, susceptibility studies were performed 
with both the wild-type reovirus and the jin-1 mutant. Four parameters were 
analyzed including infection, oncolytic efficacy, reovirus yield and infection 
of GSC spheroids. These three dimensional (3D) cultures mimic the tumor 
structure more faithfully than conventional two dimensional monolayer cultures 
[25,26]. The susceptibility to both wild-type and jin-1 reovirus differed between 
the seven GSC cultures. Furthermore, on monolayer jin-1 reovirus seems to 
perform better than wild-type while on the spheroids both viruses performed 
similarly. This difference, which is also demonstrated by Dautzenberg et al. [27], 
indicates that JAM-A expression may not be essential for infection in 3D cultures 
and that another alternative entry route may be involved. It is unclear whether 
the differences between the cultures faithfully reflect the status of the individual 
patients or that the heterogeneity is due to culturing conditions. 
 Efficient transduction of the tumor cells, especially after systematic 
administration, can be hampered by neutralizing antibodies. Other factors 
involved include scavenging by non-target tissue, non-specific binding by blood 
cells and soluble factors such as complement and pre-immune IgM that can 
reduce the uptake by target tissue [28,29]. In the oncolytic virus field different 
virus shielding and delivery strategies have been described. These studies 
suggest that delivery of significant amounts of oncolytic virus may be feasible 
[28,30,31]. The goal of chapter 9 was to investigate if reovirus could be loaded 
onto human bone marrow-derived mesenchymal stromal cells (MSC), as these 
cells have the ability to home to tumors [32]. In addition different studies have 
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already described the use of MSC as carrier cells for oncolytic viruses [33,34]. In 
this study it was shown that wild-type reovirus and jin-1 reovirus can be loaded 
onto MSC and that MSC are able to hand-off the virus to neighboring cells, in 
monolayer cultures and in spheroids. Furthermore incubation of the reovirus 
loaded MSC with neutralizing IgG only partly inactivated the virus suggesting 
that virus is, to some degree, shielded. Just as in chapter 8 jin-1 performed 
slightly better on monolayer compared to wild-type. However this difference 
disappeared again in 3D cultures. The differences between the monolayer and 
spheroid cultures show that reliable model systems to test oncolytic viruses 
are urgently needed. In conclusion these data showed that MSC are potential 
cell carriers for reovirus, although future in vitro and in vivo research need to 
confirm this. 
 Finally, despite of anecdotic evidence of oncolytic viruses as effective 
oncolytic agents, it seems that viruses as single agents are not powerful enough 
to become the ultimate oncolytic treatment. However, an enhanced antitumor 
efficacy is seen when oncolytic viruses are combined with conventional treatment 
strategies [35]. Since this is a relatively new development future research need 
to confirm the safety of this approach. 

CHAPTER 11 
CONCLUSION

Conclusion
245
11
In conclusion, the work presented in this thesis shows that: 
· Modification of capsid proteins can change the cell tropisms and these 
modifications may provide more insight into the function of the capsid 
proteins.
· Random and rational modification strategies both obtain modified vectors 
with increased oncolytic efficiency. 
· The structure of a culture, monolayer (2D) or spheroids (3D), may result in 
differences determination of the oncolytic efficacy of the viral vector
· GSC cultures show a heterogeneous susceptibility to reovirus which may 
reflect the clinical variation.
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Het voornaamste doel van het onderzoek dat beschreven is in dit proefschrift 
is het verbeteren van oncolytisch virustherapie met adenovirus en reovirus 
vectoren. Het concept om virussen te gebruiken ter bestrijding van tumoren 
heeft al een lange geschiedenis en werd voor het eerst onderzocht rond 1950. 
Helaas ging belangstelling bij het grote publiek verloren door het uitblijven van 
grote doorbraken. Rond 1990 ontstond er hernieuwde interesse in virussen 
als anti-tumor therapie. Dit werd gekenmerkt door ontwikkeling van nieuwe 
technieken en kennis op het gebied van de moleculaire biologie. Deze nieuwe 
technieken en kennis leidden tot hernieuwde aanpakken die de effectiviteit en de 
veiligheid van het gebruik van virale vectoren verhoogden. Daarnaast gaven de 
moleculaire technieken de onderzoekers de mogelijkheid om het virusgenoom te 
modificeren [1,2]. Mede hierdoor werd in de jaren 90 oncolytische virustherapie 
beschouwd als een veelbelovende behandeling van tumoren. Nu, twee 
decennia verder, kan geconcludeerd worden dat de ontwikkeling van effectieve 
oncolytische virussen een grotere uitdaging is dan destijds werd aangenomen. 
Op dit moment zijn de effectiviteit en de selectiviteit van het virus ten opzichte 
van de tumor de belangrijkste knelpunten. Afgelopen jaren hebben dan ook vele 
onderzoeksgroepen zich gericht op het ondervangen van o.a. deze knelpunten 
ter verbetering van de effectiviteit van oncolytische virus vectoren. 
 Adenovirus is het best bestudeerde virus voor het gebruik als oncolytisch 
virus vector ondanks dat het geen voorkeur heeft voor getransformeerde cellen. 
Het virus kan cellen in rust maar ook actief-delende cellen infecteren waarna het 
adenovirus ervoor zorgt dat cellen in de S-fase van de celcyclus overgaan. De 
S-fase is de ideale omgeving voor adenovirus om zich efficiënt te repliceren. Een 
aanvullende beschrijving van adenovirus biologie is gegeven in hoofdstuk 2. In 
dit hoofdstuk is ook aandacht voor modificatie strategieën die ervoor zorgen dat 
adenovirus een voorkeur krijgt voor getransformeerde cellen. Naast adenovirus 
wordt in dit proefschrift een tweede virus beschreven als oncolytisch vector, te 
weten reovirus. In hoofdstuk 3 is een gelijksoortig overzicht van de reovirus 
biologie en modificatie strategieën gegeven als voor adenovirus. In tegenstelling 
tot het adenovirus heeft reovirus wel een voorkeur voor getransformeerde 
cellen, maar is de modificatie van het genoom een grotere uitdaging. Dit wordt 
veroorzaakt doordat het genoom van een reovirus bestaat uit tien dubbel-strengs 
(ds) RNA segmenten. In de twee opeenvolgende secties worden verschillende 
strategieën beschreven die de oncolytische virustherapie met adenovirus (sectie 
2) of reovirus (sectie 3) vectoren kunnen verbeteren. In sectie 3 is daarnaast 
nog een hoofdstuk gewijd aan de gevoeligheid van een tumorceltype, dat een 
belangrijke rol speelt in het ontstaan van tumoren en uitzaaiingen. 
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In het verleden heeft het adenovirusonderzoek zich voornamelijk gericht 
op het modificeren van capside-eiwitten met als doel de selectiviteit voor 
getransformeerde cellen te verbeteren en het verlagen van de infectie van 
‘non-target’ weefsel. Het onderzoek richtte zich op fiber-modificaties maar ook 
modificaties van de andere capside-eiwitten zijn onderzocht. Deze strategieën 
focusten zich op het veranderen van het tropisme, maar ook op de afscherming 
van het virus door middel van het integreren van een extra eiwitstructuur in een 
capside-eiwit [3-6]. Uit een van die onderzoeken kwam naar voren dat onder 
andere eiwit IX (pIX) een geschikte kandidaat is voor de ‘verankering’ van kleine 
polypeptiden die het cel-tropisme veranderen [7,8]. Eiwit IX is een klein capside-
eiwit met een vooralsnog raadselachtige functie. Toch wordt gesuggereerd dat 
pIX van belang is aangezien de regio coderende voor pIX geconserveerd is in 
alle primaat adenovirussen [8]. Daarnaast hebben eerdere studies laten zien 
dat verwijdering van pIX de stabiliteit van het virus aantast [9]. Hier kan aan 
toegevoegd worden dat de verwijdering van pIX een adenovirus-vector oplevert 
met een verhoogde transgene afgifte in coxsackievirus en adenovirus receptor 
(CAR) negatieve cellen. Dit wordt beschreven in hoofdstuk 4. Bovendien 
veroorzaakt de deletie van pIX een verhoogde activatie van perifere bloed 
mononucleaire cellen (PBMC) en opname in de lever na intraveneuze toediening 
in een muismodel. Samengevat, de gepresenteerde data geven meer inzicht 
in de functie van pIX; zij suggereren een rol van pIX bij de bepaling van het 
cellulaire tropisme en in de activatie van het immuun systeem. De verkregen 
kennis kan van belang zijn in de ontwikkeling van toekomstige oncolytische 
adenovirus vectoren.
 In de zoektocht naar strategieën ter verbetering van adenovirus vectoren 
voor het gebruik als oncolytisch geneesmiddel zijn niet alleen ‘retargeting’ 
strategieën belangrijk maar ook modificaties die de infectie-efficiëntie en cel-
specificiteit verbeteren. De populariteit van adenovirus als modelvirus voor 
infectie, transcriptie, replicatie en als oncolytische vector resulteerde in niet alleen 
virus-specifieke maar ook algemene virale kennis over functies en genetische 
modificatie strategieën. Dit leidde het tot rationeel ontwerpen van adenovirus-
vectoren als basisstrategie. Daarnaast zijn er studies die laten zien dat ook 
‘random’ modificatie ook effectief kan zijn voor het verkrijgen van vectoren 
met verhoogde cytopatische activiteit [10-13]. Voorbeelden hiervan zijn twee 
afzonderlijke studies waarin wordt beschreven dat na ‘random’ mutagenesis 
en bioselectie adenovirus-mutanten kunnen worden geïsoleerd die mutaties 
hebben in de i-leader regio [11,13]. De i-leader wordt tot expressie gebracht 
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tijdens adenovirus ‘major-late’ transcriptie [14]. Toch is tot op heden de exacte 
functie van deze regio nog niet bekend, mede daardoor is deze regio niet 
eerder onderwerp van modificatiestudies geweest. In de eerst gepubliceerde 
studie beschrijven Yan et al. twee adenovirus mutanten die geïsoleerd zijn 
op de humane colorectale kanker cellijn HT29 na mutagenese en bioselectie. 
Deze twee mutanten bevatten beide meerdere puntmutaties waaronder een 
gedeelde i-leader mutatie. Analyse bevestigde dat deze gemeenschappelijke 
mutatie essentieel is voor de verbeterde cytolytische activiteit [13]. Het doel 
van de studie beschrevenn in hoofdstuk 5 was het determineren van het 
cytopatische effect van de adenovirus met i-leader mutatie op glioma-cellen in 
vergelijking met het wild-type virus. In deze studie werd doormiddel van gerichte 
mutagenese en homologe recombinatie een replicatie-competent adenovirus 
vector gecreëerd die de i-leader mutatie (RL-07) bevatte. Vergelijkingsstudies 
op gestandaardiseerde (established) cellijnen en primaire hooggradige glioma 
tumorcel kweken toonden aan dat RL-07 een hogere cytopatische activiteit 
heeft op getransformeerde celculturen dan wild-type adenovirus, maar dat 
dit niet werd gezien op niet-getransformeerde cellijnen. Hoewel het expressie 
patroon van E1A, fiber en ‘adenovirus death protein’ (ADP) in vergelijking 
tot wild-type gelijk was, kwam RL-07 toch eerder vrij uit de cellen. Hierdoor 
verbeterde de spreiding van dit virus in de culturen. Ondanks dat toekomstige 
studies nog moeten bevestigen dat de functie van de i-leader gerelateerd is aan 
de vervroegde afgifte van het virus kan dit een interessante mutatie zijn voor 
toekomstige vectoren. 
REOVIRUS
Virale transductie kan belemmerd worden door afwezigheid of door het niet-
toegankelijk zijn van specifieke receptoren op de target-cel. Voor reovirus is de 
junction adhesion molecule-A (JAM-A) receptor van groot belang voor efficiënte 
transductie; modificatie van virus-attachment eiwitten kan deze specificiteit 
veranderen. Al zijn de eerste genetische modificatie strategieën voor reovirus 
enkele jaren geleden gepubliceerd [15-17], toch blijft het ‘retargeten’ van 
reovirus door middel van genetische modificatie een uitdagend proces. Dit 
wordt veroorzaakt door het gesegmenteerde dsRNA genoom (hoofdstuk 3). 
In hoofdstuk 6 wordt een modificatie strategie beschreven die zich richt op 
de modificatie van het S1 segment coderend voor het spike-eiwit (σ1). De 
spike bindt de JAM-A receptor. De productie van het ‘geretargette’ virus wordt 
uitgevoerd met gemodificeerde cellen die het σ1 coderend-segment, ingebed 
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in een conventionele RNA polymerase II transcript, tot expressie brengen. 
Het wild-type sigma-1 eiwit en genoom-segment, worden gedurende de 
replicatie vervangen door het gemodificeerde sigma-1. Dit werd bevestigd door 
1) infectie van een resistente cellijn die de receptor voor de verankering van het 
gemodificeerde σ1 tot expressie brengt en 2) moleculaire analyse die aantoonde 
dat het gemodificeerde segment in het genoom was geïncorporeerd. Uit deze 
studie kan geconcludeerd worden, 1) dat modificatie van reovirus doormiddel 
van de bovenstaande strategie mogelijk is en 2) dat de C-terminus van de spike-
eiwit σ1 een geschikte locatie is voor het incorporeren van kleine polypeptiden 
die het cellulaire tropisme kunnen aanpassen. Vervolgexperimenten kunnen 
bepalen welke polypeptiden geschikt zijn voor de introductie van nieuwe 
sequenties in het reovirus genoom en capside.
 De hoge mutatiesnelheid in RNA virussen waaronder het reovirus wordt 
veroorzaakt door het ontbreken van de ‘proof-reading’ capaciteit van de RNA 
polymerasen [18]. In hoofdstuk 7 staat beschreven dat oncolytische vectoren 
kunnen worden verkregen door gebruik te maken van de ontbrekende ‘proof-
reading’. Waar het op neer komt is dat wild-type reovirus replicatie wordt 
geforceerd op JAM-A negatieve celculturen. In deze studie werd gebruik gemaakt 
van de JAM-A negatieve glioblastoma cellijn U118MG. Dit resulteerde in een 
virus met een aangepast cellulair tropisme. Na enkele geforceerde replicatiecycli 
werden de reovirus-isolaten die een verhoogd cytopathisch-effect induceerden 
verder gekarakteriseerd. De geïsoleerde mutanten, hier genaamd JAM-A 
onafhankelijke (jin) mutanten, kunnen een grote range aan cellen infecteren die 
resistent zijn voor wild-type reovirus. Infectie van humane fibroblast cellen bleef 
geblokkeerd. De resultaten van het nucleotide-sequencing van het S1 segment, 
coderend voor het spike-eiwit, onthulde dat in de jin mutanten mutaties zijn 
opgetreden dicht bij het siaalzuur-bindingsdomein. Aanvullende experimenten 
lieten zien dat deze mutanten tijdens infectie afhankelijk zijn van binding aan 
siaalzuur i.p.v. binding aan JAM-A. Tot slot, resultaten uit deze studie laten 
zien dat de jin mutanten van betekenis kunnen zijn als oncolytische vectoren 
voor de behandeling van tumoren die JAM-A niet tot expressie brengen op hun 
celoppervlak. Om dit te bevestigen Zijn aanvullende in vitro en in vivo studies 
zijn nodig. 
 In hoofdstuk 8 wordt de gevoeligheid van glioblastoma stem-like cells 
(GSC) voor reovirus beoordeeld. De gebruikte GSC-culturen zijn verkregen uit 
chirurgische specimen van glioblastomas (GB) van verschillende patiënten. De 
GSC representeren een kleine populatie cellen in een GB die een hoge weerstand 
hebben tegen radio- en chemotherapie. Daarnaast bevatten deze cellen de 
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eigenschap om zichzelf te vermenigvuldigen en te differentiëren in heterogene 
celtypen die de tumorgenesis aansturen [19-24]. Studies hebben uitgewezen 
dat de eigenschappen van GSC culturen meer overeenkomsten hebben met 
de klinische eigenschappen van GB dan de cellen die gekweekt worden in de 
conventionele serum-bevattende media of gestandaardiseerde (established) GB 
cellijnen [22,24]. Met behulp van flowcytometrie werd de expressie van JAM-A 
van de zeven geselecteerde GSC-culturen bepaald. Hieruit kwam naar voren 
dat er een grote variatie in JAM-A expressie bestaat tussen deze GSC-culturen. 
Mede hierdoor werd er besloten dat de studie zou worden uitgevoerd met 
wild-type reovirus en de jin-1 mutant. Vier parameters werden geanalyseerd, 
inclusief infectie-efficiëntie op monolaagculturen, oncolytische effectiviteit, 
virusopbrengst en infectie van GSC sferoïden. In literatuur staat beschreven 
dat driedimensionale (3D) culturen de tumorstructuur beter nabootsen dan de 
conventionele tweedimensionale monolaagculturen [25,26]. Uit deze studie 
kan geconcludeerd worden dat de gevoeligheid van de GSC culturen voor beide 
virussen, wild-type en jin-1, niet gelijkwaardig was. Bovendien lijkt het effect 
van jin-1 op de monolaagculturen groter dan dat van wild-type, terwijl op 
de sferoïden beide virussen vergelijkbare resultaten gaven. Het gegeven dat 
reovirus zich anders gedraagt in monolaag dan in 3D culturen is kort geleden 
gepubliceerd door Dautzenberg et al. In deze publicatie staat beschreven dat in 
3D culturen JAM-A expressie niet essentieel is voor infectie en dat er alternatieve 
infectie-routen zijn [27]. In een vervolgstudie zou moeten worden onderzocht 
of het effect van reovirus op de geselecteerde GSC een waardig beeld geeft van 
de individuele variatie tussen patiënten of dat deze verschillen voortkomen uit 
variaties in kweekcondities. 
 Het efficiënt transduceren van tumorcellen, zeker na systemische toediening, 
kan belemmerd worden door neutraliserende antilichamen. Andere factoren die 
een negatieve invloed kunnen hebben op de transductie-efficiëntie zijn o.a. het 
wegvangen van virussen door andere weefsels en niet-specifieke binding van 
virussen aan bloedcellen of oplosbare factoren zoals complementeiwitten en pre-
immuun IgM [28,29]. In de oncolytische onderzoekswereld worden verschillende 
strategieën beschreven waarbij virussen hiervoor worden afgeschermd. Deze 
studies suggereren dat de aflevering van significante hoeveelheden oncolytische 
virussen uitvoerbaar kan zijn [28,30,31]. Het doel van hoofdstuk 9 was het 
onderzoeken van de mogelijkheid om reovirus te laden op mesenchymale 
stamcellen (MSC) geisoleerd uit humaan beenmerg. Van MSC is bekend dat ze 
het vermogen hebben om naar tumoren te migreren [32]. Daarnaast hebben 
verschillende studies laten zien dat MSC gebruikt kunnen worden als drager-
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cellen voor oncolytische virussen [33,34]. In deze studies is onderzocht 1) of 
wild-type reovirus en jin-1 reovirus kunnen worden geladen op MSC en 2) of de 
MSC het virus ook weer kunnen doorgeven aan buurcellen, zowel in monolaag 
als in sferoïden. Nadat de MSC werden geladen met reovirus, werd onderzocht 
of MSC het virus kon beschermen tegen uitwendige factoren. Hiervoor werden 
de reovirus-beladen MSC geïncubeerd met neutraliserende IgG antilichamen. 
Dit gaf een gedeeltelijke inactivatie van het virus. Dit suggereert dat het virus 
in beperkte mate beschermt is. Zoals eerder vermeld in hoofdstuk 8 is het 
effect van jin-1 in vergelijking met wild-type iets beter op monolaag culturen. 
Echter dit verschil is niet meer waarneembaar in de 3D culturen. Het verschil 
tussen monolaag en 3D culturen in zowel deze studie, als ook in de vorige, 
laat zien dat het van belang is om een goed modelsysteem te hebben die 
betrouwbaar effectiviteit van oncolytische virussen in een klinisch-relevante 
omgeving representeert. Hiervoor zouden in de toekomst vergelijkingsstudies 
tussen modelsystemen en klinische studies gedaan moeten worden. De data uit 
hoofdstuk 9 laat verder zien dat MSC potentiele dragers zijn voor reovirus en dat 
uitgebreide in vitro en in vivo studies een logisch vervolg kunnen zijn. 
 Ten slotte, ondanks anekdotisch bewijs dat oncolytische virussen effectief 
kunnen zijn als oncolytisch geneesmiddel, lijkt het erop dat virussen als 
monotherapie niet krachtig genoeg zijn om de ultieme behandelmethode 
te worden. Echter een verbeterd antitumoreffect is beschreven wanneer 
oncolytische virussen worden gecombineerd met de conventionele behandelings-
strategieën [35]. Aangezien dit een relatief nieuwe ontwikkeling is zal er meer 
onderzoek moeten plaatsvinden om uit te zoeken hoe veilig en effectief deze 
combinatiestrategie is. 
CONCLUSIE
Uit de data gepresenteerd in dit proefschrift kan geconcludeerd worden dat:
· Modificatie van een capside eiwit kan leiden tot het veranderen van het 
cellulaire tropisme. Tevens kan deze modificatie meer inzicht geven in de 
biologische functie van het eiwit;
· Willekeurige en rationele modificatie strategieën kunnen beide leiden tot 
virale vectoren met een verhoogd oncolytisch-rendement; 
· De structuur van de cultuur, monolaag (2D) of sferoïde (3D), kan voor een 
verschil zorgen in de beoordeling van de oncolytische activiteit van een 
vector; en
· De gevoeligheid van GSC culturen op reovirus laat een grote variatie zien, dit 
zou de klinische variatie kunnen weergeven.
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karakter is fantastisch. Daarnaast wil ik Johannes, Cees en Bert bedanken voor 
het vertrouwen dat jullie in mij hebben. Wetsus haalt het beste in mij naar 
boven!
 Naast collega’s en korfbalvrienden wil ik ook nog twee andere speciale 
vrienden bedanken. Lotte onze promotietrajecten liepen bijna synchroon, 
hierdoor begrepen we elkaars frustraties. Bedankt voor het je luisterend oor en 
steun. Liane al hebben we niet meer zo close-contact als vroeger toch blijf je 
een vriendin waar ik van weet dat die er altijd zal zijn. 
 Aangezien ik ruim 12,5 jaar samen ben met mijn grote liefde betekend dat 
ik ook ruim 12,5 jaar een fantastische schoonfamilie heb. Een basis in Driesum 
waar wij rust vinden, die ons af en toe even uit onze sleur halen. Bedankt voor 
de afleiding en onvoorwaardelijke steun.
 Oma met haar sterke wil, ik herken eigenschappen van haar in mijzelf (al 
weet ik niet of ik daar altijd even blij mee ben). Jij hebt geen idee waar ik mij 
mee bezig heb gehouden, en dat is ook niet erg. Ik bewonder je vechtlust en 
positieve levenshouding en ben super blij dat je dit nog mag lezen. 
 Ik heb een speciale band met mijn broeders, Herwin, Gerbrant en Arjo, 
ondanks dat wij allemaal niet even spraakzaam zijn, kunnen we elkaar toch 
altijd vinden. Tegenwoordig behoren wij tot dezelfde vriendengroep (oud-VKC) 
en dat is fijn. Fantastische tijden (feesten en weekenden) met VKC staan nog 
steeds in mijn geheugen, geheimen die wij verborgen hielden voor vader en 
moeder (al gooide André wel eens roet in het eten). Betere broeders kan ik mij 
niet wensen. Annelien jij vult dit uitstekend aan.
 Pap en mam, nou zijn jullie aan de beurt. Zoals ik net al heb proberen te 
beschrijven kom ik uit een fantastisch gezin, dat is jullie verdienste. Daarnaast 
hebben jullie mij altijd gesteund, mij mijn eigen weg laten kiezen en mij 
gemotiveerd om me verder te ontwikkelen. Jullie hebben mij losgelaten door me 
als 18 jarig meisje op kamers te laten wonen. En nog geen twee jaar later ging 
ik alleen naar Australië voor ruim 6 maanden. Ik ben jullie daar enorm dankbaar 
voor. Ik kan mij geen betere ouders wensen. Ruim twee jaar geleden toen ik bij 
Wetsus werd aangenomen, mocht ik zo weer thuis-thuis komen wonen. Al was 
het onder het mom van tijdelijk, ik woon er nog steeds. En al het huishoudelijk 
werk wat voornamelijk jij mam mij uithanden hebt genomen, heeft mij de rust 
gegeven om deze promotie af te maken. Bedankt voor jullie onvoorwaardelijk 
liefde en steun. 
 Last but not least, mijn grote liefde André, wij zijn samen begonnen aan dit 
avontuur ‘promoveren’ en gaan het samen afsluiten. Een droom die in vervulling 
komt. In de onderstaande tekst heb ik geprobeerd om mijn gedachten aan, en 
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gevoelens voor jou op papier te krijgen, maar mijn woorden schieten te kort. 
Al ruim 12,5 jaar samen, in die tijd hebben wij elkaar altijd vrij gelaten om ons 
verder te ontwikkelen. Jouw steun en vertrouwen in mij hebben mij doen groeien 
tot deze vrouw. En nog steeds leer ik veel van jou. Jij helpt mij om verder te 
komen en daar ben ik je enorm dankbaar voor. Samen sluiten wij dit hoofdstuk 
af en beginnen wij aan het volgende deel van ons boek. Een toekomstdroom van 
ons is om plaats te kunnen nemen onder onze appelboom en samen genieten 
van de ondergaande zon. Laten wij nu eerst genieten van dit feest en de nabije 
toekomst. 
- The best has yet to come -
Scorpions
Liefs Sanne 


